number,prep,comp,PEG,PEGRatio,surface-coating,ligand-type,ligand,mechanism,receptor-type,receptor,Pgp,Pgp-inhibitor,size,PDI,zeta,EE%,DL,animal-model,route,ligand-density-mol,ligand-density-num,encapsulation,external,ID%,delivery-efficiency,mod-ratio-unmod,group
1,liposome,PC,0.0,0.0,none,none,,passive transport,,,,,,,,,,normal,i.v.,,,,none,0.0013,,,1
1,liposome,DPPC,0.0,0.0,none,none,,passive transport,,,,,,,,,,normal,i.v.,,,,none,0.0017,,,1
2,liposome,PC,0.0,0.0,none,none,,passive transport,,,,,,,,,,normal,i.v.,,,,none,0.0024,,,2
4,liposome,PC,0.0,0.0,none,glycosol,mannose derivative,transporter mediated,hexose transporter,GLUT-1,,,,,,,,normal,i.v.,10.0,,,none,0.019,,,4
4,liposome,PC,0.0,0.0,none,glycosol,"fucose
derivative (L-type)",transporter mediated,hexose transporter,GLUT-1,,,,,,,,normal,i.v.,10.0,,,none,0.011,,,4
4,liposome,PC,0.0,0.0,none,glycosol,"fucose
derivative (R-type)",transporter mediated,hexose transporter,GLUT-1,,,,,,,,normal,i.v.,10.0,,,none,0.0048,,,4
4,liposome,PC,0.0,0.0,none,glycosol,galactose derivative,transporter mediated,hexose transporter,GLUT-1,,,,,,,,normal,i.v.,10.0,,,none,0.0043,,,4
6,liposome,PC/PI,0.0,0.0,none,none,,passive transport,,,,,,,,,,brain tumor,through carotid artery,,,,none,0.0006,,,6
7,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,,none,0.0025,1,,7
7,liposome,DMPC/DMPG,0.0,0.0,none,none,,passive transport,,,,,,,,93.08,,normal,i.v.,,,,none,0.0035,1.4,,7
8,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,Daunomycin,none,3.1e-05,1,,8
8,liposome,DSPC/DSPE,0.0,0.0,none,none,,passive transport,,,,,85.0,,,89.9,,normal,i.v.,,,Daunomycin,none,3.1e-05,1,1,8
8,liposome,DSPC/DSPE-PEG2000,1.0,3.0,none,none,,passive transport,,,,,85.0,,,89.9,,normal,i.v.,,,Daunomycin,none,0.0,,0,8
8,liposome,DSPC/DSPE-PEG2000,1.0,3.0,none,antibody,OX26,receptor mediated,transferrin receptor,transferrin receptor,,,85.0,,,89.9,,normal,i.v.,3.0,,Daunomycin,none,0.00011,3.55,3.55,8
9,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,Cisplatin,none,0.0,,,9
9,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,Cisplatin,heat,0.0,,,9
9,liposome,DPPC/DSPC,0.0,0.0,none,none,,passive transport,,,,,,,,,,normal,i.v.,,,Cisplatin,none,0.0,,,9
9,thermosensitive liposome,DPPC/DSPC,0.0,0.0,none,none,,passive transport,,,,,,,,,,normal,i.v.,,,Cisplatin,heat,0.0027,,,9
10,free drug,,,,,,,,,,,,,,,,,normal,i.p.,,,SiPc,none,0.009,1,,10
10,liposome,DPPC,0.0,0.0,none,none,,passive transport,,,,,,,,,,normal,i.p.,,,SiPc,none,0.016,1.78,,10
11,liposome,DMPC/NPPE,0.0,0.0,none,none,,passive transport,,,,,106.3,0.173,-27.5,,,normal,through carotid artery,,,,none,3.2e-05,,1,11
11,liposome,DMPC/NPPE,0.0,0.0,none,glycosol,glucose,transporter mediated,hexose transporter,GLUT-1,,,105.4,0.102,-27.8,,,normal,through carotid artery,10.0,,,none,6e-06,,0.1875,11
11,liposome,DMPC/NPPE,0.0,0.0,none,glycosol,mannose,transporter mediated,hexose transporter,GLUT-1,,,113.3,0.059,-28.2,,,normal,through carotid artery,10.0,,,none,4.2e-05,,1.3125,11
11,liposome,DMPC/NPPE,0.0,0.0,none,glycosol,monosialoganglioside,transporter mediated,hexose transporter,GLUT-1,,,121.5,0.144,-15.5,,,normal,through carotid artery,10.0,,,none,0.000466,,14.5625,11
11,liposome,DMPC/NPPE,0.0,0.0,none,others,sulfatide,receptor mediated,,,,,102.8,0.119,-27.4,,,normal,through carotid artery,10.0,,,none,2.5e-05,,0.78125,11
12,liposome,PC/PG,0.0,0.0,none,none,,passive transport,,,,,,,,,,normal,i.v.,,,paclitaxel,none,0.00017,1.13333333333333,,12
12,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,paclitaxel,none,0.00015,1,,12
13,free drug,,,,,,,,,,,,,,,,,ischemic stroke/reperfusion,i.v.,,,diclofenac sodium,none,0.024,1,,13
13,liposome,PC/PS,0.0,0.0,none,none,none,passive transport,,,,,1190.0,,,,,ischemic stroke/reperfusion,i.v.,,,diclofenac sodium,none,0.019,0.792,1,13
13,liposome,PC/PE/PS,0.0,0.0,none,peptide,RGD,receptor mediated,others,αvβ1,,,1210.0,,,,,ischemic stroke/reperfusion,i.v.,10.0,,diclofenac sodium,none,0.033,1.375,1.73684210526316,13
13,liposome,PC/PS,0.0,0.0,none,none,none,passive transport,,,,,1190.0,,,,,ischemic stroke/reperfusion,i.v.,,,diclofenac sodium,magnetic field,0.14,5.833,7.36842105263158,13
13,liposome,PC/PE/PS,0.0,0.0,none,peptide,RGD,receptor mediated,others,αvβ1,,,1210.0,,,,,ischemic stroke/reperfusion,i.v.,10.0,,diclofenac sodium,magnetic field,0.22,9.167,11.5789473684211,13
13,,,,,,,,,,,,,,,,,,,,,,,,,,,13
14,liposome,PC/sulfatides,0.0,0.0,none,none,none,passive transport,,,,,45.0,,,,,normal,i.v.,,,cAMP,none,0.0005,1.429,,14
14,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,cAMP,none,0.00036,1,,14
14,,,,,,,,,,,,,,,,,,,,,,,,,,,14
15,liposome,EPC/DSPE-PEG,1.0,5.7,none,none,none,passive transport,,,,,70.0,,,,,normal,i.v.,,,none,none,0.00027,,1,15
15,liposome,EPC/DSPE-PEG,1.0,5.7,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,,,,70.0,,,,,normal,i.v.,0.94,,none,none,0.00035,,1.2962962962963,15
15,,,,,,,,,,,,,,,,,,,,,,,,,,,15
16,free drug,,,,,,,,,,,,,,,,,normal,i.p.,,,gentamicin,none,0.00019,1,,16
16,liposome,PC,0.0,0.0,none,none,none,passive transport,,,,,3170.0,,,,,normal,i.p.,,,gentamicin,none,0.00017,0.895,1,16
16,liposome,PC,0.0,0.0,none,none,none,passive transport,,,,,3170.0,,,,,normal,i.p.,,,gentamicin,none,0.00032,1.684,1.88235294117647,16
16,cationic liposome,PC,0.0,0.0,none,none,none,absorption mediated,,,,,3170.0,,,,,normal,i.p.,,,gentamicin,none,0.00026,1.368,1.52941176470588,16
16,,,,,,,,,,,,,,,,,,,,,,,,,,,16
17,liposome,DSPC/DSPE-PEG/bio-PEGDSPE,1.0,13.0,none,none,IgG2a-DSPE-PEG,passive transport,,,,,150.0,,,,,normal,i.v.,,,daunomycin,none,0.0001,0.909,1,17
17,liposome,DSPC/DSPE-PEG/bio-PEGDSPE,1.0,13.0,none,antibody,OX26-DSPE-PEG,receptor mediated,transferrin receptor,,,,150.0,,,,,normal,i.v.,9.6,,daunomycin,none,0.00018,1.636,1.8,17
17,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,daunomycin,none,0.00011,1,,17
17,,,,,,,,,,,,,,,,,,,,,,,,,,,17
18,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,"Nerve Growth
Factor",none,0.00037,1,,18
18,liposome,SPC,0.0,0.0,none,none,none,passive transport,,,,,73.37,,,,,normal,i.v.,,,"Nerve Growth
Factor",none,0.0004,1.081,1,18
18,liposome,SPC/DSPE-PEG,1.0,6.0,none,cell-penetrating peptide,Cereport (RMP-7)-PEGDSPE,absorption mediated,,,,,69.57,,,,,normal,i.v.,1.0,,"Nerve Growth
Factor",none,0.0035,9.46,8.75,18
18,,,,,,,,,,,,,,,,,,,,,,,,,,,18
19,free drug,,,,,,,,,,,,,,,,,ischemic stroke/reperfusion,i.v.,,,ferulic acid,none,1e-05,1,,19
19,liposome,,,,none,none,none,passive transport,,,,,,,,,,ischemic stroke/reperfusion,i.v.,,,ferulic acid,,3.1e-05,3.1,1,19
19,liposome,,,,none,peptide,RGD,receptor mediated,others,αvβ1,,,,,,,,ischemic stroke/reperfusion,i.v.,,,ferulic acid,,0.00011,11,3.54838709677419,19
19,,,,,none,,,,,,,,,,,,,,,,,,,,,,19
20,free drug,,,,,,,,,,,,,,,,,ischemic stroke/reperfusion,i.v.,,,ferulic acid,none,0.0002,1,,20
20,liposome,SPC,0.0,0.0,none,none,none,passive transport,,,,,152.0,,,,,ischemic stroke/reperfusion,i.v.,,,ferulic acid,none,0.0026,13,1,20
20,liposome,SPC,0.0,0.0,none,peptide,RGD,receptor mediated,others,αvβ1,,,155.0,,,,,ischemic stroke/reperfusion,i.v.,3.8,,ferulic acid,none,0.0077,38.5,2.96153846153846,20
20,,,,,,,,,,,,,,,,,,,,,,,,,,,20
23,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,5-fluorouracil,none,0.022,1,,23
23,liposome,PC,0.0,0.0,none,none,none,passive transport,,,,,750.0,,,37.6,,normal,i.v.,,,5-fluorouracil,none,0.25,11.364,1,23
23,liposome,PC,0.0,0.0,none,non-antibody protein,transferrin-stearylamine,receptor mediated,transferrin receptor,,,,1010.0,,,29.16,,normal,i.v.,10.0,,5-fluorouracil,none,0.47,21.636,1.88,23
23,,,,,,,,,,,,,,,,,,,,,,,,,,,23
25,liposome,POPC/POPG,1.0,3.0,none,,none,passive transport,,,,,134.0,,-4.06,95.0,,normal,i.v.,,,"[32P]oligodeoxy
nucleotides
(ODN)",none,0.00011,,1,25
25,liposome,POPC/POPG,1.0,3.0,none,antibody,Anti-transferrin receptor antibody (8D3)-PEGDSPE,receptor mediated,transferrin receptor,,,,142.0,,-0.71,95.0,,normal,i.v.,0.3,,"[32P]oligodeoxy
nucleotides
(ODN)",none,0.0015,,13.6363636363636,25
25,,,,,,,,,,,,,,,,,,,,,,,,,,,25
27,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,doxorubicin,none,0.011,1,,27
27,liposome,,0.0,0.0,none,none,none,passive transport,,,,,273.9,0.21,-22.8,95.32,0.095,normal,i.v.,,,doxorubicin,none,0.024,2.182,1,27
27,cationic liposome,,0.0,0.0,none,none,none,absorption mediated,,,,,184.23,0.29,-23.83,90.99,0.092,normal,i.v.,,,doxorubicin,none,0.048,4.364,2,27
27,cationic liposome,,0.0,0.0,none,non-antibody protein,Lactoferrin,receptor mediated,transferrin receptor,,,,208.97,0.13,-5.37,90.99,0.089,normal,i.v.,,,doxorubicin,none,0.067,6.091,2.79166666666667,27
27,,,,,,,,,,,,,,,,,,,,,,,,,,,27
28,free drug,,,,,,,,,,,,,,,,,brain tumor,i.v.,,,doxorubicin,none,0.00018,1,,28
28,liposome,EPC,1.0,3.8,none,none,none,passive transport,,,,,121.66,,,99.47,,brain tumor,i.v.,,,doxorubicin,none,0.0003,1.666666667,1,28
28,thermosensitive liposome,DPPC/MSPC,1.0,4.2,none,none,none,passive transport,,,,,123.51,,,99.65,,brain tumor,i.v.,,,doxorubicin,heat,0.0011,6.111111111,3.66666666666667,28
28,,,,,,,,,,,,,,,,,,,,,,,,,,,28
29,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,indinavir,none,0.0065,1,,29
29,emulsion,,0.0,0.0,none,none,none,passive transport,,,,,251.1,0.06,-33.9,,,normal,i.v.,,,indinavir,none,0.0089,1.369230769,1,29
29,emulsion,,1.0,,none,none,none,passive transport,,,,,241.3,0.21,-42.3,,,normal,i.v.,,,indinavir,none,0.019,2.923076923,2.13483146097778,29
29,emulsion,,1.0,,none,none,none,passive transport,,,,,271.9,0.17,-28.6,,,normal,i.v.,,,indinavir,none,0.016,2.461538462,1.79775280962883,29
29,,,,,,,,,,,,,,,,,,,,,,,,,,,29
30,others,,,,none,,,,,,,,,,,,,normal,,,,,none,,,,30
30,others,,,,none,,,,,,,,,,,,,normal,,,,,none,,,,30
30,,,,,,,,,,,,,,,,,,,,,,,,,,,30
31,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,Doxorubicin,none,0.00049,1,,31
31,liposome,SPC,0.0,0.0,none,none,none,passive transport,,,,,166.1,0.184,-8.2,96.65,,normal,i.v.,,,Doxorubicin,none,0.00043,0.87755102,1,31
31,liposome,SPC,1.0,8.0,none,none,none,passive transport,,,,,100.2,0.161,-6.43,97.96,,normal,i.v.,,,Doxorubicin,none,0.0018,3.673469388,4.18604651162791,31
31,liposome,SPC,1.0,3.0,none,peptide,细胞穿透肽TAT (AYGRKKRRQRRR),absorption mediated,,,,,105.1,0.179,22.87,93.53,,normal,i.v.,5.0,,Doxorubicin,none,0.0031,6.326530612,7.20930232558139,31
31,,,,,,,,,,,,,,,,,,,,,,,,,,,31
32,liposome,SPC,0.0,0.0,none,none,none,passive transport,,,,,143.4,0.262,-22.66,,,normal,i.v.,,,coumarin-6,none,0.003,,1,32
32,cationic liposome,DOPE,0.0,0.0,none,none,none,absorption mediated,,,,,89.1,0.276,36.37,,,normal,i.v.,,,coumarin-6,none,0.0032,,1.06666666666667,32
32,liposome,SPC/PEG-CH,1.0,8.0,none,none,none,passive transport,,,,,119.7,0.21,-8.0,,,normal,i.v.,,,coumarin-6,none,0.0038,,1.26666666666667,32
32,liposome,SPC/PEG-CH,1.0,3.0,none,peptide,细胞穿透肽TAT (AYGRKKRRQRRR)-PEG-CH,absorption mediated,,,,,147.6,0.207,3.87,,,normal,i.v.,5.0,,coumarin-6,none,0.0061,,2.03333333333333,32
32,,,,,,,,,,,,,,,,,,,,,,,,,,,32
32,,,,,,,,,,,,,,,,,,,,,,,,,,,32
32,,,,,,,,,,,,,,,,,,,,,,,,,,,32
35,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,daunorubicin,none,0.0049,1,,35
35,liposome,EPC,1.0,5.0,none,none,none,passive transport,,,,,115.87,0.25,-8.28,,,normal,i.v.,,,daunorubicin,none,0.0064,1.306122449,1,35
35,liposome,EPC,1.0,4.5,none,glycosol,DSPEPEG-mannose,transporter mediated,hexose transporter,,,,127.27,0.13,-7.46,,,normal,i.v.,0.5,,daunorubicin,none,0.0036,0.734693878,0.5625,35
35,liposome,EPC,1.0,4.5,none,non-antibody protein,DSPEPEG-transferrin,receptor mediated,transferrin receptor,,,,121.33,0.23,-11.38,,,normal,i.v.,0.5,,daunorubicin,none,0.008,1.632653061,1.25,35
35,liposome,EPC,1.0,4.0,none,glycosol,DSPEPEG-mannose/DSPEPEG-transferrin,transporter mediated,hexose transporter,,,,122.8,0.17,-6.37,,,normal,i.v.,1.0,,daunorubicin,none,0.0174,3.551020408,2.71875,35
35,,,,,,,,,,,,,,,,,,,,,,,,,,,35
36,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,doxorubicin,none,0.00059,1,,36
36,others,,0.0,0.0,none,others,N-palmitoylglucosamine (NPG),receptor mediated,others,,,,161.0,0.3,,57.8,,normal,i.v.,9.1,,doxorubicin,none,0.0017,2.881355932,,36
36,,,,,,,,,,,,,,,,,,,,,,,,,,,36
37,,,,,,,,,,,,,,,,,,normal,,,,,,,,,37
37,,,,,,,,,,,,,,,,,,,,,,,,,,,37
38,,,,,,,,,,,,,,,,,,normal,,,,,,,,,38
38,,,,,,,,,,,,,,,,,,,,,,,,,,,38
39,liposome,DSPC,0.0,0.0,none,none,none,passive transport,,,,,,,,0.974,,ischemic stroke/reperfusion,i.v.,,,isopropylidene shikimic acid,none,0.0026,,,39
39,,,,,,,,,,,,,,,,,,,,,,,,,,,39
40,liposome,PC,0.0,0.0,none,none,none,passive transport,,,,,158.0,0.172,-60.4,,,normal,i.v.,,,coumarin-6,none,0.00042,,1,40
40,liposome,PC,1.0,34.0,none,glycosol, glucose-PEG200-CH,transporter mediated,hexose transporter,,,,86.3,0.27,-33.3,,,normal,i.v.,34.0,,coumarin-6,none,0.0006,,1.42857142857143,40
40,liposome,PC,1.0,34.0,none,glycosol, glucose-PEG400-CH,transporter mediated,hexose transporter,,,,81.5,0.252,-36.2,,,normal,i.v.,34.0,,coumarin-6,none,0.00072,,1.71428571428571,40
40,liposome,PC,1.0,34.0,none,glycosol, glucose-PEG1000-CH,transporter mediated,hexose transporter,,,,100.0,0.265,-24.9,,,normal,i.v.,34.0,,coumarin-6,none,0.0017,,4.04761904761905,40
40,liposome,PC,1.0,34.0,none,glycosol, glucose-PEG2000-CH,transporter mediated,hexose transporter,,,,104.9,0.289,-20.9,,,normal,i.v.,34.0,,coumarin-6,none,0.00096,,2.28571428571429,40
40,,,,,,,,,,,,,,,,,,,,,,,,,,,40
41,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,paclitaxel,none,0.002,1,,41
41,cationic liposome,,,,none,none,none,absorption mediated,,,,,,,,,,normal,i.v.,,,paclitaxel,magnetic field,0.01,5,,41
41,cationic liposome,,,,none,none,none,absorption mediated,,,,,,,,,,normal,through carotid artery,,,paclitaxel,magnetic field,0.0097,4.85,,41
41,,,,,,,,,,,,,,,,,,,,,,,,,,,41
41,,,,,,,,,,,,,,,,,,,,,,,,,,,41
43,,,,,none,,,,,,,,,,,,,normal,,,,,,,,,43
43,,,,,none,,,,,,,,,,,,,,,,,,,,,,43
43,solid lipid nanoparticles,,,,,,,passive transport,,,,,,,,,,,,,,,,,,,43
44,free drug,,,0.0,none,none,none,,,,,,,,,,,normal,i.v.,,,camptothecin,none,0.00045,1,,44
44,solid lipid nanoparticles,soybean lecithin,0.0,,none,none,none,passive transport,,,,,196.8,,-45.2,99.6,0.048,normal,i.v.,,,camptothecin,none,0.0041,9.111111111,,44
44,,,,,,,,,,,,,,,,,,,,,,,,,,,44
45,free drug,,,0.0,none,none,none,,,,,,,,,,,normal,i.v.,,,doxorubicin,none,0.0,,,45
45,solid lipid nanoparticles,hexadecylphosphate,0.0,0.0,none,none,none,passive transport,,,,,80.0,0.18,,,0.05,normal,i.v.,,,doxorubicin,none,0.0,,,45
45,solid lipid nanoparticles,hexadecylphosphate,1.0,0.15,none,none,none,passive transport,,,,,90.0,0.19,,,0.05,normal,i.v.,,,doxorubicin,none,0.00012,,,45
45,,,,,,,,,,,,,,,,,,,,,,,,,,,45
46,polymer-based nanoparticles,PHDCA,0.0,0.0,none,none,none,passive transport,,,,,137.0,,,,,normal,i.v.,,,none,none,4.5e-05,,1,46
46,polymer-based nanoparticles,PHDCA,1.0,25.0,none,none,none,passive transport,,,,,164.0,,,,,normal,i.v.,,,none,none,7.7e-05,,1.71111111111111,46
46,,,,,,,,,,,,,,,,,,,,,,,,,,,46
47,solid lipid nanoparticles,,,,none,,,,,,,,,,,,,normal,,,,,none,,,,47
47,,,,,,,,,,,,,,,,,,,,,,,,,,,47
47,,,,,,,,,,,,,,,,,,,,,,,,,,,47
52,polymer-based nanoparticles,butyl-2-cyano[3-14C]acrylate,0.0,,none,none,none,passive transport,none,,,,201.5,,-14.0,,,brain tumor,,,,,none,0.0049,,1,52
52,polymer-based nanoparticles,butyl-2-cyano[3-14C]acrylate,0.0,,polysorbate 80,none,none,absorption mediated,none,,,,214.0,,-10.0,,,brain tumor,,,,,none,0.0076,,1.55,52
52,,,,,,,,,,,,,,,,,,,,,,,,,,,52
53,free drug,,,,,,,,,,,,,,,,,,,,,methotrexate,none,5e-05,1,,53
53,solid lipid nanoparticles,n-Butyl-cyanoacrylate,0.0,,polysorbate 80,none,none,absorption mediated,none,,,,70.0,,,,,normal,i.v.,,,methotrexate,none,0.00023,4.6,,53
53,solid lipid nanoparticles,n-Butyl-cyanoacrylate,0.0,,polysorbate 80,none,none,absorption mediated,none,,,,170.0,,,,,normal,i.v.,,,methotrexate,none,0.00021,4.2,,53
53,solid lipid nanoparticles,n-Butyl-cyanoacrylate,0.0,,polysorbate 80,none,none,absorption mediated,none,,,,220.0,,,,,normal,i.v.,,,methotrexate,none,0.0002,4,,53
53,solid lipid nanoparticles,n-Butyl-cyanoacrylate,0.0,,polysorbate 80,none,none,absorption mediated,none,,,,345.0,,,,,normal,i.v.,,,methotrexate,none,0.00018,2.3,,53
53,solid lipid nanoparticles,n-Butyl-cyanoacrylate,0.0,,none,none,none,passive transport,none,,,,170.0,,,,,normal,i.v.,,,methotrexate,none,0.0,0,,53
53,,,,,,,,,,,,,,,,,,,,,,,,,,,53
54,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,,,0.0145,1,,54
54,solid lipid nanoparticles,,0.0,,none,none,none,passive transport,none,,,,108.2,0.024,15.4,,,normal,i.v.,0.0,,querquinine dihydrochloride,none,0.032,2.21,1,54
54,solid lipid nanoparticles,,0.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,,,,126.4,0.068,3.7,,,normal,i.v.,,,quinine dihydrochloride,none,0.15,10.34,4.68,54
54,,,,,,,,,,,,,,,,,,,,,,,,,,,54
55,albumin nanoparticles,Mal-PEG-PLA/MPEG-PLA,0.0,,cationic bovine srum albumin,none,,absorption mediated,none,,,,100.3,,16.78,,,normal,i.v.,,,coumarin-6,none,0.0005,,,55
55,albumin nanoparticles,Mal-PEG-PLA/MPEG-PLA,0.0,,cationic bovine srum albumin,none,,absorption mediated,none,,,,97.4,,16.23,,,normal,i.v.,,,coumarin-6,none,0.00042,,,55
55,albumin nanoparticles,Mal-PEG-PLA/MPEG-PLA,0.0,,cationic bovine srum albumin,none,,absorption mediated,none,,,,104.1,,13.98,,,normal,i.v.,,,coumarin-6,none,0.00072,,,55
55,albumin nanoparticles,Mal-PEG-PLA/MPEG-PLA,0.0,,cationic bovine srum albumin,none,,absorption mediated,none,,,,105.4,,12.19,,,normal,i.v.,,,coumarin-6,none,0.0011,,,55
55,albumin nanoparticles,Mal-PEG-PLA/MPEG-PLA,0.0,,cationic bovine srum albumin,none,,absorption mediated,none,,,,105.9,,9.78,,,normal,i.v.,,,coumarin-6,none,0.0009,,,55
55,,,,,,,,,,,,,,,,,,,,,,,,,,,55
56,others,,0.0,,none,none,,,none,,,,,,,,,normal,i.v.,,,,,0.00053,,1,56
56,others,,0.0,,none,peptide,OX26,receptor mediated,transferrin receptor,,,,,,,,,normal,i.v.,35.0,,,none,0.00057,,1.2,56
56,others,,0.0,,none,antibody,OX26 and Fab',receptor mediated,transferrin receptor,,,,,,,,,normal,i.v.,35.0,,,none,0.0008,,1.6,56
56,,,,,,,,,,,,,,,,,,,,,,,,,,,56
57,magnetic liposome,iron oxide,0.0,,none,none,,passive transport,none,,,,193.0,0.262,-0.22,,,normal,i.v.,,,,none,0.0064,,,57
57,,,,,,,,,,,,,,,,,,,,,,,,,,,57
58,free drug,,,,,,,,,,,,,,,,,normal,s.c.,,,didanosine,none,0.023,1,,58
58,others,type A gelatin,0.0,,none,none,,,none,,,,120.0,18.6,,71.2,,normal,s.c.,,,didanosine,none,0.12,5.22,1,58
58,others,type A gelatin,0.0,,none,glycosol,,receptor mediated,hexose transporter,,,,140.0,7.2,,79.5,,normal,s.c.,,,didanosine,none,0.25,10.87,2.08,58
58,,,,,,,,,,,,,,,,,,,,,,,,,,,58
59,polymer-based nanoparticles,PEG-PCL,0.0,,none,none,,,none,,,,95.0,,20.4,,0.007,normal,i.v.,0.0,,coumarin-6,none,0.0009,,1,59
59,polymer-based nanoparticles,PEG-PCL,0.0,,none,antibody,OX 26,receptor mediated,transferrin receptor,,,,102.0,,-20.6,,0.007,normal,i.v.,5.0,,coumarin-6,none,0.00126,,1.44,59
59,polymer-based nanoparticles,PEG-PCL,0.0,,none,antibody,OX 26,receptor mediated,transferrin receptor,,,,102.0,,-20.6,,0.007,normal,i.v.,34.0,,coumarin-6,none,0.00252,,2.78,59
59,polymer-based nanoparticles,PEG-PCL,0.0,,none,antibody,OX 26,receptor mediated,transferrin receptor,,,,102.0,,-20.6,,0.007,normal,i.v.,92.0,,coumarin-6,none,0.00126,,1.44,59
59,,,,,,,,,,,,,,,,,,,,,,,,,,,59
60,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,ritonavir,none,4e-05,1,,60
60,polymer-based nanoparticles,PLA,0.0,,none,cell-penetrating peptide,TAT-peptide :Tyr-Gly-Arg- (Lys)2-(Arg)2-Gln-(Arg)3,absorption mediated,none,,,,340.0,0.14,2.4,89.7,0.183,normal,i.v.,,2012.0,ritonavir,none,0.032,800,6.67,60
60,polymer-based nanoparticles,PLA,0.0,,none,none,,,none,,,,300.0,0.1,-19.3,89.7,0.183,normal,i.v.,,0.0,ritonavir,none,0.0048,120,1,60
60,,,,,,,,,,,,,,,,,,,,,,,,,,,60
61,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,Tacrine,none,0.00044,1,,61
61,polymer-based nanoparticles,poly(n-butylcyanoacrylate),0.0,,none,none,,passive transport,none,,,,35.58,,-41.8,,17.18,normal,i.v.,,,Tacrine,none,0.00056,1.27,1,61
61,polymer-based nanoparticles,poly(n-butylcyanoacrylate),0.0,,polysorbate 80,none,,absorption mediated,none,,,,35.58,,-39.5,,14.68,normal,i.v.,,,Tacrine,none,0.0018,4.09,3.22,61
61,,,,,,,,,,,,,,,,,,,,,,,,,,,61
63,polymer-based nanoparticles,PEG-PLA,0.0,,none,none,,passive transport,none,,,,100.0,,,0.71,,normal,i.v.,,,coumarin-6,none,0.0038,,,63
63,polymer-based nanoparticles,PEG-PLA,0.0,,none,non-antibody protein,Lactoferrin,receptor mediated,transferrin receptor,,,,131.0,,,0.69,,normal,i.v.,55.0,,coumarin-6,none,0.019,,,63
63,,,,,,,,,,,,,,,,,,,,,,,,,,,63
64,free drug,,,,,,,,,,,,,,,,,,,,,,,0.087,1,,64
64,polymer-based nanoparticles,poly(butyl cyanoacrylate),0.0,,none,none,,passive transport,none,,,,,,,97.0,,Parkinson's disease,i.v.,,,nerve growth factor,none,0.093,1.07,1,64
64,polymer-based nanoparticles,poly(butyl cyanoacrylate),0.0,,polysorbate 80,none,,absorption mediated,none,,,,,,,96.0,,Parkinson's disease,i.v.,,,nerve growth factor,none,0.23,2.64,1.49,64
64,,,,,,,,,,,,,,,,,,,,,,,,,,,64
65,polymer-based nanoparticles,PLGA,0.0,,none,none,,,none,,,,167.0,0.17,-18.2,,,normal,i.v.,,,rhodamine,none,0.0,,,65
65,polymer-based nanoparticles,PLGA,0.0,,none,glycosol,Gly-L- Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser(O-β-D-glucose)- CONH2.,transporter mediated,none,,,,189.0,0.19,-15.5,,,normal,i.v.,,,rhodamine,none,0.28,,,65
65,,,,,,,,,,,,,,,,,,,,,,,,,,,65
67,free drug,,,,,,,passive transport,,,,,,,,,,,,,,,,1.9e-06,1,,67
67,solid lipid nanoparticles,compritol 888 ATO,0.0,,none,none,,passive transport,none,,,,88.0,0.27,-45.8,,0.145,normal,i.v.,,,,none,4.1e-05,21.58,,67
67,,,,,,,,,,,,,,,,,,,,,,,,,,,67
68,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,none,,,,239.1,0.265,-22.8,47.69,,normal,i.v.,,,coumarin-6,none,0.0025,,1,68
68,polymer-based nanoparticles,poly(lactide)-D-a- Tocopheryl polyethylene glycol succinate,0.0,,none,none,,passive transport,none,,,,228.6,0.265,-30.0,58.83,,normal,i.v.,,,coumarin-6,none,0.0049,,1.96,68
68,polymer-based nanoparticles,poly(lactide)-D-a- Tocopheryl polyethylene glycol succinate,0.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,,,,245.8,0.271,-29.0,60.84,,normal,i.v.,,,coumarin-6,none,0.011,,2.24,68
68,,,,,,,,,,,,,,,,,,,,,,,,,,,68
69,gold nanoparticles,Au,0.0,,none,none,,passive transport,none,,,,12.0,,,,,normal,i.v.,,0.0,,none,4.8e-05,,,69
69,gold nanoparticles,Au,0.0,,none,peptide,CLPFFD,receptor mediated,others,,,,,,,,,normal,i.v.,,400.0,,none,0.00024,,,69
69,,,,,,,,,,,,,,,,,,,,,,,,,,,69
70,others,CdSe/ZnS-core/shell-typed quantom dots,0.0,,none,none,,passive transport,none,,,,13.5,,,,,normal,i.p.,,,,none,0.001,,,70
70,,,,,,,,,,,,,,,,,,,,,,,,,,,70
71,free drug,,,,,,,passive transport,,,,,,,,,,,,,,,,0.0,,,71
71,others,Fe,0.0,,oleic acid,none,,absorption mediated,none,,,,236.0,0.34,-13.62,57.0,,normal,i.v.,,,,magnetic field,0.0186,,,71
71,,,,,,,,,,,,,,,,,,,,,,,,,,,71
72,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,none,,,,187.0,0.12,-21.7,,,normal,i.v.,,,rhodamine-123,none,0.0014,,1,72
72,polymer-based nanoparticles,PLGA,0.0,,none,peptide,NH2-Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser(O-β-D-Glucose)-COOH,receptor mediated,others,,,,169.0,0.09,-18.9,,,normal,i.v.,,,rhodamine-123,none,0.21,,150,72
72,polymer-based nanoparticles,PLGA,0.0,,none,peptide,NH2-Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser(O-β-D-Glucose)-COOH,receptor mediated,others,,,,197.0,0.22,-15.9,,,normal,i.v.,,,rhodamine-123,none,0.087,,62.1,72
72,,,,,,,,,,,,,,,,,,,,,,,,,,,72
73,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,none,,,,224.2,-22.4,0.25,44.6,,normal,i.v.,,,coumarin-6,none,0.0067,,,73
73,polymer-based nanoparticles,PLGA- PEG-PLGA,0.0,,none,none,,passive transport,none,,,,196.5,-0.4,0.21,60.3,,normal,i.v.,,,coumarin-6,none,0.009,,1,73
73,polymer-based nanoparticles,PLGA- PEG-PLGA,0.0,,polysorbate 80,none,,receptor mediated,low density lipoprotein-related receptor,,,,190.3,1.2,0.25,62.4,,normal,i.v.,,,coumarin-6,none,0.012,,1.3,73
73,polymer-based nanoparticles,PLGA- PEG-PLGA,0.0,,poloxamer 188,none,,receptor mediated,low density lipoprotein-related receptor,,,,200.5,2.4,0.28,57.8,,normal,i.v.,,,coumarin-6,none,0.016,,1.78,73
73,,,,,,,,,,,,,,,,,,,,,,,,,,,73
73,,,,,,,,,,,,,,,,,,,,,,,,,,,73
75,polymer-based nanoparticles,PEG-PLGA,0.0,,none,none,,passive transport,none,,,,,,,,,Parkinson's disease,i.v.,,,coumarin-6,none,0.015,,1,75
75,polymer-based nanoparticles,PEG-PLGA,0.0,,none,non-antibody protein,Lactoferrin,receptor mediated,transferrin receptor,,,,,,,,,Parkinson's disease,i.v.,42.0,,coumarin-6,none,0.036,,2.4,75
75,,,,,,,,,,,,,,,,,,,,,,,,,,,75
76,free drug,,,,tween 80,,,passive transport,,,,,,,,,,,,,,coumarin-6,none,0.0088,1,,76
76,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,none,,,,177.0,0.088,-31.1,60.23,,normal,i.v.,,,coumarin-6,none,0.032,3.64,1,76
76,polymer-based nanoparticles,PLGA,0.0,,polysorbate 80,none,,receptor mediated,low density lipoprotein-related receptor,,,,194.0,0.096,-23.1,34.21,,normal,i.v.,,,coumarin-6,none,0.045,5.11,1.4,76
76,polymer-based nanoparticles,PLGA,0.0,,poloxamer 407,none,,receptor mediated,low density lipoprotein-related receptor,,,,188.0,0.102,-20.6,38.45,,normal,i.v.,,,coumarin-6,none,0.064,7.27,2,76
76,polymer-based nanoparticles,PLGA,0.0,,poloxamer 188,none,,receptor mediated,low density lipoprotein-related receptor,,,,196.0,0.14,-20.2,37.74,,normal,i.v.,,,coumarin-6,none,0.066,7.5,2.06,76
76,,,,,,,,,,,,,,,,,,,,,,,,,,,76
77,polymer-based nanoparticles,PEG-poly(caprolactone),0.0,,none,none,,passive transport,none,,,,98.2,,-20.3,,,normal,i.v.,,,coumarin-6,none,0.00076,,1,77
77,polymer-based nanoparticles,PEG-poly(caprolactone),1.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,,,,101.4,,-19.9,,,normal,i.v.,,,coumarin-6,none,0.0017,,2.13,77
77,,,,,,,,,,,,,,,,,,,,,,,,,,,77
78,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,none,,,,294.2,,6.1,,,normal,i.v.,,,coumarin-6,none,0.025,,,78
78,polymer-based nanoparticles,PLGA,0.0,,polysorbate 80,none,,receptor mediated,low density lipoprotein-related receptor,,,,214.9,,-20.3,,,normal,i.v.,,,coumarin-6,none,0.014,,,78
78,polymer-based nanoparticles,PLGA,0.0,,poloxamer 188,none,,receptor mediated,low density lipoprotein-related receptor,,,,232.4,,-19.0,,,normal,i.v.,,,coumarin-6,none,0.015,,,78
78,,,,,,,,,,,,,,,,,,,,,,,,,,,78
79,free drug,,,,,,,passive transport,,,,,,,,,,,,,,,,0.00035,1,,79
79,polymer-based nanoparticles,PBCA,0.0,,none,none,,passive transport,none,,,,135.8,0.191,-24.8,44.23,,normal,i.v.,,,Temozolomide,none,0.00051,1.48,1,79
79,polymer-based nanoparticles,PBCA,0.0,,polysorbate 80,none,,receptor mediated,low density lipoprotein-related receptor,,,,,,,,,normal,i.v.,,,Temozolomide,none,0.00079,2.26,1.53,79
79,,,,,,,,,,,,,,,,,,,,,,,,,,,79
80,polymer-based nanoparticles,PLGA,0.0,,none,none,,,none,,,,182.0,0.14,-17.5,,0.0033,normal,i.v.,,,rhodamine 123,none,0.0081,,1,80
80,polymer-based nanoparticles,PLGA,0.0,,none,peptide,H2N-Gly- l-Phe-d-Thr-Gly-l-Phe-l-Leu-l-Ser[O-b-d- glucose]-CONH2; g7,receptor mediated,others,,,,179.0,0.14,-18.2,,0.0036,normal,i.v.,,,rhodamine 123,none,0.16,,19.75,80
80,,,,,,,,,,,,,,,,,,,,,,,,,,,80
81,polymer-based nanoparticles,PBCA,0.0,,none,none,,passive transport,none,,,,189.7,0.236,-19.0,62.6,0.205,normal,i.v.,,,doxorubicin,none,0.0014,,1,81
81,polymer-based nanoparticles,PBCA,0.0,,polysorbate 80,none,,receptor mediated,low density lipoprotein-related receptor,,,,,,,,,normal,i.v.,,,doxorubicin,none,0.0036,,2.57,81
81,,,,,,,,,,,,,,,,,,,,,,,,,,,81
82,free drug,,,,,,,passive transport,none,,,,,,,,,normal,i.v.,,,paclitaxel,none,0.0086,1,,82
82,polymer-based nanoparticles,Fe,0.0,,none,none,,passive transport,none,,,,202.0,0.14,23.0,95.0,,normal,i.v.,,,paclitaxel,none,0.035,4.07,,82
82,,,,,,,,,,,,,,,,,,,,,,,,,,,82
83,gold nanoparticles,Au,,,none,none,,passive transport,,,,,20.0,,,,,normal,i.v.,,,,ultrasound,0.0004,,2,83
83,gold nanoparticles,Au,,,none,none,,passive transport,,,,,,,,,,normal,i.v.,,,,none,0.0002,,1,83
83,,,,,,,,,,,,,,,,,,,,,,,,,,,83
84,free drug,,,,,,,,,,,,,,,,,,,,,rhodamine 123,none,0.001,1,,84
84,polymer-based nanoparticles,PLGA-PEG-PLA,1.0,,oleic acid,none,,receptor mediated,other,,,,266.0,0.13,,,,normal,i.v.,,,rhodamine 123,none,0.0025,2.5,1,84
84,polymer-based nanoparticles,PLGA-PEG-PLA,1.0,,oleic acid,none,,receptor mediated,other,,,,266.0,0.13,,,,normal,i.v.,,,rhodamine 123,magnet,0.01,11,4.4,84
84,,,,,,,,,,,,,,,,,,,,,,,,,,,84
85,free drug,,,,,,,passive transport,,,,,,,,,,,,,,,,0.00024,1,,85
85,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,none,,,,141.0,0.053,-10.32,73.57,,normal,i.v.,,,,none,0.00034,1.42,1,85
85,polymer-based nanoparticles,PLGA,0.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,,,,157.5,0.091,-11.6,71.49,,normal,i.v.,,,,none,0.0011,4.58,3.23,85
85,polymer-based nanoparticles,PLGA,0.0,,none,non-antibody protein,lactoferrin,receptor mediated,transferrin receptor,,,,158.8,0.111,-9.35,71.16,,normal,i.v.,,,,none,0.002,8.3,5.85,85
85,,,,,,,,,,,,,,,,,,,,,,,,,,,85
86,free drug,,,,,,,passive transport,,,,,,,,,,normal,i.v.,,,,,0.00015,,,86
86,others,chitosan Quaternary ammonium palmitoyl glycol chitosan,0.0,,none,none,,passive transport,none,,,,,,,,,normal,i.v.,,,,none,0.00024,,,86
86,others,chitosan Quaternary ammonium palmitoyl glycol chitosan,0.0,,none,none,,passive transport,none,,,,,,,,,normal,p.o.,,,,none,0.00017,,,86
86,others,chitosan Quaternary ammonium palmitoyl glycol chitosan,0.0,,none,none,,passive transport,none,,,,,,,,,normal,p.o.,,,,none,0.00027,,,86
86,others,chitosan Quaternary ammonium palmitoyl glycol chitosan,0.0,,none,none,,passive transport,none,,,,,,,,,normal,p.o.,,,,none,0.00027,,,86
86,,,,,,,,,,,,,,,,,,,,,,,,,,,86
87,free drug,,,,,,,passive transport,,,,,,,,,,,,,,tamshinone IIA,,3.6e-05,1,,87
87,albumin nanoparticles,methoxy PEG-PLA/maleimide PEG-PLA,1.0,,cationic bovine srum albumin,none,,passive transport,none,,,,118.0,,-19.6,83.2,0.0569,ischemic stroke/reperfusion,i.v.,,,tamshinone IIA,none,0.00011,3.6,,87
87,,,,,,,,,,,,,,,,,,,,,,,,,,,87
88,free drug,,,,,,,passive transport,none,,,,,,,,,,,,,noscapine,none,0.00025,1,,88
88,solid lipid nanoparticles,stearoyl chloride,0.0,,none,none,,passive transport,none,,,,61.3,0.06,-35.1,80.4,,normal,i.v.,,,noscapine,none,0.11,440,1,88
88,solid lipid nanoparticles,stearoyl chloride/mPEG,1.0,,none,none,,passive transport,none,,,,80.5,0.08,-42.4,83.6,,normal,i.v.,,,noscapine,none,0.15,600,1.36,88
88,,,,,,,,,,,,,,,,,,,,,,,,,,,88
89,gold nanoparticles,Au,0.0,,none,none,,passive transport,,,,,13.0,,,,,normal,i.v.,,,,none,0.0001,,,89
89,gold nanoparticles,Au,0.0,,none,peptide,CLPFFD,receptor mediated,others,,,,,,,,,normal,i.v.,,,,none,0.00048,,,89
89,gold nanoparticles,Au,0.0,,none,peptide,THRPPMWSPVWP,receptor mediated,transferrin receptor,,,,,,,,,normal,i.v.,,125.0,,none,0.00017,,,89
89,gold nanoparticles,Au,0.0,,none,peptide,THRPPMWSPVWP,receptor mediated,transferrin receptor,,,,,,,,,normal,i.v.,,125.0,,none,0.00062,,,89
89,,,,,,,,,,,,,,,,,,,,,,,,,,,89
90,free drug,,,,,,,passive transport,,,,,,,,,,,,,,,none,0.0007,1,,90
90,solid lipid nanoparticles,Glyceryl monostearate Glycerol/poly- oxyethylene glycol palmitostearat,0.0,,none,none,,passive transport,none,,,,125.3,0.12,-18.3,67.68,0.078,normal,i.v.,,,,none,0.0049,7,1,90
90,solid lipid nanoparticles,Glyceryl monostearate Glycerol/poly- oxyethylene glycol palmitostearat,0.0,,none,others,borneol,receptor mediated,,,,,113.7,0.12,-17.7,65.55,0.0679,normal,i.v.,,,,none,0.0024,3.43,0.489795918367347,90
90,solid lipid nanoparticles,Glyceryl monostearate Glycerol/poly- oxyethylene glycol palmitostearat,0.0,,none,others,borneol,receptor mediated,,,,,123.0,0.11,-16.5,66.87,0.0618,normal,i.v.,,,,none,0.0052,7.43,1.06122448979592,90
90,solid lipid nanoparticles,Glyceryl monostearate Glycerol/poly- oxyethylene glycol palmitostearat,0.0,,none,others,borneol,receptor mediated,,,,,142.5,0.13,-15.1,62.76,0.0497,normal,i.v.,,,,none,0.0027,3.86,0.551020408163265,90
90,,,,,,,,,,,,,,,,,,,,,,,,,,,90
93,free drug,,,,,,,passive transport,,,,,,,,,,normal,i.v.,,,docetaxel,none,3.2e-05,1,,93
93,solid lipid nanoparticles,monostearin/vitamine E/soya lecithin,0.0,,none,none,,passive transport,none,,,,76.4,0.17,-28.6,99.8,,normal,i.v.,,,docetaxel,none,0.00021,6.56,1,93
93,solid lipid nanoparticles,monostearin/vitamine E/soya lecithin,0.0,,none,others,β-Hydroxybutyric acid,receptor mediated,monocarboxylic acid transporter,,,,90.1,0.22,-33.8,95.8,,normal,i.v.,,,docetaxel,none,0.00063,19.69,3,93
93,,,,,,,,,,,,,,,,,,,,,,,,,,,93
94,free drug,,,,,,,passive transport,,,,,,,,,,normal,i.v.,,,,none,0.0003,1,,94
94,solid lipid nanoparticles,glyceryl monostearate/vitamine E/SPC,0.0,,none,none,,passive transport,none,,,,80.8,0.19,-32.1,,,normal,i.v.,,,,none,0.00048,16,1,94
94,solid lipid nanoparticles,glyceryl monostearate/vitamine E/SPC,0.0,,none,folic acid,folic acid,receptor mediated,folic acid receptor,,,,95.9,0.21,-24.4,,,normal,i.v.,,,,none,0.0011,36.67,2.29,94
94,,,,,,,,,,,,,,,,,,,,,,,,,,,94
95,polymer-based nanoparticles,PEG-PLA,1.0,,none,none,,passive transport,,,,,90.0,,-20.5,,,normal,i.v.,,,coumarin-6,none,7e-05,,1,95
95,polymer-based nanoparticles,PEG-PLA,1.0,,none,cell-penetrating peptide,RQIKIWFQNRRMKWKK,absorption mediated,none,,,,100.0,,-4.42,,,normal,i.v.,,,coumarin-6,none,0.00018,,2.57142857142857,95
95,polymer-based nanoparticles,PEG-PLA,1.0,,none,peptide,CVSRRRRRRGGRRRR,receptor mediated,none,,,,,,,,,normal,i.v.,,,coumarin-6,none,0.0001,,1.42857142857143,95
95,,,,,,,,,,,,,,,,,,,,,,,,,,,95
95,,,,,,,,,,,,,,,,,,,,,,,,,,,95
3,free drug,,,0.0,,,,passive transport,,,0.0,,,,,,,normal,i.v.,,,coumarin 6,none,0.0045,1,,3
3,polymer-based nanoparticles,PLGA,0.0,0.0,none,none,,passive transport,,,0.0,,224.2,0.25,-22.4,44.6,,normal,i.v.,,,coumarin 6,none,0.0164,3.64444444444444,,3
3,polymer-based nanoparticles,PLGA-PEG-PLGA,1.0,0.0,none,none,,passive transport,,,0.0,,196.5,0.21,-0.4,60.3,,normal,i.v.,,,coumarin 6,none,0.0221,4.91111111111111,,3
3,polymer-based nanoparticles,PLGA-PEG-PLGA,1.0,0.0,polysorbate 80,none,,receptor mediated,low density lipoprotein-related receptor,,0.0,,190.3,0.25,1.2,62.4,,normal,i.v.,,,coumarin 6,none,0.0306,6.8,,3
3,polymer-based nanoparticles,PLGA-PEG-PLGA,1.0,0.0,poloxamer 188,none,,receptor mediated,low density lipoprotein-related receptor,,0.0,,200.5,0.28,2.4,57.8,,normal,i.v.,,,coumarin 6,none,0.0389,8.64444444444444,,3
6,free drug,,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,docetaxel,none,0.00162,1,,6
6,solid lipid nanoparticles,SPC,0.0,0.0,none,none,,passive transport,,,0.0,,76.4,0.18,-31.7,99.8,0.15,normal,i.v.,,,docetaxel,none,0.00432,2.5,,6
6,solid lipid nanoparticles,SPC,0.0,0.0,none,none,,passive transport,,,1.0,ketoconazole,80.8,0.19,-32.1,95.4,0.1,normal,i.v.,,,docetaxel,none,0.00576,3.5,,6
6,solid lipid nanoparticles,SPC,0.0,0.0,none,folic acid,,receptor mediated,,folic acid receptor,1.0,ketoconazole,95.9,0.21,-24.4,97.7,0.1,normal,i.v.,,,docetaxel,none,0.01404,9,,6
20,free drug,,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,docetaxel,none,0.001,1,,20
20,solid lipid nanoparticles,SPC,0.0,0.0,none,none,,receptor mediated,monocarboxylic acid transporter,monocarboxylic acid transporter ,0.0,,76.4,0.17,-28.6,99.8,,normal,i.v.,,,docetaxel,none,0.002718,3,,20
20,,,,,,,,,,,,,,,,,,,,,,,,,,,20
20,,,,,,,,,,,,,,,,,,,,,,,,,,,20
31,polymer-based nanoparticles,cationic bovine serum albumin-PEG-PLA,1.0,,none,none,,absorption mediated,,,0.0,,118.0,,,83.2,5.69,ischemic stroke,i.v.,0.0,,tanshinone IIA,none,0.0077,2.6551724137931,1.395,31
31,free drug,,,,,,,passive transport,,,0.0,,,,,,,ischemic stroke,i.v.,,,tanshinone IIA,none,0.0029,1,,31
32,solid lipid nanoparticles,Stearic acid,0.0,0.0,none,none,,passive transport,,,0.0,,61.3,0.06,-35.1,80.4,,brain tumor,i.v.,0.0,,noscapine,none,0.5636,1.34,1.31174591909155,32
32,solid lipid nanoparticles,Stearic acid,1.0,,none,none,,passive transport,,,0.0,,80.5,0.08,-42.4,83.6,,brain tumor,i.v.,0.0,,noscapine,none,0.7393,1.76,,32
32,free drug,,,,,,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,noscapine,none,0.4198,1,,32
44,solid lipid nanoparticles,Glycerol/polyoxyethylene glycol palmitostearate/Cremophor ELP;polyoxyethylene caster oil,0.0,0.0,none,others,borneol,receptor mediated,,,0.0,,125.3,0.12,-18.3,67.68,7.8,normal,i.v.,,,ganciclovir,none,0.000204,,,44
44,solid lipid nanoparticles,Glycerol/polyoxyethylene glycol palmitostearate/Cremophor ELP;polyoxyethylene caster oil,0.0,0.0,none,others,borneol,receptor mediated,,,0.0,,113.7,0.12,-17.7,65.55,6.79,normal,i.v.,,,ganciclovir,none,0.000238,,,44
44,solid lipid nanoparticles,Glycerol/polyoxyethylene glycol palmitostearate/Cremophor ELP;polyoxyethylene caster oil,0.0,0.0,none,others,borneol,receptor mediated,,,0.0,,123.0,0.11,-16.5,66.87,6.18,normal,i.v.,,,ganciclovir,none,0.00049,,,44
44,solid lipid nanoparticles,Glycerol/polyoxyethylene glycol palmitostearate/Cremophor ELP;polyoxyethylene caster oil,0.0,0.0,none,others,borneol,,,,0.0,,142.5,0.13,-15.1,62.76,4.97,normal,i.v.,,,ganciclovir,none,0.005271,,,44
53,polymer-based nanoparticles,Chitosan,0.0,0.0,none,none,,passive transport,,,0.0,,157.4,0.31,52.54,,,Parkinson's disease,i.n.,,,Bromocriptine,none,,,,53
53,free drug,Bromocriptine,,0.0,none,none,,passive transport,,,0.0,,,,,,,Parkinson's disease,i.n.,,,Bromocriptine,none,0.0009,1,,53
53,polymer-based nanoparticles,Bromocriptine/Chitosan,0.0,0.0,none,none,,passive transport,,,0.0,,161.3,0.44,40.32,,,Parkinson's disease,i.n.,,,Bromocriptine,none,0.0015,1.66666666666667,,53
67,polymer-based nanoparticles,chitosan,0.0,,tween 80,none,,passive transport,,,0.0,,,0.4,30.0,,,normal,i.v.,,,Minocycline hydrochloride,none,0.062,8.85,6.13,67
81,free drug,,,,none,none,,passive transport,others,,0.0,none,,,,,,brain tumor,i.v.,,,doxorubicin,none,0.0001,1,,81
81,liposome,PC,1.0,0.0,none,none,,passive transport,,,,,,,,,,brain tumor,i.v.,,,doxorubicin,,0.0026,26,,81
121,free drug,,,0.0,none,none,,,,,0.0,,,,,,,Alzheimer's disease,i.v.,,,donepezil ,,0.000126,1,,121
121,liposome,PLGA,0.0,0.0,tween 80,none,,,,,1.0,tween 80,89.67,0.013,-36.0,88.65,18.04,Alzheimer's disease,i.v.,,,donepezil ,none,0.0011,8.42,,121
141,polymer-based nanoparticles,"Me-PEG-PCL/Chitosan
",1.0,0.0,none,others,Lactoferrin,receptor mediated,transferrin receptor,Lactoferrin recepter,0.0,,88.4,0.22,23.56,47.61,0.62,Alzheimer's disease,i.n.,46.0,,coumarin-6,none,0.000384,2.18,,141
141,,,,,,,,,,,,,,,,,,,,,,,,,,,141
141,,,,,,,,,,,,,,,,,,,,,,,,,,,141
141,,,,,,,,,,,,,,,,,,,,,,,,,,,141
150,polymer-based nanoparticles,PAMAM(G5),0.0,0.0,none,none,H-Thr(Bzl)-Phe-Phe-Tyr(Br-Z)-Gly-Gly-Ser(Bzl)-Arg(Tos)-Gly-Lys(Cl-Z)-Arg(Tos)-Asn(Xan)-Asn(Xan)-Phe-Lys(Cl-Z)-Thr(Bzl)-Glu(OcHex)-Glu(OcHex)-Tyr(Br-Z)-Cys(PMeBzl)-OH,receptor mediated,low density lipoprotein-related receptor,Lactoferrin recepter,0.0,,7.2,0.314,6.1,,,normal,i.v.,1.2,,,none,0.00023,1.92,,150
150,polymer-based nanoparticles,PAMAM(G5),0.0,0.0,none,none,H-Thr(Bzl)-Phe-Phe-Tyr(Br-Z)-Gly-Gly-Ser(Bzl)-Arg(Tos)-Gly-Lys(Cl-Z)-Arg(Tos)-Asn(Xan)-Asn(Xan)-Phe-Lys(Cl-Z)-Thr(Bzl)-Glu(OcHex)-Glu(OcHex)-Tyr(Br-Z)-Cys(PMeBzl)-OH,receptor mediated,low density lipoprotein-related receptor,Lactoferrin recepter,0.0,,7.4,0.345,6.4,,,normal,i.v.,4.2,,,none,0.00043,3.58,,150
150,polymer-based nanoparticles,PAMAM(G5),0.0,0.0,none,none,H-Thr(Bzl)-Phe-Phe-Tyr(Br-Z)-Gly-Gly-Ser(Bzl)-Arg(Tos)-Gly-Lys(Cl-Z)-Arg(Tos)-Asn(Xan)-Asn(Xan)-Phe-Lys(Cl-Z)-Thr(Bzl)-Glu(OcHex)-Glu(OcHex)-Tyr(Br-Z)-Cys(PMeBzl)-OH,receptor mediated,low density lipoprotein-related receptor,Lactoferrin recepter,0.0,,7.9,0.269,7.2,,,normal,i.v.,8.1,,,none,0.00017,1.42,,150
152,polymer-based nanoparticles,chitosan,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,,i.v.,,,pcDNA3.1-gC,none,,1.52,,152
152,liposome,PC/Cholesterol,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,,i.v.,,,pcDNA3.1-gC,none,,1.17,,152
164,solid lipid nanoparticles,SPC,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,99m Tc,none,,1.86,,164
164,solid lipid nanoparticles,SPC,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,p.o.,,,99m Tc,none,,2.424,,164
167,magnetic liposome,octadecyl quaternized carboxymethyl chitosan/Fe3O4/cholesterol,0.0,0.0,none,none,,passive transport,,,0.0,,,,,0.95,0.096,normal,i.v.,,,paclitaxel,magnetic field,0.0062,4.59,,167
186,polymer-based nanoparticles,PEG-PLGA,1.0,,none,peptide,aprotinin,receptor mediated,low density lipoprotein-related receptor,low density lipoprotein receptor-related protein,0.0,,91.0,0.052,-25.9,,,normal,i.v.,,,huperzine A,none,0.0052,1.16,,186
186,polymer-based nanoparticles,PEG-PLGA,1.0,,none,others,others,passive transport,,,1.0,borneol,91.0,0.052,-25.9,,,normal,p.o.,,,huperzine A,none,0.0063,1.37,,186
196,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,others,,0.0,,79.0,,,59.5,0.2857,normal,iv.,,,Zidovudine,none,,2.59,,196
196,polymer-based nanoparticles,PLGA,0.0,,tween 80,none,,receptor madiated,others,,0.0,,83.0,,-20.0,57.27,0.2857,normal,iv.,,,Zidovudine,none,,6.99,,196
204,polymer-based nanoparticles,ethylene oxide/propylene oxide,0.0,,none,,,passive transport,,,,,97.7,0.16,,72.92,1.78,others,i.n.,,,olanzapine,none,0.0044,1.51,,204
204,polymer-based nanoparticles,ethylene oxide/propylene oxide,0.0,,none,,,passive transport,,,,,97.7,0.16,,72.92,1.78,others,i.n.,,,olanzapine,none,0.0027,0.93,,204
204,free drug,,,,,,,passive transport,,,,,,,,,,others,i.v.,,,olanzapine,none,0.0029,1,,204
204,,,,,,,,,,,,,,,,,,,,,,,,,,,204
204,,,,,,,,,,,,,,,,,,,,,,,,,,,204
207,polymer-based nanoparticles,PNIPAM (Polymeric N-isopropyl acryl amide: vinyl Pyrilidone: acrylic acid),0.0,,none,,,passive transport,,,,,,,,,,ischemic stroke,i.n.,,,curcumin (Cur),none,0.002025,0.43,,207
207,free drug,,,,,,,passive transport,,,,,,,,,,ischemic stroke,i.n.,,,curcumin (Cur),none,0.004725,1,,207
207,polymer-based nanoparticles,PNIPAM (Polymeric N-isopropyl acryl amide: vinyl Pyrilidone: acrylic acid),0.0,,none,,,passive transport,,,,,,,,,,ischemic stroke,i.n.,,,demethoxycurcumin (DMC),none,0.001985,0.41,,207
207,free drug,,,,,,,passive transport,,,,,,,,,,ischemic stroke,i.n.,,,demethoxycurcumin (DMC),none,0.00483,1,,207
207,polymer-based nanoparticles,PNIPAM (Polymeric N-isopropyl acryl amide: vinyl Pyrilidone: acrylic acid),0.0,,none,,,passive transport,,,,,,,,,,ischemic stroke,i.n.,,, bisdemethoxycurcumin (BDMC),none,0.0015,0.32,,207
207,free drug,,,,,,,passive transport,,,,,,,,,,ischemic stroke,i.n.,,, bisdemethoxycurcumin (BDMC),none,0.00476,1,,207
207,,,,,,,,,,,,,,,,,,,,,,,,,,,207
207,,,,,,,,,,,,,,,,,,,,,,,,,,,207
246,polymer-based nanoparticles,PEI,0.0,0.0,none,none,,passive transport,,,0.0,,46.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,,246
246,polymer-based nanoparticles,PEI,1.0,25.0,none,none,,passive transport,,,0.0,,46.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,1.7974025974026,246
246,polymer-based nanoparticles,PEI,1.0,50.0,none,none,,passive transport,,,0.0,,46.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,0.24987012987013,246
246,polymer-based nanoparticles,PEI,0.0,0.0,none,none,,passive transport,,,0.0,,85.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,,246
246,polymer-based nanoparticles,PEI,1.0,25.0,none,none,,passive transport,,,0.0,,85.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,0.21382322713258,246
246,polymer-based nanoparticles,PEI,1.0,50.0,none,none,,passive transport,,,0.0,,85.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,0.7327852004111,246
246,polymer-based nanoparticles,PEI,0.0,0.0,none,none,,passive transport,,,0.0,,210.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,,246
246,polymer-based nanoparticles,PEI,1.0,25.0,none,none,,passive transport,,,0.0,,210.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,0.70725294650952,246
246,polymer-based nanoparticles,PEI,1.0,50.0,none,none,,passive transport,,,0.0,,210.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,0.707651858567543,246
246,polymer-based nanoparticles,PEI,0.0,0.0,none,none,,passive transport,,,0.0,,46.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,,246
246,polymer-based nanoparticles,PEI,0.0,0.0,none,non-antibody protein,Apolipopretoein E,receptor mediated,low density lipoprotein-related receptor,apolipoprotein E receptor ,0.0,,46.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,1.07615505090055,246
246,polymer-based nanoparticles,PEI,0.0,0.0,none,non-antibody protein,Apolipopretoein E,receptor mediated,low density lipoprotein-related receptor,apolipoprotein E receptor ,0.0,,46.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,1.82850430696946,246
246,polymer-based nanoparticles,PEI,0.0,0.0,none,non-antibody protein,Apolipopretoein E,receptor mediated,low density lipoprotein-related receptor,apolipoprotein E receptor ,0.0,,46.0,0.22,3.7,,,normal,i.v.,,,3H labeled,none,,,2.46671887235709,246
249,polymer-based nanoparticles,Dendrigraft poly-l-lysine ,0.0,0.0,none,none,,,,,0.0,,141.6,,3.19,,,normal,i.v.,,,ethidium monoazide bromide ,none,,,,249
249,polymer-based nanoparticles,Dendrigraft poly-l-lysine ,0.0,0.0,none,peptide,T7 序列： CHAIYPRH,receptor mediated,transferrin receptor,transferrin receptor,0.0,,141.6,,3.19,,,normal,i.v.,,,ethidium monoazide bromide ,none,,,2.77341597796143,249
257,free drug,cyclobenzaprine HCl solution ,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,99mTC labeled,none,,1,,257
257,free drug,cyclobenzaprine HCl solution ,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,p.o.,,,99mTC labeled,none,,1,,257
257,free drug,cyclobenzaprine HCl solution ,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,99mTC labeled,none,,1,,257
257,polymer-based nanoparticles,low molecular weight chitosan,0.0,0.0,none,none,,passive transport,,,0.0,,472.6,,24.7,,,normal,i.n.,,,99mTC labeled,none,,5.25905118601748,,257
257,polymer-based nanoparticles,medium molecular weight chitosan,0.0,0.0,none,none,,passive transport,,,0.0,,628.2,,25.1,,,normal,i.n.,,,99mTC labeled,none,,5.19662921348315,,257
257,polymer-based nanoparticles,low molecular weight thiolated chitosan,0.0,0.0,none,none,,passive transport,,,0.0,,272.1,,20.9,,,normal,i.n.,,,99mTC labeled,none,,11.8149188514357,,257
257,polymer-based nanoparticles,medium molecular weight thiolated chitosan,0.0,0.0,none,none,,passive transport,,,0.0,,282.9,,27.7,,,normal,i.n.,,,99mTC labeled,none,,9.8876404494382,,257
264,polymer-based nanoparticles,mPEG-PEI,1.0,,none,non-antibody protein,Arg-Gly-Asp (RGD),receptor mediated,others,αvβ3 integrin,0.0,,233.1,0.153,2.9,,,brain tumor,i.v.,,,DNA coding EGFP,none,,,,264
264,polymer-based nanoparticles,mPEG-ss-PEI,1.0,,none,non-antibody protein,Arg-Gly-Asp (RGD),receptor mediated,others,αvβ3 integrin,0.0,,205.5,0.14,4.6,,,brain tumor,i.v.,,,DNA coding EGFP,none,,,,264
266,free drug,docetaxel,,0.0,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,docetaxel,none,,1,,266
266,others,nano-diamonds,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,docetaxel,none,,1.09433962324922,,266
267,free drug,,,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,coumarin-6,none,0.0025,1,,267
267,solid lipid nanoparticles,cetyl palmitate,0.0,0.0,none,none,,passive transport,,,0.0,,99.7,0.19,-13.0,,,normal,i.v.,,,coumarin-6,none,0.01,4.2,,267
273,free drug,,,0.0,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,coumarin-6,none,0.00025,1,,273
273,polymer-based nanoparticles,PLGA/chitosan,0.0,0.0,none,none,,passive transport,,,0.0,,177.0,,19.6,,,brain tumor,i.v.,,,coumarin-6,none,0.00084,3.391304348,,273
273,,,,,,,,,,,,,,,,,,,,,,,,,,,273
273,,,,,,,,,,,,,,,,,,,,,,,,,,,273
281,free drug,,,,,,,passive transport,,,,,,,,,,normal,i.v.,,,camptothecin,none,0.005,1,,281
281,solid lipid nanoparticles,ceytl palmitate,0.0,0.0,polysorbate 60,none,,receptor mediated,low density lipoprotein-related receptor,apolipoprotein E receptor,0.0,,131.2,0.13,-21.4,,,normal,i.v.,,,camptothecin,none,0.019,3.8,,281
281,solid lipid nanoparticles,ceytl palmitate,0.0,0.0,polysorbate 80,none,,receptor mediated,low density lipoprotein-related receptor,apolipoprotein E receptor,0.0,,159.7,0.16,-24.0,,,normal,i.v.,,,camptothecin,none,0.035,7,,281
282,free drug,,,,,,,passive transport,,,,,,,,,,brain tumor,i.n.,,,Alexa-dextran,none,0.081,1,,282
282,polymer-based nanoparticles,polyethylene glycolepolycaprolactone,1.0,0.0,none,cell-penetrating peptide,Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg- Gly (Tat),absorption mediated,others,,0.0,,65.0,,,,,brain tumor,i.v.,,,Alexa-dextran,none,0.025,0.308641975308642,,282
282,polymer-based nanoparticles,polyethylene glycolepolycaprolactone,1.0,0.0,none,cell-penetrating peptide,Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg- Gly (Tat),absorption mediated,others,,0.0,,65.0,,,,,brain tumor,i.n.,,,Alexa-dextran,none,0.374,4.61728395061728,4.62,282
292,polymer-based nanoparticles,PEG-PLA,1.0,0.0,none,none,,passive transport,,,0.0,,123.8,,-9.7,,,brain tumor,i.v.,,,DiR,none,,,,292
292,polymer-based nanoparticles,PEG-PLA,1.0,0.0,none,peptide,Peptide-22 (NH2-C6-[cMPRLRGC]c-NH2),receptor mediated,low density lipoprotein-related receptor,low density lipoprotein-related receptor,0.0,,137.4,,-30.1,,,brain tumor,i.v.,,,DiR,none,,,1.33,292
292,polymer-based nanoparticles,PEG-PLA,1.0,0.0,none,none,,passive transport,,,0.0,,123.8,,-9.7,,,brain tumor,i.v.,,,DiR,none,,,,292
292,polymer-based nanoparticles,PEG-PLA,1.0,0.0,none,peptide,Peptide-22 (NH2-C6-[cMPRLRGC]c-NH2),receptor mediated,low density lipoprotein-related receptor,low density lipoprotein-related receptor,0.0,,137.4,,-30.1,,,brain tumor,i.v.,,,DiR,none,,,2.46,292
304,free drug,,,,,,,passive transport,,,,,,,,,,brain tumor,i.v.,,,oxaliplatin,none,,1,,304
304,polymer-based nanoparticles,RGD-PEG-b-poly(l-glutamic acid),1.0,100.0,none,peptide,Arg-Gly-Asp (RGD),receptor mediated,others,αvβ3 integrin,0.0,,29.0,0.099,,,,brain tumor,i.v.,20.0,,oxaliplatin,none,,2.97335701598579,1.395,304
304,polymer-based nanoparticles,RAD-PEG-b-poly(l-glutamic acid),1.0,100.0,none,peptide,Arg-Ala-Asp (RAD),passive transport,,,0.0,,31.0,0.101,,,,brain tumor,i.v.,20.0,,oxaliplatin,none,,2.13143872113677,,304
307,polymer-based nanoparticles,PEG-PLA,1.0,100.0,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,153.3,,-9.6,78.2,4.35,brain tumor,i.p.,20.0,,"Resveratrol (trans-3,40,5-trihydroxystilbene)",none,3.79728e-06,2.11693872089912,1.81,307
307,polymer-based nanoparticles,PEG-PLA,1.0,100.0,none,none,,passive transport,,,0.0,,145.7,,-10.0,80.5,4.4,brain tumor,i.p.,0.0,,"Resveratrol (trans-3,40,5-trihydroxystilbene)",none,2.09424e-06,1.16751404870217,,307
307,free drug,,,,,,,passive transport,,,0.0,,12107.5,,,,,brain tumor,i.p.,,,"Resveratrol (trans-3,40,5-trihydroxystilbene)",none,1.79376e-06,1,,307
310,polymer-based nanoparticles,fluorescent carboxylated-polystyrene,0.0,0.0,none,none,,passive transport,,,0.0,,24.0,0.33,41.86,,,normal,i.v.,0.0,,none,none,0.004335,,,310
310,polymer-based nanoparticles,fluorescent carboxylated-polystyrene,0.0,0.0,none,none,,passive transport,,,0.0,,56.0,0.13,42.68,,,normal,i.v.,0.0,,none,none,0.006375,,,310
310,polymer-based nanoparticles,fluorescent carboxylated-polystyrene,0.0,0.0,none,none,,passive transport,,,0.0,,110.0,0.03,43.06,,,normal,i.v.,0.0,,none,none,0.006583,,,310
310,polymer-based nanoparticles,fluorescent carboxylated-polystyrene,0.0,0.0,none,none,,passive transport,,,0.0,,200.0,0.03,44.54,,,normal,i.v.,0.0,,none,none,0.0113,,,310
310,polymer-based nanoparticles,fluorescent carboxylated-polystyrene,0.0,0.0,none,none,,passive transport,,,0.0,,490.0,0.13,44.4,,,normal,i.v.,0.0,,none,none,0.01245,,,310
320,free drug,,,0.0,,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,Methotrexate,none,,1,,320
320,others,chitosan nanogels,0.0,0.0,none,none,,absorption mediated,,,0.0,,118.54,21.92,0.34,61.82,0.5368,normal,i.v.,0.0,,Methotrexate,none,,2.12526278906797,,320
320,others,chitosan nanogels,0.0,0.0,polysorbate 80,none,,receptor mediated,low density lipoprotein-related receptor,,0.0,,106.68,16.13,0.36,,,normal,i.v.,0.0,,Methotrexate,none,,2.14681149264191,1.01013931250515,320
327,polymer-based nanoparticles,Lactoferrin (Lf)/β-cyclodextrin (β-CD)/heterobifunctional polyethyleneglycol (PEG) linker NHS-PEG-MAL/IR-775chloride(IR),0.0,0.0,none,peptide,Lactoferrin (Lf),receptor mediated,others,lactoferrin receptor,0.0,,,,,,,normal,i.v.,,,IR-775chloride(IR),none,,7.6009,,327
327,polymer-based nanoparticles,β-cyclodextrin (β-CD)/heterobifunctional polyethyleneglycol (PEG) linker NHS-PEG-MAL/ IR-775chloride(IR),0.0,0.0,none,peptide,Transferrin (Tf),receptor mediated,transferrin receptor,transferrin receptor,0.0,,,,,,,normal,i.v.,,,IR-775chloride(IR),none,,3.9337,,327
327,polymer-based nanoparticles,heterobifunctional polyethyleneglycol (PEG) linker NHS-PEG-MAL/IR-775chloride(IR),0.0,0.0,none,peptide,Transferrin (Tf),receptor mediated,transferrin receptor,transferrin receptor,0.0,,,,,,,normal,i.v.,,,IR-775chloride(IR),none,,2.5334,,327
327,polymer-based nanoparticles,β-cyclodextrin (β-CD)/heterobifunctional polyethyleneglycol (PEG) linker NHS-PEG-MAL/IR-775chloride(IR),0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,IR-775chloride(IR),none,,1.9337,,327
327,free drug,IR-775chloride(IR),,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,IR-775chloride(IR),none,,1,,327
335,polymer-based nanoparticles,Ethylenediamine-core poly-(amidoamine) [PAMAM] hydroxyl-terminated generation-4 dendrimer [G4(OH)64],0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,none,none,,,,335
335,polymer-based nanoparticles,Ethylenediamine-core poly-(amidoamine) [PAMAM] hydroxyl-terminated generation-4 dendrimer [G4(OH)64],0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,others,i.v.,,,none,none,,,,335
337,gold nanoparticles,Au,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,siRNA targeting the oncoprotein Bcl2Like12 (Bcl2L12),none,,,,337
337,gold nanoparticles,Au,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,siRNA targeting the oncoprotein Bcl2Like12 (Bcl2L12),none,,,,337
337,gold nanoparticles,Au,0.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,siRNA targeting the oncoprotein Bcl2Like12 (Bcl2L12),none,,,,337
345,polymer-based nanoparticles,DSPE-PEG2000,0.0,,none,peptide,CREKA,receptor mediated,others,"肿瘤区域内沉积的纤维蛋白
",0.0,,8.2,,-12.6,,,brain tumor,i.v.,,,cy7,none,,,7.64,345
345,polymer-based nanoparticles,DSPE-PEG2001,0.0,,none,none,,passive transport,,,,,7.6,,-27.4,,,brain tumor,i.v.,,,cy8,none,,,,345
351,liposome,DOPE/DOTAP/cholesterol,1.0,,none,cell-penetrating peptide,CPPs-TAT,absorption mediated,,,0.0,,183.0,0.319,13.16,68.38,,normal,i.v.,,,Doxorubicin,none,0.029,4.2,,351
351,liposome,DOPE/DOTAP/cholesterol,1.0,,none,cell-penetrating peptide,Penetratin,absorption mediated,,,0.0,,186.82,0.201,15.28,65.81,,normal,i.v.,,,Doxorubicin,none,0.037,5.36,,351
351,liposome,DOPE/DOTAP/cholesterol,1.0,,none,cell-penetrating peptide,Mastoparan,absorption mediated,,,0.0,,188.3,0.212,11.28,66.73,,normal,i.v.,,,Doxorubicin,none,0.0228,3.3,,351
355,others,,0.0,,none,antibody,血小板-内皮细胞黏附分子抗体,receptor mediated,others,血小板-内皮细胞黏附分子,0.0,,130.0,,28.0,,,normal,颈动脉注射,63.67,,Doxorubicin,none,1.6e-05,,,355
368,free drug,,,,,,,passive transport,,,,,,,,,,,i.v.,,,"Basic
fibroblast growth factor",none,0.00306,1,,368
368,free drug,,,,,,,passive transport,,,,,,,,,,,i.n.,,,"Basic
fibroblast growth factor",none,0.00423,1,,368
368,polymer-based nanoparticles,PEG-PLGA,0.0,10.0,none,,,passive transport,,,0.0,,104.8,,-33.87,94.48,0.06,normal,i.n.,,,"Basic
fibroblast growth factor",none,0.004464,1.05531914893617,,368
368,polymer-based nanoparticles,PEG-PLGA,0.0,10.0,none,peptide,"Solanum
tuberosum lectin",receptor mediated,others,,0.0,,118.7,,-31.18,69.21,0.05,normal,i.n.,,,"Solanum
tuberosum lectin-Basic
fibroblast growth factor",none,0.005004,1.18297872340426,1.1,368
377,free drug,,,,none,,,passive transport,,,,,,,,,,normal,i.v.,,,docetaxel,none,0.0006,1,,377
377,liposome,SPC,0.0,,none,,,passive transport,,,,,121.6,0.219,-64.1,93.54,0.076,normal,i.v.,,,docetaxel,none,0.0011,1.70857142857143,,377
377,liposome,SPC,0.0,,none,glycosol,Glucose,receptor mediated,transferrin receptor,glucose transporter-1,0.0,,118.3,0.264,-44.8,84.79,0.076,normal,i.v.,,,docetaxel,none,0.00213,4.05714285714286,2.37,377
377,liposome,SPC,0.0,,none,glycosol,L- disulfide system- glucose,receptor mediated,transferrin receptor,glucose transporter-1,0.0,,133.4,0.245,-37.6,82.83,0.076,normal,i.v.,,,docetaxel,none,0.00225,4.28571428571429,2.51,377
378,polymer-based nanoparticles,GD-DTPA-chitosan,0.0,,none,antibody,IgG4.1,passive transport,low density lipoprotein-related receptor,amyloid beta (Aβ) 40 and 42 proteins,0.0,,145.0,,7.7,,3e-05,Alzheimer's disease,i.v.,,,Curcumin,none,,,,378
378,polymer-based nanoparticles,GD-DTPA-chitosan,0.0,,none,antibody,IgG4.1,passive transport,low density lipoprotein-related receptor,amyloid beta (Aβ) 40 and 42 proteins,0.0,,145.0,,7.7,,3e-05,Alzheimer's disease,i.v.,,,Curcumin,none,,,,378
380,,,,,,,,passive transport,,,,,,,,,,,,,,curcumin,none,0.1789,,,380
380,polymer-based nanoparticles,PLGA,0.0,,none,,,passive transport,,,0.0,,200.0,,-19.0,77.0,,normal,i.v.,,,curcumin,none,0.4867,2.72,,380
380,free drug,,,,,,,passive transport,,,,,,,,,,others,i.v.,,,Breviscapine,none,7e-06,1,,380
380,,,,,,,,,,,,,,,,,,,,,,,,,,,380
380,,,,,,,,,,,,,,,,,,,,,,,,,,,380
490,gold nanoparticles,,0.0,,none,peptide,chlorotoxin ,receptor mediated,others,,,,44.2,,-16.2,,,brain tumor,i.v.,,,,magnetic field,,,,490
491,polymer-based nanoparticles,PEG-PLGA,1.0,,none,non-antibody protein,lactoferrin,receptor mediated,others,TfR,,,120.0,,-4.0,21.78,0.78,Alzheimer's disease,i.v.,,101.0,S14G-humanin,none,0.0266,2.1,,491
494,solid lipid nanoparticles,glycerol monostearate,0.0,,tween 80,none,,absorption mediated,,,,,149.0,,-38.27,61.9,,others,i.n.,,,        rosmarinic acid,none,0.0379,,,494
495,liposome,Medium chain triglyceride,0.0,,none,none,,passive transport,,,,,123.4,,-34.4,97.18,19.54,others,i.n.,,,artemether,none,0.027,,,495
503,polymer-based nanoparticles,PEG-PLA,1.0,0.0,none,none,,passive transport,,,0.0,,123.1,,-9.5,,,brain tumor,i.v.,,,DiR,none,,,,503
503,polymer-based nanoparticles,PEG-PLA,1.0,0.0,none,non-antibody protein,EGFP-EGF1 (a protein derived from factor VII ),receptor mediated,others,,0.0,,133.3,,-18.9,,,brain tumor,i.v.,,,DiR,none,,,1.08239700374532,503
503,polymer-based nanoparticles,PEG-PLA,1.0,0.0,none,none,,passive transport,,,0.0,,123.1,,-9.5,,,brain tumor,i.v.,,,DiR,none,,,,503
503,polymer-based nanoparticles,PEG-PLA,1.0,0.0,none,non-antibody protein,EGFP-EGF1 (a protein derived from factor VII ),receptor mediated,others,,0.0,,133.3,,-18.9,,,brain tumor,i.v.,,,DiR,none,,,2.40898748577929,503
508,polymer-based nanoparticles,PEG-PCL,1.0,0.0,none,none,,passive transport,,,0.0,,103.1,0.187,-10.23,,,brain tumor,i.v.,,,DiR,none,,,,508
508,polymer-based nanoparticles,PEG-PCL,1.0,0.0,none,peptide,IL-13,receptor mediated,others,,0.0,,110.5,0.195,-9.98,,,brain tumor,i.v.,,,DiR,none,,,2.43877551020408,508
508,polymer-based nanoparticles,PEG-PCL,1.0,0.0,none,peptide,Arg-Gly-Asp (RGD),receptor mediated,others,,0.0,,121.3,0.204,-10.29,,,brain tumor,i.v.,,,DiR,none,,,2.94897959183673,508
508,polymer-based nanoparticles,PEG-PCL,1.0,0.0,none,peptide,Arg-Gly-Asp (RGD)+IL-13,receptor mediated,others,,0.0,,120.1,0.187,-9.67,,,brain tumor,i.v.,,,DiR,none,,,3.8469387755102,508
512,polymer-based nanoparticles,PLGA-PEG,1.0,0.0,none,none,,passive transport,,,0.0,,101.9,,,49.39,1.51,brain tumor,i.v.,,,DiR,none,,,,512
512,polymer-based nanoparticles,PLGA-PEG,1.0,0.0,none,peptide,cNGR(CNGRCG),receptor mediated,others,,0.0,,124.2,,,47.63,1.47,brain tumor,i.v.,,689.0,DiR,none,,,1.49315028298005,512
512,polymer-based nanoparticles,PLGA-PEG,1.0,0.0,none,peptide,iNGR(CRNGRGPDC),receptor mediated,others,,0.0,,127.8,,,48.05,1.43,brain tumor,i.v.,,627.0,DiR,none,,,2.6164375044101,512
515,,,,,,,,,,,0.0,,,,,,,normal,i.v.,,,Glial cell line-derived neutrophic factor(GNDF),none,,,,515
515,liposome,SPC/Cholesterol,0.0,0.0,none,none,,receptor mediated,others,,0.0,,85.65,,,33.25,,normal,i.v.,,,Glial cell line-derived neutrophic factor(GNDF),none,,,1.10474308300395,515
515,liposome,SPC/Cholesterol/DSPE-PEG,1.0,,none,peptide,RMP-7,receptor mediated,others,,0.0,,81.5,,,37.46,,normal,i.v.,,,Glial cell line-derived neutrophic factor(GNDF),none,,,7.15217391304348,515
524,polymer-based nanoparticles,MPEG-PCL/HOOC-PEG-PCL,1.0,,none,none,,passive transport,,,0.0,,106.9,0.209,-1.52,,,brain tumor,i.v.,,,DiR,none,,,,524
524,polymer-based nanoparticles,MPEG-PCL/HOOC-PEG-PCL,1.0,0.0,none,peptide,IL-13,receptor mediated,others,Lactoferrin,0.0,,104.3,0.221,-0.54,,,brain tumor,i.v.,,,DiR,none,,,1.08,524
524,polymer-based nanoparticles,MPEG-PCL/HOOC-PEG-PCL,1.0,,none,none,,passive transport,,,0.0,,106.9,0.209,-1.52,,,brain tumor,i.v.,,,DiR,none,,,,524
524,polymer-based nanoparticles,MPEG-PCL/HOOC-PEG-PCL,1.0,0.0,none,peptide,IL-13,receptor mediated,others,,0.0,,104.3,0.221,-0.54,,,brain tumor,i.v.,,,DiR,none,,,1.73,524
529,liposome,EPC/PEG2000-DSPE/NH2-PEG2000-DSPE,1.0,,none,none,,,,H-Thr(Bzl)-Phe-Phe-Tyr(Br-Z)-Gly-Gly-Ser(Bzl)-Arg(Tos)-Gly-Lys(Cl-Z)-Arg(Tos)-Asn(Xan)-Asn(Xan)-Phe-Lys(Cl-Z)-Thr(Bzl)-Glu(OcHex)-Glu(OcHex)-Tyr(Br-Z)-Cys(PMeBzl)-OH,0.0,,112.9,0.19,-10.73,86.84,,normal,i.v.,,,DiR,none,,,,529
529,liposome,EPC/PEG2000-DSPE/NH2-PEG2000-DSPE,1.0,,none,glycosol,p-aminophenyl-α-D-mannopyranoside,receptor mediated,hexose transporter,H-Thr(Bzl)-Phe-Phe-Tyr(Br-Z)-Gly-Gly-Ser(Bzl)-Arg(Tos)-Gly-Lys(Cl-Z)-Arg(Tos)-Asn(Xan)-Asn(Xan)-Phe-Lys(Cl-Z)-Thr(Bzl)-Glu(OcHex)-Glu(OcHex)-Tyr(Br-Z)-Cys(PMeBzl)-OH,0.0,,121.2,0.25,-11.77,84.22,,normal,i.v.,,,DiR,none,,,1.71,529
543,free drug,,,,none,none,,passive transport,,H-Thr(Bzl)-Phe-Phe-Tyr(Br-Z)-Gly-Gly-Ser(Bzl)-Arg(Tos)-Gly-Lys(Cl-Z)-Arg(Tos)-Asn(Xan)-Asn(Xan)-Phe-Lys(Cl-Z)-Thr(Bzl)-Glu(OcHex)-Glu(OcHex)-Tyr(Br-Z)-Cys(PMeBzl)-OH,0.0,,,,,,,normal,i.n.,,,Bromocriptine,none,,1,,543
543,polymer-based nanoparticles,chitosan,0.0,0.0,none,none,,passive transport,,,0.0,,161.3,0.44,,84.2,37.8,normal,i.v.,,,Bromocriptine,none,,3.08,,543
543,polymer-based nanoparticles,chitosan,0.0,0.0,none,none,,passive transport,,,0.0,,161.3,0.44,,84.2,37.8,normal,i.n.,,,Bromocriptine,none,,1.4,,543
548,polymer-based nanoparticles,mPEG-DSPE,1.0,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,DiR,none,,,,548
548,polymer-based nanoparticles,mPEG-DSPE,1.0,0.0,none,peptide,LAngiopep,receptor mediated,low density lipoprotein-related receptor,,0.0,,14.0,,,,,normal,i.v.,,,DiR,none,,,1.47,548
548,polymer-based nanoparticles,mPEG-DSPE,1.0,0.0,none,peptide,DAngiopep,receptor mediated,low density lipoprotein-related receptor,,0.0,,14.0,,,,,normal,i.v.,,,DiR,none,,,1.66,548
559,polymer-based nanoparticles,PAMAM,1.0,90.91,none,others,,passive transport,,,0.0,,6.713,0.133,11.6,,,normal,i.v.,,,Rhodamine,none,,,,559
559,polymer-based nanoparticles,PAMAM,1.0,94.12,none,others,adenosine-based agonists,transporter mediated,nucleoside transporter,,0.0,,7.967,0.271,6.04,,,normal,i.v.,16.7,,Rhodamine,none,,,2.58,559
567,polymer-based nanoparticles,MPEG-PCL,1.0,0.0,none,cell-penetrating peptide,(Tat)GlyArgLysLysArgArgGlnArgArg- ArgCysGly,absorption mediated,,,0.0,,64.0,,13.0,,,brain tumor,i.v.,,,"antirat Raf-1
siRNA",none,0.0148,,,567
567,polymer-based nanoparticles,MPEG-PCL,1.0,0.0,none,cell-penetrating peptide,(Tat)GlyArgLysLysArgArgGlnArgArg- ArgCysGly,absorption mediated,,,0.0,,64.0,,13.0,,,brain tumor,i.n.,,,"antirat Raf-1
siRNA",none,0.0401,,,567
569,magnetic nanoparticles,MnFe2O4,0.0,0.0,none,none,,passive transport,,,0.0,,59.0,,-37.0,,,normal,i.v.,,,,none,0.0027,,,569
577,free drug,,,,,,,passive transport,,,,,,,,,,normal,i.n.,,,rasagiline,none,,1,,577
577,polymer-based nanoparticles,Chitosan glutamate,0.0,,none,,,passive transport,,,0.0,,151.1,0.38,,96.43,,normal,i.n.,,2012.0,rasagiline,none,,1.62,,577
583,solid lipid nanoparticles,Precirol®ATO 5/Transcutol,0.0,0.0,none,none,,passive transport,,,0.0,,313.7,0.562,-18.7,70.5,,normal,i.v.,,0.0,Itraconazole,none,0.002279475,1.99988155868767,,583
583,free drug,,,0.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,Itraconazole,none,0.001139805,1,,583
597,free drug,,,0.0,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,0.038592,1,,597
597,albumin nanoparticles,serum albumin,0.0,0.0,none,none,,passive transport,,,0.0,,132.48,,-27.78,0.985,,brain tumor,i.v.,,,doxorubicin,none,0.032292,0.8368,,597
597,albumin nanoparticles,mPEG2000/serum albumin,1.0,97.0,none,none,,passive transport,,,0.0,,149.78,,-13.32,,,brain tumor,i.v.,,,doxorubicin,none,0.05274,1.3666,,597
597,albumin nanoparticles,lactoferrin/mPEG2000/serum albumin ,1.0,97.0,none,peptide,Lactofferin,receptor mediated,others,lactoferrin receptor,0.0,,154.33,,-8.28,,,brain tumor,i.v.,,,doxorubicin,none,0.070668,1.8312,,597
597,,,,,,,,,,,,,,,,,,,,,,,,,,,597
617,polymer-based nanoparticles,MePEG-PLA/Male-PEG-PLA,1.0,,none,none,,passive transport,,,0.0,,112.8,,-35.5,,,brain tumor,i.v.,,,paclitaxel,none,,,,617
617,polymer-based nanoparticles,MePEG-PLA/Male-PEG-PLA,1.0,,none,peptide,EDB-targeted peptide APT,receptor mediated,,extra domain B (EDB),0.0,,125.93,,-30.87,,,brain tumor,i.v.,,,paclitaxel,none,,,2.58,617
645,polymer-based nanoparticles,PLGA LMW-b-PEG-TPP(triphenylphosphonium),0.0,0.0,none,none,,passive transport,,,0.0,,50.1,0.154,35.7,0.466,14.0,normal,i.v.,,,Platin-M,none,0.02801232,72.4506517690875,,645
645,polymer-based nanoparticles,PLGA LMW-b-PEG-OH,0.0,0.0,none,none,,passive transport,,,0.0,,50.6,0.156,31.1,0.507,14.6,normal,i.v.,,,Platin-M,none,0.0,,,645
648,polymer-based nanoparticles,PLGA,0.0,0.0,polysorbate 80,none,,passive transport,,,0.0,,77.0,0.391,-19.0,0.5711,20.5,normal,i.v.,,,Bacoside-A,none,0.0598,9.34390139596444,,648
648,,,,,,,,,,,,,,,,,,,,,,,,,,,648
650,polymer-based nanoparticles,PEG-PAMAM,1.0,1.0,none,peptide,"internalizing Tumor-penetrating peptide, iRGD",receptor mediated,others,,0.0,,20.11,,2.45,,,brain tumor,i.v.,,,DOX,none,0.016856,6.07554786620531,0.16639684106614,650
650,polymer-based nanoparticles,PEG-PAMAM,1.0,1.0,none,peptide,"internalizing Tumor-penetrating peptide, iRGD",receptor mediated,others,,0.0,,,,,,,brain tumor,i.v.,,,DOX,none,0.015239,5.49271914648212,0.150434353405726,650
650,polymer-based nanoparticles,PEG-PAMAM,1.0,1.0,none,peptide,"penetrating peptide, RGD",receptor mediated,others,,0.0,,,,,,,brain tumor,i.v.,,,DOX,none,0.012184,4.39158016147635,0.120276406712734,650
650,polymer-based nanoparticles,PEG-PAMAM,1.0,1.0,none,peptide,"penetrating peptide, RGD",receptor mediated,others,,0.0,,,,,,,brain tumor,i.v.,,,DOX,none,0.01051,3.78820645905421,0.103751233958539,650
650,polymer-based nanoparticles,PEG-PAMAM,1.0,1.0,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,DOX,none,0.010134,3.65268166089965,0.100039486673248,650
650,free drug,PEG-PAMAM,,0.0,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,DOX,none,0.002774,0.999855824682814,0.0273840078973346,650
652,polymer-based nanoparticles,PLA,0.0,,none,none,PLA,passive transport,others,,0.0,,234.0,0.455,-29.9,60.55,,brain tumor,i.v.,,,temozolomide,none,0.2523,4.012,,652
661,others,cetyl palmitate/squalene/Myverol/PF68/SPC,1.0,0.2,none,none,,passive transport,,,,,196.38,0.23,-37.52,73.74,,others,i.v.,,,"DSM-RX78 , novel and highly selective PDE4 inhibitors",none,0.005993,0.0638,0.0036,661
661,others,cetyl palmitate/squalene/Myverol/PF68/SPC,1.0,0.2,none,none,,passive transport,,,,,194.8,0.22,-34.5,73.16,,others,i.v.,,0.0,"EFB-1, novel and highly selective PDE4 inhibitors",none,0.069685,2.2504,0.2904,661
661,others,cetyl palmitate/squalene/Myverol/PF68/SPC,0.0,0.0,none,none,,passive transport,,,,,193.85,0.22,-36.95,81.9,,others,i.v.,,400.0,"DSM-RX78 , novel and highly selective PDE4 inhibitors",none,0.165854,1.7662,,661
661,others,cetyl palmitate/squalene/Myverol/PF68/SPC,0.0,0.0,none,none,,passive transport,,,,,190.26,0.2,-36.68,90.52,,others,i.v.,,,"EFB-1, novel and highly selective PDE4 inhibitors",none,0.24,7.7504,,661
661,free drug,,,,,none,,passive transport,,,,,,,,,,others,i.v.,,,"DSM-RX78 , novel and highly selective PDE4 inhibitors",none,0.093902,1,,661
661,free drug,,,,,none,,passive transport,,,,,,,,,,others,i.v.,,,"EFB-1, novel and highly selective PDE4 inhibitors",none,0.030966,1,,661
662,solid lipid nanoparticles,palmitic acid/cholesterol/TPGS,0.0,,N-trimethyl chitosan(TMC),none,,passive transport,,,0.0,,412.0,0.26,35.7,93.13,,normal,p.o.,,,curcumin,none,,,1.43,662
662,solid lipid nanoparticles,palmitic acid/cholesterol/TPGS,0.0,,chitosan,non-antibody protein,Apolipopretoein E,receptor mediated,,,0.0,,311.9,0.24,27.08,93.12,,normal,p.o.,,,curcumin,none,,,,662
662,solid lipid nanoparticles,palmitic acid/cholesterol/TPGS,0.0,,none,non-antibody protein,Apolipopretoein E,receptor mediated,,,0.0,,138.8,0.15,-29.67,93.12,,normal,p.o.,,,curcumin,none,,,,662
670,solid lipid nanoparticles,Compritol 888 ATO,0.0,,2.5% (w/v) tween 80 and 0.5% (w/v) polyvinyl alcohol,peptide,T7 序列： CHAIYPRH,receptor mediated,,,,,248.3,0.277,-25.49,33.93,,normal,i.p.,,,resveratrol,none,0.06228,5.01,,670
670,free drug,,,,,,,passive transport,,,,,,,,,,normal,i.p.,,,resveratrol,none,0.01242,1,,670
671,albumin nanoparticles,PEG-PLA,1.0,,none,none,,passive transport,,,,,115.0,0.118,-27.6,66.0,0.61,Alzheimer's disease,i.v.,,,H102 peptide,none,0.00512,,,671
671,albumin nanoparticles,PEG-PLA,1.0,,none,peptide,TGNYKALHPHNGC,receptor mediated,others,,,,119.0,0.131,-28.22,57.68,0.53,Alzheimer's disease,i.v.,3.0,,H102 peptide,none,0.03075,6.03,,671
671,albumin nanoparticles,PEG-PLA,1.0,,none,peptide,"TGNYKALHPHNGC, QSHYRHISPAQVC",receptor mediated,others,Aβ42,,,125.0,0.127,-29.33,58.49,0.54,Alzheimer's disease,i.v.,3.0,,H102 peptide,none,0.03712,7.3,,671
681,free drug,,,,none,,,,,,,,,,,,,,,,,,,0.000487,1,,681
681,polymer-based nanoparticles,non-crosslinked PEG-pLys-pPhe,1.0,,none,none,,passive transport,,,0.0,,,,,,,others,i.v.,,,itraconazole,none,0.001125,2.31274274,,681
681,polymer-based nanoparticles,non-crosslinked PEG-pLys-pPhe,1.0,,none,none,,passive transport,,,0.0,,,,,,,others,i.v.,,,itraconazole,none,0.001511,3.10597374,,681
681,polymer-based nanoparticles,non-crosslinked PEG-pLys-pPhe,1.0,,none,others,dehydroascorbic acid,transporter mediated,hexose transporter,Glucose transporter-1,0.0,,,,,,,others,i.v.,,,itraconazole,none,0.001294,2.65896061,1.15,681
681,polymer-based nanoparticles,non-crosslinked PEG-pLys-pPhe,1.0,,none,others,dehydroascorbic acid,transporter mediated,hexose transporter,Glucose transporter-1,0.0,,,,,,,others,i.v.,,,itraconazole,none,0.00165,3.39023488,1.09,681
688,magnetic liposome,Fe3O4,0.0,,none,none,,passive transport,,,0.0,,240.0,0.092,,79.32,,,carotid artery injection,,,amphotericin B,magnetic field,0.036275,,,688
688,magnetic liposome,Fe3O4,0.0,,none,none,,passive transport,,,0.0,,240.0,0.092,,79.32,,,carotid artery injection,,,amphotericin B,none,0.015383,,,688
707,liposome,EPG/bovine serum albumin,0.0,,none,none,,passive transport,,,0.0,,113.2,0.151,-23.19,92.5,2.98,brain tumor,i.v.,,,PTX,none,,1.63,,707
707,free drug,,,,,,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,PTX,none,,1,,707
716,liposome,,1.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,0.0106668,,,716
739,liposome,DSPE/PEG1000-Maleimide,1.0,71.0,none,none,,passive transport,,,0.0,,99.7,0.157,-6.69,,,brain tumor,i.v.,,,doxorubicin,none,3e-06,1.4981,,739
739,liposome,DSPE/PEG1000-Maleimide,1.0,71.0,none,peptide,T7 (HAIYPRH) peptide,receptor mediated,transferrin receptor,transferrin receptor,0.0,,110.5,0.17,-5.62,,,brain tumor,i.v.,6.0,,doxorubicin,none,8.5e-05,41.4475,,739
739,liposome,DSPE/PEG1000-Maleimide,1.0,55.0,none,peptide,TAT (AYGRKKRRQRRR) peptide,absorption mediated,,Cell-penetrating peptides (CPPs),0.0,,101.0,0.187,-5.02,,,brain tumor,i.v.,0.7,,doxorubicin,none,7.6e-05,37.2023,,739
739,liposome,DSPE/PEG1000-Maleimide,1.0,70.0,none,peptide,"T7 (HAIYPRH) peptide, TAT (AYGRKKRRQRRR) peptide",receptor mediated,,Combo,0.0,,118.0,0.204,-6.32,,,brain tumor,i.v.,6.7,,doxorubicin,none,0.000117,56.6809,,739
739,free drug,,,0.0,none,none,,,,,0.0,,,,,,,,,,,doxorubicin,none,2e-06,1,,739
741,others,,1.0,,none,none,,,,,0.0,,2640.0,,,,8.91,normal,i.v.,,,MTX,none,0.0729,3.73,,741
748,polymer-based nanoparticles,PLGA,0.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,转铁蛋白受体,0.0,,151.0,0.107,-12.88,76.05,,normal,i.v.,,,LTG（拉莫三嗪）,none,0.0009,1.81,,748
748,polymer-based nanoparticles,PLGA,0.0,,none,non-antibody protein,lactoferrin,receptor mediated,others,乳铁蛋白受体,0.0,,150.4,0.083,-11.21,,,normal,i.v.,,,LTG（拉莫三嗪）,none,0.001,2.05,,748
748,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,133.9,0.048,-12.07,78.28,,normal,i.v.,,,LTG（拉莫三嗪）,none,0.0006,1.16,,748
755,others,Precirol ATO5/capmul MCM,0.0,,tween 80,,,passive transport,,,0.0,,146.8,0.18,-21.4,0.9086,,normal,i.n.,,,CRM(姜黄素),none,,1.59,,755
759,others,,1.0,,,peptide,Angiopep-2,receptor mediated,low density lipoprotein-related receptor,LRT-1,0.0,,38.0,,-23.5,,,brain tumor,i.v.,,,香豆素-6,none,,,1.58,759
759,,,1.0,,,none,,none,,,0.0,,35.0,,-23.5,,,brain tumor,i.v.,,,香豆素-6,none,,,,759
761,free drug,,,,,,,,,,,,,,,,,normal,i.n.,0.0,,resveratrol,none,,1,,761
761,emulsion,vitamin E/sefol,0.0,0.0,none,none,,passive transport,,,0.0,,102.0,0.158,-35.0,,,normal,i.n.,0.0,,resveratrol,none,,1.42,,761
769,free drug,,,,,,,,,,,,,,,,,,i.n.,0.0,,haloperidol,none,0.045418,1,,769
769,solid lipid nanoparticles,,0.0,0.0,none,none,,passive transport,,,0.0,,115.1,0.409,-16.7,71.56,26.35,normal,i.n.,0.0,,haloperidol,none,0.165875,3.69,,769
780,others,,,,,,,passive transport,,,,,,,,,,,i.n.,0.0,,rimonabant,none,0.217979,,,780
780,solid lipid nanoparticles,tristearin/miglyol,1.0,,polysorbate 80,none,,passive transport,,,1.0,polysorbate 80,204.0,,,98.0,,normal,i.n.,0.0,,rimonabant,none,0.24313,1.12,,780
865,solid lipid nanoparticles,phosphatidyl choline/lecithin/Glyceryl monostearate,0.0,,poloxamer 188,none,,,,,1.0,Venlafaxine,186.3,0.262,-22.8,74.9,35.9,normal,i.v.,,,Venlafaxine,none,,,,865
872,liposome,,1.0,,none,peptide,LCDX (FKESWREARGTRIERG),receptor mediated,transferrin receptor,nicotine acetylcholine receptors (nAChRs),,,,,,,,,i.v.,,,Rhodamine B,none,,,1.77,872
872,liposome,,1.0,,none,peptide,"DCDX, the retro–inverso isomer ofLCDX,",receptor mediated,transferrin receptor,nicotine acetylcholine receptors (nAChRs),,,,,,,,,i.v.,,,Rhodamine B,none,,,2.53,872
872,liposome,,1.0,,none,,,passive transport,,,,,,,,,,,i.v.,,,Rhodamine B,none,,,,872
941,solid lipid nanoparticles,Glyceryl monostearate/SA/SL,0.0,,none,glycosol,p-Amino-phenyl-a-D-mannopyranoside,receptor mediated,others,GLUT-1,0.0,,127.9,,-6.38,83.8,,others,i.v.,82.0,,DTX,none,,,1.7416624499747,941
952,polymer-based nanoparticles,CS-PAA,0.0,,none,none,,passive transport,,,0.0,,212.0,,,,,normal,i.v.,,,Gd-DTPA,none,,8,,952
967,free drug,,,,,,,passive transport,,,,,,,,,,normal,i.v.,,,efavirenz,none,0.001488,1,,967
967,solid lipid nanoparticles,tristearin/HSPC/DSPE,0.0,,none,none,,passive transport,,,0.0,,113.0,0.214,-28.8,72.1,,normal,i.v.,,,efavirenz,none,0.003864,2.59,,967
967,solid lipid nanoparticles,tristearin/HSPC/DSPE,0.0,,none,others,phenylalanine,receptor mediated,amino acid transporter,l-amino acid transporter,0.0,,163.0,0.22,-36.2,63.5,,normal,i.v.,,,efavirenz,none,0.006692,4.51,1.74,967
972,free drug,,,,none,,,passive transport,,,,,,,,,,normal,i.v.,,,methotrexate,none,0.00082,1,,972
972,others,chitosan,0.0,,none,none,,passive transport,,,0.0,,118.0,,,,0.6182,normal,i.v.,,,methotrexate,none,0.001715,2.09,,972
972,others,chitosan,0.0,,polysorbate 80,none,,receptor mediated,low density lipoprotein-related receptor,Apo E,1.0,polysorbate 80,106.0,,,,0.5368,normal,i.v.,,,methotrexate,none,0.001708,2.08,1,972
915,polymer-based nanoparticles,superparamagnetic iron oxide nanoparticles (SPIONs)/polythylene glycol-block-polycaprolactone,1.0,,none,none,,passive transport,,,0.0,,92.1,,,,,brain tumor,i.v.,,,Cy 5.5,none,,,,915
915,polymer-based nanoparticles,superparamagnetic iron oxide nanoparticles (SPIONs)/polythylene glycol-block-polycaprolactone,1.0,,none,others,lactoferrin,transporter mediated,transferrin receptor,transferrin receptor,0.0,,390.4,0.083,2.53,,,brain tumor,i.v.,,,Cy 5.5,none,,,2.35,915
915,polymer-based nanoparticles,superparamagnetic iron oxide nanoparticles (SPIONs)/polythylene glycol-block-polycaprolactone,1.0,,none,none,,passive transport,,,0.0,,92.1,,,,,brain tumor,i.v.,,,Cy 5.5,none,,,,915
915,polymer-based nanoparticles,superparamagnetic iron oxide nanoparticles (SPIONs)/polythylene glycol-block-polycaprolactone,1.0,,none,others,lactoferrin,transporter mediated,transferrin receptor,transferrin receptor,0.0,,390.4,0.083,2.53,,,brain tumor,i.v.,,,Cy 5.5,none,,,5.77,915
915,,,,,,,,,,,,,,,,,,,,,,,,,,,915
933,dendrimer,Hydroxyl-terminated generation 4 poly(amidoamine) (PAMAM G4-OH),0.0,0.0,none,,,passive transport,,,0.0,,4.0,,4.5,,,brain tumor,i.v.,,,cy-5,none,0.000266,,,933
938,dendrimer,Polyamidoamine,1.0,,none,none,,passive transport,,,0.0,,6.53,0.19,3.26,,,brain tumor,i.v.,,,FITC,none,0.0067,,,938
938,dendrimer,Polyamidoamine,1.0,,none,peptide,Tumor-homing peptide CREKA,receptor mediated,,,0.0,,7.52,0.21,3.39,,,brain tumor,i.v.,,11.4,FITC,none,0.0097,,1.4478,938
938,,,,,,,,,,,,,,,,,,,,,,,,,,,938
1002,gold nanoparticles,Thiol-alkyl-hydrazone bond-DOX (SH-R-Hyz-DOX),0.0,,none,peptide,tandem peptide of RGD and octarginine,receptor mediated,others,others,0.0,,188.2,0.251,-4.32,,,brain tumor,i.v.,,,DOX,none,,2.96974722347857,1.15747723043776,1002
1002,gold nanoparticles,,0.0,,none,none,,passive transport,,,,,33.6,0.281,-12.77,,,brain tumor,i.v.,,125.0,DOX,none,,2.56570681943816,1,1002
1002,gold nanoparticles,,0.0,,none,none,,passive transport,,,,,179.3,0.232,-5.62,,,brain tumor,i.v.,,125.0,DOX,none,,1.81823207196342,1.13207133917397,1002
1002,gold nanoparticles,,0.0,,none,none,,passive transport,,,,,30.38,0.263,-14.58,,,brain tumor,i.v.,,,DOX,none,,1.6061108598422,1,1002
1002,free drug,,,,,,,,,,,,,,,,,brain tumor,i.v.,,,DOX,none,,1,,1002
1004,polymer-based nanoparticles,poly(n-butylcyanoacrylate) ,0.0,,polysorbate 80,none,,passive transport,,,0.0,,166.6,,-25.57,74.58,,normal,p.o.,,,Quercetin,none,,1.9,1.12,1004
1004,polymer-based nanoparticles,poly(n-butylcyanoacrylate) ,0.0,,none,none,,passive transport,,,0.0,,161.1,,-7.28,79.86,,normal,p.o.,,,Quercetin,none,,1.4,,1004
1004,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,p.o.,,,Quercetin,none,,1,,1004
1011,liposome,phosphatidyl choline,0.0,,none,peptide,Lactoferrin,transporter mediated,transferrin receptor,transferrin receptor,0.0,,103.8,0.15,5.8,96.51,2.6,Alzheimer's disease,i.v.,0.0057,,Curcumin,none,,,2.78,1011
1011,,,,,,,,,,,,,,,,,,,,,,,,,,,1011
1018,liposome,EPC,0.0,,none,none,,passive transport,,,0.0,,211.1,,-26.9,91.37,,normal,p.o.,,,G. bilobaextract (GbE),none,,3,,1018
1018,,,,,,,,,,,,,,,,,,,,,,,,,4.84,,1018
1018,,,,,,,,,,,,,,,,,,,,,,,,,11.43,,1018
1018,,,,,,,,,,,,,,,,,,,,,,,,,2,,1018
1018,,,,,,,,,,,,,,,,,,,,,,,,,2.67,,1018
1018,,,,,,,,,,,,,,,,,,,,,,,,,6,,1018
1018,,,,,,,,,,,,,,,,,,,,,,,,,2.23,,1018
1018,,,,,,,,,,,,,,,,,,,,,,,,,,,1018
1020,polymer-based nanoparticles,PLGA,0.0,,tween 80,peptide,Transferrin,transporter mediated,transferrin receptor,transferrin receptor,1.0,Tween 80,93.47,0.188,-11.38,70.1,,brain tumor,i.v.,,,methotrexate(Mtx),none,0.0185,4.617351,2.494424,1020
1020,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,1.0,Tween 80,85.59,0.168,11.08,73.6,,brain tumor,i.v.,,,methotrexate(Mtx),none,0.0247,2.957729,1.597849,1020
1020,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,83.34,0.168,11.08,76.3,,brain tumor,i.v.,,,methotrexate(Mtx),none,0.1111,2.298108,1.241503,1020
1020,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,77.21,0.099,14.37,80.7,,brain tumor,i.v.,,,methotrexate(Mtx),none,0.1234,1.851069,1,1020
1020,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,methotrexate(Mtx),none,0.8519,0.787171,0.425252,1020
1021,polymer-based nanoparticles,PAMAM-PEG,1.0,,none,peptide,Serine–Arginine–Leucine,receptor mediated,others,others,0.0,,150.0,0.62,20.0,,,normal,i.v.,,,BODIPY,none,,,2.25,1021
1037,polymer-based nanoparticles,PLA-PEG,1.0,,none,peptide,scrambled peptide (HWPYAHPTHPSW),receptor mediated,others,others,0.0,,322.0,0.17,-15.8,,5.65,brain tumor,i.v.,,,Tylocrebrine,none,0.0046,0.92,,1037
1037,polymer-based nanoparticles,PLA-PEG,1.0,,,peptide,EGFR-targeting peptide (YHWYGYTPQNVI),receptor mediated,others,others,0.0,,365.0,0.17,-14.8,,5.78,brain tumor,i.v.,,,Tylocrebrine,none,0.0048,3.95,4.29,1037
1037,,,,,,,,,,,0.0,,74.45,0.21,13.17,,,brain tumor,i.v.,,,——,none,,,,1037
1037,,,,,,,,,,,,,,,,,,,,,,,,,,,1037
1041,liposome,DOPC/cholesterol/stearylamine,0.0,,none,none,,,,,,,,,,,,others,i.n.,,,glial cell line- derived neurotrophic factor (GDNF),none,,3.82,,1041
1041,liposome,DOPC/cholesterol/stearylamine,0.0,,none,none,,,,,,,,,,,,others,i.n.,,,none,none,,,,1041
1041,free drug,DOPC/cholesterol/stearylamine,,,,,,,,,,,,,,,,others,i.n.,,,glial cell line- derived neurotrophic factor (GDNF),none,,1,,1041
1043,others,O-Carboxymethyl chitosan/O-carboxymethyl chitosan (O-CMC),0.0,,none,none,,,,,,,132.0,0.112,24.5,87.5,32.5,ischemic stroke/reperfusion,i.v.,,,Acetyl-11-keto-β-boswellic acid (AKBA),none,,3.9,,1043
1043,free drug,,,,,,,,,,,,,,,,,,,,,,,,1,,1043
1045,others,,,,,none,,,,,,,,,,,,ischemic stroke,i.p.,,,dendrimer,none,1e-06,1.12,,1045
1049,liposome,lecithin/cholesterol/span 65,1.0,,,peptide,Glutathione ,absorption mediated,transferrin receptor,,,,90.0,0.29,-64.3,75.65,,,i.v.,,,flucytosine,none,0.044,2.36,,1049
1049,free drug,,,,,,,,,,,,,,,,,,i.v.,,,flucytosine,none,0.01848,1,,1049
1054,solid lipid nanoparticles,Tristearin/HSPC /SA/ALB/PRD/LA,0.0,,Lactic acid,none,,,,,,,100.2,0.376,-23.6,62.2,70.2,others,i.v.,,,Albendazole (ALB)  and Prednisolone (PRD),none,,0.57,0.92；0.83,1054
1054,solid lipid nanoparticles,Tristearin/HSPC /SA/ALB/PRD/LA,,,none,none,,,,,,,95.4,0.265,-25.6,73.6,78.3,others,i.v.,,,Albendazole (ALB)  and Prednisolone (PRD),none,,0.62,,1054
1054,free drug,,,,,,,,,,,,,,,,,others,i.v.,,,Albendazole (ALB)  and Prednisolone (PRD),none,,1,,1054
1056,polymer-based nanoparticles,thiolated chitosan(TCS)/tripolyphosphates/sodium alginate,0.0,,none,none,,,,,,,226.7,0.483,,81.13,48.75,others,i.n.,,,Buspirone hydrochloride (BUH),none,,1.91,,1056
1056,free drug,,,,,,,,,,,,,,,,,,i.v.,,,Buspirone hydrochloride (BUH),none,,1,,1056
1056,free drug,,,,,,,,,,,,,,,,,,i.n.,,,Buspirone hydrochloride (BUH),none,,1,,1056
1084,free drug,,,0.0,none,,,,,,0.0,,,,,,,normal,i.v.,,,asiatic acid,none,,1,,1084
1084,albumin nanoparticles,bovine serum albumin,0.0,0.0,none,none,,,,,0.0,,,,,,,normal,i.v.,,,asiatic acid,none,,7.95,1,1084
1084,albumin nanoparticles,bovine serum albumin,0.0,0.0,none,peptide,glutathione,receptor mediated,amino acid transporter,,0.0,,,,,,,normal,i.v.,,,asiatic acid,none,,10.63,1.34,1084
1115,free drug,Labrafac Lipophile/Labrafac PG,0.0,0.0,none,,,,,,0.0,,,,,,,normal,i.n.,,,resveratrol,none,,1,,1115
1115,emulsion,Labrafac Lipophile/Labrafac PG,0.0,0.0,none,none,,passive transport,,,0.0,,115.2,0.235,-23.9,,,normal,i.n.,,,resveratrol,none,,6.9317165647244,,1115
1115,free drug,Labrafac Lipophile/Labrafac PG,0.0,0.0,none,,,,,,0.0,,,,,,,normal,i.n.,,,curcumin,none,,1,,1115
1115,emulsion,Labrafac Lipophile/Labrafac PG,0.0,0.0,none,none,,passive transport,,,0.0,,115.2,0.235,-23.9,,,normal,i.n.,,,curcumin,none,,9.7341011093234,,1115
1116,free drug,,,0.0,none,,,,,,0.0,,,,,,,brain tumor,i.v.,,,Doxorubicin,none,3.9282e-05,1,,1116
1116,polymer-based nanoparticles,polybutylcyanoacrylate,0.0,0.0,none,none,,passive transport,,,0.0,,120.5,,-9.0,87.49,0.106,brain tumor,i.v.,,,Doxorubicin,none,5.973e-05,1.52054376050099,,1116
1120,free drug,,,,,,,,,,0.0,,,,,,,normal,i.v.,,,Acetylpuerarin,none,0.000107316,1,,1120
1120,polymer-based nanoparticles,PLGA,0.0,0.0,polysorbate 80,none,,passive transport,,,0.0,,145.0,,-14.81,90.51,0.171,normal,i.v.,,,Acetylpuerarin,none,0.000203292,1.89433076148943,,1120
1134,others,TPGS-COOH,1.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,16.79,0.275,,84.0,21.0,normal,i.v.,,,DTX,none,0.167,23.5833463805629,4.49206380251955,1134
1142,others,quantum dots,0.0,,none,antibody,8d3,passive transport,,,0.0,,,,,,,normal,i.v.,3.5,,,none,0.0006,,,1142
1142,others,quantum dots,0.0,,none,antibody,Ri7217.1.4,receptor mediated,transferrin receptor,murine transferrin receptor,0.0,,,,,,,normal,i.v.,3.5,,,none,0.0021,,3.5,1142
1143,others,lipids extracted from grapefruit exosome-like nanoparticle,0.0,,none,none,,,,,0.0,,87.2,,-13.9,,,brain tumor,i.n.,,,grapefruit exosome,none,,,,1143
1143,others,lipids extracted from grapefruit exosome-like nanoparticle,0.0,,none,folic acid,folic acid,receptor mediated,amino acid transporter,folate ligand,0.0,,,,,,,brain tumor,i.n.,,,grapefruit exosome,none,,,2.99,1143
1157,polymer-based nanoparticles,PLGA,0.0,,none,peptide,biotin,passive transport,,,0.0,,138.0,,,,,normal,i.n.,,,camptothecin,none,0.0013,,,1157
1157,polymer-based nanoparticles,PLGA,0.0,,none,peptide,"RVG29-biotin peptide (sequence: N term-YTIWMPENPRPGTPCDIFTNSRGKRASNG-
C2-Biotin)",receptor mediated,low density lipoprotein-related receptor,"neural cell adhesion molecule (NCAM);p75 neurotrophin receptor (P75NTR);
nicotinic acetylcholine receptors (NAChRs)",0.0,,156.0,,,,,normal,i.n.,,,camptothecin,none,0.0019,,1.43,1157
1181,polymer-based nanoparticles,PEG-PLGA,1.0,100.0,none,peptide,Pep-1 (CGEMGWVRC) peptide,receptor mediated,others,IL-13Rα2 endocytosis,0.0,,95.78,0.137,34.5,77.27,3.77,brain tumor,i.v.,,,PTX,none,0.00023,2.58,1.922,1181
1181,polymer-based nanoparticles,,,,,,,,,,,,,,,,,,,,,,,0.00012,1.34,,1181
1181,free drug,,,,,,,,,,,,,,,,,,,,,,,9.1e-05,1,,1181
1261,free drug,,,,,,,,,,,,,,,,,normal,p.o.,,,nimodipine,none,2.34e-05,1,,1261
1261,others,Solutol®HS15,1.0,,none,none,,passive transport,,,0.0,,12.57,0.071,,95.75,0.0323,normal,p.o.,,,nimodipine,none,7.02e-05,3,,1261
1269,others,,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,,,1269
1269,others,,0.0,,none,peptide,cRGD,receptor mediated,others,,0.0,,28.5,,,,,brain tumor,i.v.,,,DiR,none,,1.51237935375577,,1269
1269,,,,,,,,,,,,,,,,,,,,,,,,,,,1269
1283,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,183.5,,33.63,,0.2,normal,i.v.,,,thymoquinone,none,0.001636,,,1283
1283,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,183.5,,33.63,,0.2,normal,i.n.,,,thymoquinone,none,0.000655,,2.74,1283
1291,others,Low-density lipoprotein,0.0,,none,none,,passive transport,,,0.0,,20.13,,-14.14,,,normal,i.v.,,,DHA,,,,,1291
1291,others,Low-density lipoprotein,0.0,,none,none,,passive transport,,,0.0,,20.13,,-14.14,,,normal,i.v.,,,DHA,focused ultrasound,,,64.1,1291
1299,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,donepezil,none,0.000719,,,1299
1299,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,donepezil,none,0.001076,,1.5,1299
1321,polymer-based nanoparticles,mal-PEG-PLGA/mPEG-PLGA,1.0,100.0,none,peptide,Bovine Lf,receptor mediated,transferrin receptor,transferrin receptor,0.0,,122.0,0.194,21.28,,,Parkinson's disease,i.n.,18.99,1.44,rotigotine,none,,,6.33,1321
1321,,,,,,,,,,,,,58.1,0.137,20.44,,,Parkinson's disease,i.n.,,,rotigotine,none,,,,1321
1322,others,soybean lecithin/Chitosan,0.0,,,,,,,,0.0,,204.5,0.098,48.45,98.53,,normal,i.n.,,,simvastatin,none,,27.96,,1322
1326,polymer-based nanoparticles,Chitosan,0.0,,none,none,,passive transport,,,0.0,,80.0,,,,,normal,i.n.,,,rutin,none,0.001043,9,,1326
1326,free drug,,,,,none,,passive transport,,,,,,,,,,,,,,,none,0.000146,1,,1326
1367,others,PAMAM,0.0,,folic acid (FA)， borneol (BO),none,,receptor mediated,,,,,22.0,,7.6,64.58,6.64,brain tumor,i.v.,,,doxorubicin,none,0.045624,64.07,0.4,1367
1367,others,PAMAM,0.0,,borneol (BO),none,,passive transport,,,,,,,,,,brain tumor,i.v.,,,doxorubicin,none,0.114696,161.09,,1367
1367,free drug,,,,,none,,passive transport,,,,,,,,,,brain tumor,i.v.,,,doxorubicin,none,0.000712,1,,1367
1373,others, Pluronic P123/ Pluronic F68,0.0,,chitosan,none,,passive transport,,,,,51.5,,22.38,91.72,15.63,brain tumor,i.g.,,,myricetin,none,0.005408,2.04,,1373
1373,free drug,,,,,none,,passive transport,,,,,,,,,,brain tumor,i.g.,,,myricetin,none,0.002656,1,,1373
1376,emulsion,oleic acid/carbitol/Smix/tween20/labrasol/cremophore ELv,0.0,,none,none,,passive transport,,,,,94.8,0.26,-13.5,,,ischemic stroke/reperfusion,i.n.,,,Thymoquinone,none,0.006187,6.79,,1376
1376,emulsion,oleic acid/carbitol/Smix/tween20/labrasol/cremophore ELv,0.0,,none,none,,passive transport,,,,,94.8,0.26,-13.5,,,ischemic stroke/reperfusion,i.v.,,,Thymoquinone,none,0.001506,,,1376
1376,free drug,,,,,none,,passive transport,,,,,,,,,,ischemic stroke/reperfusion,i.n.,,,Thymoquinone,none,0.000912,1,,1376
1376,free drug,,,,,,,,,,,,,,,,,ischemic stroke/reperfusion,i.v.,,,Thymoquinone,none,0.000543,1,,1376
1405,,,0.0,0.0,none,,,passive transport,,,0.0,,,,,,,normal,i.v.,,,docetaxel,none,9e-05,1,,1405
1405,liposome,phospholipid/cholestrol/quantum dot,0.0,0.0,none,none,,passive transport,,,0.0,,168.2,0.278,-8.31,69.75,,normal,i.v.,,,docetaxel,none,0.00049,5.44,1,1405
1405,liposome,phospholipid/cholestrol/quantum dot,0.0,0.0,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,182.5,0.365,-1.89,64.1,,normal,i.v.,,,docetaxel,none,0.000881,9.79,1.8,1405
1456,solid lipid nanoparticles,PC,0.0,,polysorbate 80,non-antibody protein,lactoferrin,receptor mediated,others,lactoferrin  receptor,1.0,PS80,90.5,0.145,20.39,94.39,3.29,normal,i.v.,,,DiR,none,,,2.32,1456
1456,,,,,,,,,,,,,177.6,0.126,13.96,96.22,3.81,normal,i.v.,,,DiR,none,,,,1456
1456,,,,,,,,,,,,,,,,,,,,,,,,,,,1456
1463,polymer-based nanoparticles,PLGA/Pluronic ®F-68 (PF-68) ,0.0,,none,none,,passive transport,,,,,133.13,0.21,-30.25,64.11,,Alzheimer's disease,i.n.,,,tarenflurbil,none,0.084176,1.93,,1463
1463,solid lipid nanoparticles,glyceryl monostearate/stearic acid/soya lecithin,0.0,,none,none,,passive transport,,,,,169.87,0.24,-23.13,57.81,,Alzheimer's disease,i.n.,,,tarenflurbil,none,0.073392,1.69,,1463
1463,free drug,,,,none,none,,passive transport,,,,,,,,,,Alzheimer's disease,i.n.,,,tarenflurbil,none,0.043478,1,,1463
1463,free drug,,,,none,none,,passive transport,,,,,,,,,,Alzheimer's disease,i.v.,,,tarenflurbil,none,0.047653,1,,1463
1463,free drug,,,,none,none,,passive transport,,,,,,,,,,Alzheimer's disease,p.o.,,,tarenflurbil,none,0.018086,1,,1463
1464,liposome,PC/cholesterol,1.0,,D-􏱀-tocopheryl polyethylene glycol 1000 succinate (TPGS),none,,passive transport,,,1.0,d-􏱀-tocopheryl polyethylene glycol 1000 succinate (TPGS),64.5,0.398,-1.05,83.05,,brain tumor,i.v.,,,resveratrol (RSV),none,0.01784,10.25,1.22,1464
1464,liposome,PC/cholesterol,0.0,,none,none,,passive transport,,,,,,,,,,brain tumor,i.v.,,,resveratrol (RSV),none,0.01468,8.44,,1464
1464,free drug,,,,none,none,,passive transport,,,,,,,,,,brain tumor,i.v.,,,resveratrol (RSV),none,0.00174,1,,1464
1467,polymer-based nanoparticles,,0.0,,none,none,,passive transport,,,,,110.0,0.201,-28.3,,,normal,i.p.,,,Efavirenz,none,0.004169,2.34,,1467
1467,free drug,,,,,none,,passive transport,,,,,,,,,,normal,i.p.,,,Efavirenz,none,0.001779,1,,1467
1502,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,rutin,none,,1,,1502
1502,polymer-based nanoparticles,chitosan,0.0,,none,none,,passive transport,,,0.0,,92.28,0.206,31.04,84.98,,normal,i.v.,,,rutin,none,,7.03,,1502
1502,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,rutin,none,,1,,1502
1502,polymer-based nanoparticles,chitosan,0.0,,none,none,,passive transport,,,0.0,,92.28,0.206,31.04,84.98,,normal,i.n.,,,rutin,none,,3.48,,1502
1505,free drug,,,,,,,,,,0.0,,,,,,,brain tumor,i.v.,,,,none,,1,,1505
1505,albumin nanoparticles,human serum albumin,0.0,,none,none,,passive transport,,,0.0,,140.0,0.189,21.4,84.9,,brain tumor,i.v.,,,,none,,4.34,,1505
1519,others,silicon,0.0,,graphene oxide,peptide,RVG,receptor mediated,choline transporter,acetylcholine receptor,0.0,,170.0,,,,,others,i.v.,,,,none,,,,1519
1519,others,silicon,0.0,,none,peptide,RVG,receptor mediated,choline transporter,acetylcholine receptor,0.0,,190.0,,22.1,,,others,i.v.,,,,none,,,2.5,1519
1524,polymer-based nanoparticles,MPEG-PLA/Male-PEG-PLA,1.0,,none,none,,passive transport,,,0.0,,105.2,0.09,-27.4,45.3,,brain tumor,i.v.,,,DiR,none,,,1,1524
1524,polymer-based nanoparticles,MPEG-PLA/Male-PEG-PLA,1.0,,none,peptide,tLyp-1,receptor mediated,others,neuropilin-1,0.0,,112.6,0.12,-21.6,38.2,,brain tumor,i.v.,,,DiR,none,,,2.18603194,1524
1524,polymer-based nanoparticles,MPEG-PLA/Male-PEG-PLA,1.0,,none,peptide,FHK(FHKHKSPALSPV),receptor mediated,others,tenascin C,0.0,,124.8,0.13,-34.5,39.6,,brain tumor,i.v.,,,DiR,none,,,1.95352333,1524
1524,polymer-based nanoparticles,MPEG-PLA/Male-PEG-PLA,1.0,,none,peptide,tLyp-1 and FHK,receptor mediated,others,neuropilin-1 and tenascin C,0.0,,132.5,0.17,-30.3,36.8,,brain tumor,i.v.,,,DiR,none,,,2.86050736,1524
1526,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,1,,1526
1526,dendrimer,heptadecanoic acids/cholesterols/D-α-tocopherol succinates,0.0,,none,none,,passive transport,,,,,32.0,,-3.0,,,brain tumor,i.v.,,,DiR,none,,3.37,,1526
1589,liposome,DPPC/cholesterol,0.0,,none,peptide,arginine–glycine–aspartic acid (RGD),receptor mediated,others,𝛂v𝛃3,1.0,D-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS or TPGS),182.3,0.265,1.1,68.45,,normal,i.v.,,,docetaxel (DTX) and quantum dots (QDs),none,0.044,,,1589
1589,liposome,DPPC/cholesterol,0.0,,none,none,,passive transport,,,1.0,D-alpha-tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS or TPGS),178.2,0.189,0.95,70.04,,normal,i.v.,,,docetaxel (DTX) and quantum dots (QDs),none,0.024,,,1589
1589,liposome,DPPC/cholesterol,0.0,,none,none,,passive transport,,,,,175.6,0.148,-1.95,72.15,,normal,i.v.,,,docetaxel (DTX) ,none,0.000586,,,1589
1606,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,donepezil,none,,1,,1606
1606,polymer-based nanoparticles,mango gum polymer,0.0,,none,none,,passive transport,,,0.0,,135.5,0.53,8.25,72.0,51.0,normal,i.v.,,,donepezil,none,,4.3,,1606
1606,polymer-based nanoparticles,mango gum polymer,0.0,,none,none,,passive transport,,,0.0,,95.1,0.26,25.92,85.0,76.0,normal,i.v.,,,donepezil,none,,12.7,,1606
1617,others,,0.0,,none,none,,passive transport,,,0.0,,241.0,0.234,-8.8,,,normal,i.n.,,,resveratrol,none,0.0005,,,1617
1617,others,,0.0,,none,none,,passive transport,,,0.0,,241.0,0.234,-8.8,,,normal,i.v.,,,resveratrol,none,0.0002,,,1617
1613,dendrimer,PAMAM,1.0,,none,none,,passive transport,,,0.0,,5.1,0.18,3.15,,,brain tumor,i.v.,,,Cy5.5,none,,,1,1613
1613,dendrimer,PAMAM,1.0,,none,peptide,Pep-1(CGEMGWVRC),receptor mediated,others,IL-13R􏰇2,0.0,,8.0,0.2,2.07,,,brain tumor,i.v.,,,Cy5.5,none,,,2.02,1613
1635,free drug,,,,,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,, risperidone,none,,1,,1635
1635,liposome,SPC/cholesterol,0.0,,none,none,,passive transport,,,0.0,,91.86,,53.8,49.6,,normal,i.n.,,, risperidone,none,,2.41,,1635
1635,liposome,SPC/cholesterol/stearylamine,0.0,,none,none,,passive transport,,,0.0,,98.55,,15.61,51.13,,normal,i.n.,,, risperidone,none,,2.05,,1635
1635,liposome,SPC/cholesterol,1.0,2.2,none,none,,passive transport,,,0.0,,98.51,,28.6,58.86,,normal,i.n.,,, risperidone,none,,1.69,,1635
1640,polymer-based nanoparticles,PEG-PLA,1.0,,none,none,,passive transport,,,0.0,,102.0,0.13,-37.5,,,brain tumor,i.v.,,,DiR,none,,,,1640
1640,polymer-based nanoparticles,PEG-PLA,1.0,,none,peptide,ATWLPPR,receptor mediated,,heparan sulfate proteoglycan,0.0,,113.0,0.14,-31.6,,,brain tumor,i.v.,,,DiR,none,,,2.03,1640
1640,polymer-based nanoparticles,PEG-PLA,1.0,,none,peptide,CGCRK,receptor mediated,,neuropilin-1,0.0,,119.0,0.17,-14.6,,,brain tumor,i.v.,,,DiR,none,,,3.33,1640
1640,polymer-based nanoparticles,PEG-PLA,1.0,,none,peptide,CGKRKGYGATWLLPPR,receptor mediated,,heparan sulfate proteoglycan and neuropilin-1,0.0,,123.0,0.15,-11.4,,,brain tumor,i.v.,,,DiR,none,,,5.47,1640
1640,,,,,,,,,,,,,,,,,,,,,,,,,,,1640
1653,free drug,,,,,none,,,,,,,,,,,,,,,,,,,,,1653
1653,polymer-based nanoparticles,PEG-PLGA,1.0,,poloxamer 188,none,,,,,,,,,,,,,,,,,none,,,,1653
1653,polymer-based nanoparticles,PEG-PLGA,1.0,,poloxamer 188,peptide, Pep-1 (CGEMGWVRC),receptor mediated,others,heparan sulfate,,,,,,,,,,,,,none,,,,1653
1653,polymer-based nanoparticles,PEG-PLGA,1.0,,poloxamer 188,peptide,CGKRK ,receptor mediated,amino acid transporter,IL-13Rα2,,,,,,,,,,,,,none,,,,1653
1653,polymer-based nanoparticles,PEG-PLGA,1.0,,poloxamer 188,peptide,CGKRK &  Pep-1 (CGEMGWVRC),receptor mediated,amino acid transporter,IL-13Rα2 and heparan sulfate,,,,,,,,,,,,,none,,,,1653
1682,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,,none,0.01584,1,,1682
1682,others,EPC/chitosan,0.0,,none,none,,passive transport,,,0.0,,204.5,0.098,48.45,98.52,,normal,i.n.,,,,none,0.47322,29.875,,1682
1697,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,,i.v.,,,,none,0.0135,1,,1697
1697,others,tocopherol/compritol/phospholipon 90G,0.0,,none,none,,passive transport,,,0.0,,67.46,,-7.7,,,,i.v.,,,quercetin,none,0.0436,5.6,,1697
1697,solid lipid nanoparticles,compritol,0.0,,none,none,,passive transport,,,0.0,,74.61,,-8.9,,,,i.v.,,,quercetin,none,0.0768,3.2,,1697
1697,,,,,,,,,,,,,,,,,,,,,,,,,,,1697
1692,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.p.,,,,none,0.000612,1,,1692
1692,micelle,polysialic acid-octadecylamine copolymer,0.0,,none,none,,passive transport,,,0.0,,107.0,,-20.8,,,normal,i.p.,,,,none,0.001278,2.09,,1692
1701,others,Schisantherin A,0.0,,none,none,,passive transport,,,,,160.0,,,,,Parkinson's disease,p.o.,,,,none,0.0515,5.47,,1701
1701,free drug,Schisantherin A,,,,none,,passive transport,,,,,,,,,,Parkinson's disease,p.o.,,,,none,0.0094,1,,1701
1704,others,polysialic acid,0.0,,none,none,,passive transport,,,,,107.0,,-20.8,90.0,3.6,others,i.p.,,,calmodulin antagonist,none,0.005,2.04,,1704
1704,free drug,,,,,none,,passive transport,,,,,,,,,,,i.p.,,,calmodulin antagonist,none,0.00248,1,,1704
1717,emulsion,,0.0,,none,none,,passive transport,,,,,26.33,0.203,-8.46,,,others,p.o.,,,olmesartan,none,0.00023976,24.47,,1717
1717,free drug,,,,,none,,passive transport,,,,,,,,,,others,p.o.,,,olmesartan,none,9.84e-06,1,,1717
1717,,,,,,,,,,,,,,,,,,,,,,,,,,,1717
1718,others,poly(ethylene oxide)-poly(propylene oxide) -poly(ethylene oxide),0.0,,polysorbate 80,none,,passive transport,,,,,571.5,0.43,,,,normal,i.n.,,,Nimodipine,none,0.001836,1.24,,1718
1718,others,poly(ethylene oxide)-poly(propylene oxide) -poly(ethylene oxide),0.0,,none,none,,passive transport,,,,,,,,,,normal,i.v.,,,Nimodipine,none,0.002196,1.49,,1718
1718,free drug,,,,,,,passive transport,,,,,,,,,,normal,i.v.,,,Nimodipine,none,0.001476,1,,1718
1726,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,DOX,none,0.004,1,,1726
1726,magnetic nanoparticles,mesoporous silica,0.0,,none,none,,passive transport,,,0.0,,156.1,,-24.0,,,brain tumor,i.v.,,,DOX,none,0.0037,0.93,,1726
1726,magnetic nanoparticles,mesoporous silica,0.0,,none,peptide,Asn-Gly-Arg (NGR),receptor mediated,,"aminopeptidase N (cluster of differentiation 13, CD13) ",0.0,,168.0,,-22.0,19.02,0.408,brain tumor,i.v.,,,DOX,none,0.0063,1.56,1.68,1726
1727,albumin nanoparticles,Bovine Serum Albumin,0.0,,none,none,,receptor mediated,, SPARC (secreted protein acidic and rich in cysteine) and glycoprotein 60 (gp60),0.0,,140.0,0.089,-30.0,51.63,3.6,brain tumor,i.v.,,,Cy5,none,,6.58,,1727
1727,albumin nanoparticles,Bovine Serum Albumin,0.0,,none,peptide,LMWP,receptor mediated,, SPARC (secreted protein acidic and rich in cysteine) and glycoprotein 60 (gp60),0.0,,145.0,0.074,-16.0,53.24,3.7,brain tumor,i.v.,,,Cy5,none,,9.68,1.472,1727
1731,gold nanoparticles,Au,0.0,,none,none,,passive transport,,,0.0,,34.57,0.388,,,,brain tumor,i.v.,,,Cy5.5,none,,1.44,1.36,1731
1731,gold nanoparticles,Au/PEG,1.0,,none,none,,passive transport,,,0.0,,32.28,0.322,,,0.0387,brain tumor,i.v.,,,Cy5.5,none,,1.01,,1731
1731,gold nanoparticles,Au,0.0,,none,none,,passive transport,,,0.0,,33.46,0.367,,,0.0387,brain tumor,i.v.,,,Cy5.5,none,,1.06,,1731
1731,gold nanoparticles,Au,0.0,,none,none,,passive transport,,,0.0,,31.93,0.353,,,0.0391,brain tumor,i.v.,,,Cy5.5,none,,1.06,,1731
1734,polymer-based nanoparticles,PVA-COOH-(SS-alkynyl),0.0,,none,peptide,cRGD(Arg-Gly-Asp),receptor mediated,others,αvβ3,0.0,,168.0,0.2,-10.9,65.4,,brain tumor,i.v.,,,DOX,none,0.055,7.27,1.82,1734
1734,polymer-based nanoparticles,PVA-COOH-(SS-alkynyl),0.0,,none,none,,passive transport,,,0.0,,154.0,0.18,-12.7,79.2,,brain tumor,i.v.,,,DOX,none,0.032,4,,1734
1734,polymer-based nanoparticles,PVA-N3,0.0,,none,none,,passive transport,,,0.0,,92.0,0.15,-28.7,77.0,,brain tumor,i.v.,,,DOX,none,0.017,2.18,,1734
1734,free drug,,,,none,none,,,,,0.0,,,,,,,brain tumor,i.v.,,,DOX,none,0.0072,1,,1734
1783,polymer-based nanoparticles,dodecylamine / terpolymer/starch,0.0,,polysorbate 80,none,,passive transport,,,,,100.1,0.17,-48.0,98.2,6.8,others,i.v.,,,docetaxel (DTX),none,0.000702,3.11,,1783
1783,free drug,,,,,,,,,,,,,,,,,,i.v.,,,docetaxel (DTX),none,0.000225,1,,1783
1784,polymer-based nanoparticles,PLGA/chitosan,0.0,,none,none,,passive transport,,,,,172.5,0.254,35.63,76.4,30.8,others,i.n.,,,Desvenlafaxine,none,,1.69,,1784
1784,polymer-based nanoparticles,PLGA/chitosan,0.0,,none,none,,passive transport,,,,,172.5,0.254,35.63,76.4,30.8,others,i.v.,,,Desvenlafaxine,none,,0.7,,1784
1784,free drug,,,,none,none,,passive transport,,,,,,,,,,others,i.n.,,,Desvenlafaxine,none,,1,,1784
1806,free drug,,,,,,,passive transport,,,,,,,,,,brain tumor,i.v.,,,Cy5-SiRNA,none,,1,,1806
1806,liposome, DSPE- PEG2000/cholesterol/malate dehydrogenases ,1.0,,none,,,passive transport,,,0.0,,114.0,0.154,3.99,,,brain tumor,i.v.,,,Cy5-SiRNA,none,,1.64444444,,1806
1806,liposome,Bis(palmitoyloxy)- 3-(dimethylamino)propane,1.0,,none,,,passive transport,,,0.0,,103.1,0.161,3.44,,,brain tumor,i.v.,,,Cy5-SiRNA,none,,1.2,,1806
1808,polymer-based nanoparticles,PEG2000/chitosan,1.0,,none,none,,passive transport,,,0.0,,233.6,0.101,-28.1,85.4,,normal,i.v.,,,DiR,none,,,1,1808
1808,polymer-based nanoparticles,PEG2000/chitosan,1.0,,lactoferrin,none,,receptor mediated,low density lipoprotein-related receptor,low density lipoprotein-related receptor,0.0,,232.5,0.095,-24.6,84.3,,normal,i.v.,,,DiR,none,,,2.39,1808
1835,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,,i.v.,,,docetaxel,none,,1,,1835
1835,liposome,DSPE-PEG2000/cholestrol,1.0,,none,none,,passive transport,,,0.0,,169.4,,,18.7,,brain tumor,i.v.,,,docetaxel,none,,2.51,,1835
1841,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,Agomelatine,none,,1,,1841
1841,solid lipid nanoparticles,tripalmitin/EPC,0.0,,none,none,,passive transport,,,0.0,,167.7,,-17.9,91.25,,normal,i.n.,,,Agomelatine,none,,1.37060741456346,,1841
1851,liposome,DSPE-PEG2000/DPPC/cholesterol,1.0,10.0,none,none,,passive transport,,,0.0,,98.3,0.171,,,,brain tumor,i.v.,,,Paclitaxel,none,0.00078246,,,1851
1851,liposome,DSPE-PEG2000/DPPC/cholesterol,1.0,10.0,none,none,,passive transport,,,0.0,,98.3,0.171,,,,brain tumor,i.v.,,,Paclitaxel,focused ultrasound,0.00117378,1.50011502185415,,1851
1853,polymer-based nanoparticles,dendrigraft poly-L-lysine,1.0,,none,none,,passive transport,,,0.0,,97.21,,5.41,58.53,,ischemic stroke/reperfusion,i.v.,,,BODIPY 650/665,none,,,1,1853
1853,polymer-based nanoparticles,dendrigraft poly-L-lysine,1.0,,none,peptide,N-acetyl Pro-Gly-Pro,receptor mediated,,,0.0,,99.56,,5.6,70.69,,ischemic stroke/reperfusion,i.v.,,,BODIPY 650/665,none,,,3.83647798742138,1853
1853,,,,,,,,,,,,,,,,,,,,,,,,,,,1853
1894,cationic liposome,nicotinylated amphiphiles,0.0,,none,non-antibody protein,NIC-1,receptor mediated,others,nicotinicreceptor,0.0,,121.4,,12.3,,,normal,i.v.,,,WP-1066,none,0.000822,,,1894
1894,cationic liposome,,,,none,non-antibody protein,NIC-2,receptor mediated,others,nicotinicreceptor,0.0,,126.4,,12.1,,,normal,i.v.,,,WP-1067,none,0.001151,,,1894
1894,cationic liposome,,,,none,none,,passive transport,,,0.0,,116.3,,18.0,,,normal,i.v.,,,WP-1068,none,8e-05,,,1894
1894,,,,,,,,,,,,,,,,,,,,,,,,,,,1894
1927,polymer-based nanoparticles,PLGA/quantum dots,,,none,none,,passive transport,,,0.0,,296.0,0.12,-4.65,,,normal,i.v.,,,quantum dots,none,0.0135,,1,1927
1927,polymer-based nanoparticles,PLGA/quantum dots,,,none,cell-penetrating peptide,TAT-biotin peptide (sequence: Biotin-YGRKKRRQRRR) ,absorption mediated,,,0.0,,280.0,0.12,-2.97,,,normal,i.v.,,,quantum dots,none,0.018,,1.3,1927
1935,magnetic liposome,PLGA/SPION,0.0,,none,none,,,,,0.0,,110.0,0.11,,,,brain tumor,i.v.,,,Cy5.5,none,,,1,1935
1935,magnetic liposome,PLGA/SPION,0.0,,none,others,adipose-derived stem cells,cell-mediated transportation,,,0.0,,,,,,,brain tumor,i.v.,,,Cy5.5,none,,,1.9,1935
1932,polymer-based nanoparticles,"poly(lactic-co-glycolic)-
block-poly ethylene glycol (PLGA-b-PEG)",1.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,Bodipy,none,,,1,1932
1932,polymer-based nanoparticles,"poly(lactic-co-glycolic)-
block-poly ethylene glycol (PLGA-b-PEG)",1.0,,none,aptamer,anti-PDGFRβ aptamer,receptor mediated,others,platelet-derived growth factor receptors,0.0,,52.0,0.169,-13.1,,,brain tumor,i.v.,5.4,,Bodipy,none,,,23.8,1932
1938,micelle,mPEG2000-PLA2000,1.0,,none,none,,passive transport,,,,,,,,,,brain tumor,i.v.,,,DiR,none,,,1,1938
1938,micelle,mPEG2000-PLA2000,1.0,,none,peptide,stapled RGD,receptor mediated,,αvβ3,0.0,,33.7,0.054,-1.67,,,brain tumor,i.v.,,,DiR,none,,,1.9,1938
1938,micelle,mPEG2000-PLA2000,1.0,,none,peptide,cylic RGD,receptor mediated,,αvβ3,0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,,1.2,1938
1952,albumin nanoparticles,Bovine serum albumin,0.0,,none,none,,,,,1.0,sinapic acid,32.67,,8.33,,,brain tumor,i.v.,,,FITC,none,,,1.62,1952
1952,,,,,,,,,,,,,,,,,,,,,,,,,,,1952
1991,others,,1.0,,none,peptide,I6P7,receptor mediated,amino acid transporter,IL-6R,0.0,,99.0,,15.9,,,brain tumor,i.v.,,,DNA,none,,64,2.46,1991
1991,others,,1.0,,none,peptide,I6P7scr,receptor mediated,amino acid transporter,IL-6R ,0.0,,111.6,,17.5,,,brain tumor,i.v.,,,DNA,none,,26,,1991
1991,,,,,,,,,,,,,,,,,,,,,,,,,,,1991
1998,others,PEG-PLA,1.0,,none,none,,,others,,,,,,,,,brain tumor,i.v.,,,,none,,0.75,,1998
1998,others,PEG-PLA,1.0,,none,peptide,cRGD,receptor mediated,others,αvβ3,0.0,,,,,,,brain tumor,i.v.,,,,none,,1.21,1.613,1998
1998,others,PEG-PLA,1.0,,none,peptide,sRGD,receptor mediated,others,αvβ3,0.0,,,,,,,brain tumor,i.v.,,,,none,,1.8,2.4,1998
1998,,,,,,,,,,,,,,,,,,,,,,,,,,,1998
2025,gold nanoparticles,Au/PEG/2-Cyano-6-aminobenzothiazole,1.0,,none,peptide,R8-RGD,receptor mediated,others,αvβ3,0.0,,172.9,,,,,brain tumor,i.v.,,,Cy5.5,none,,,2.565,2025
2025,gold nanoparticles,Au/PEG/2-Cyano-6-aminobenzothiazole,1.0,,none,none,,,,,,,202.3,,,,,brain tumor,i.v.,,,Cy5.5,none,,,1.911,2025
2025,gold nanoparticles,Au/PEG,1.0,,none,peptide,R8-RGD,receptor mediated,others,αvβ3,0.0,,32.41,0.301,-8.77,,,brain tumor,i.v.,,,Cy5.5,none,,,1.468,2025
2025,gold nanoparticles,Au/PEG,1.0,,none,none,,,,,,,33.09,0.275,-12.23,,,brain tumor,i.v.,,,Cy5.5,none,,,1,2025
2025,gold nanoparticles,Au/PEG/2-Cyano-6-aminobenzothiazole,1.0,,none,peptide,R8-RGD,receptor mediated,others,αvβ3,0.0,,172.9,,,,,brain tumor,i.v.,,,Cy5.5,none,,,1.491526,2025
2025,gold nanoparticles,Au/PEG/2-Cyano-6-aminobenzothiazole,1.0,,none,none,,,,,,,202.3,,,,,brain tumor,i.v.,,,Cy5.5,none,,,1.466102,2025
2025,gold nanoparticles,Au/PEG,1.0,,none,peptide,R8-RGD,receptor mediated,others,αvβ3,0.0,,32.41,0.301,-8.77,,,brain tumor,i.v.,,,Cy5.5,none,,,1.279661,2025
2025,gold nanoparticles,Au/PEG,1.0,,none,none,,,,,,,33.09,0.275,-12.23,,,brain tumor,i.v.,,,Cy5.5,none,,,1,2025
2025,,,,,,,,,,,,,,,,,,,,,,,,,,,2025
2026,polymer-based nanoparticles,Pluronic F127,0.0,,none,none,,passive transport,,,0.0,,20.73,0.17,,,,normal,i.v.,,,DiR,none,,,1,2026
2026,polymer-based nanoparticles,Pluronic F127/D-α-tocopheryl polyethylene glycol succinate (TPGS),0.0,,none,none,,passive transport,,,1.0,D-α-tocopheryl polyethylene glycol succinate (TPGS),20.03,0.18,,,,normal,i.v.,,,DiR,none,,,5.375,2026
2026,,,,,,,,,,,,,,,,,,,,,,,,,,,2026
2027,polymer-based nanoparticles,β‑cyclodextrin (CD)/poly(L‑lysine) dendron (PLLD),0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,DOX,none,0.003928,,,2027
2027,,,,,,,,,,,,,,,,,,,,,,,,,,,2027
2068,liposome,DPC/DPPC/DOTA/DPE,1.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,Cy5.5,none,,,1,2068
2068,liposome,DPC/DPPC/DOTA/DPE,1.0,,none,others,integrin antagonist ,receptor mediated,others,αvβ3,0.0,,100.0,,,,,brain tumor,i.v.,,,Cy5.5,none,,,2.81,2068
2068,,,,,,,,,,,,,,,,,,,,,,,,,,,2068
2070,others,boron,0.0,,none,peptide,RGD-k,receptor mediated,others,αvβ3,0.0,,90.0,,14.8,,,brain tumor,i.v.,,,,none,0.05055,,,2070
2071,gold nanoparticles,Au,1.0,,insulin,none,,receptor mediated,insulin receptor,insulin receptor,0.0,,33.93,,-2.92,,,normal,i.v.,,,,none,0.001324,,,2071
2071,gold nanoparticles,Au,1.0,,insulin,none,,receptor mediated,insulin receptor,insulin receptor,0.0,,70.18,,-4.08,,,normal,i.v.,,,,none,0.001581,,,2071
2071,gold nanoparticles,Au,1.0,,insulin,none,,receptor mediated,insulin receptor,insulin receptor,0.0,,94.05,,-4.1,,,normal,i.v.,,,,none,0.00011,,,2071
2071,,,,,,,,,,,,,,,,,,,,,,,,,,,2071
2093,free drug,,,,none,,,,,,0.0,,,,,,,brain tumor,i.v.,,,farnesylthiosalicylic acid,none,4.6e-05,1,,2093
2093,free drug,,,,none,,,,,,0.0,,,,,,,brain tumor,i.n.,,,farnesylthiosalicylic acid,none,2e-05,1,,2093
2093,polymer-based nanoparticles,PLGA,1.0,30.0,none,none,,absorption mediated,,,0.0,,164.3,0.192,-12.0,97.7,0.035,brain tumor,i.v.,,,farnesylthiosalicylic acid,none,0.000316,6.8695652173913,,2093
2093,polymer-based nanoparticles,PLGA,1.0,30.0,none,none,,absorption mediated,,,0.0,,164.3,0.192,-12.0,97.7,0.035,brain tumor,i.n.,,,farnesylthiosalicylic acid,none,0.000373,18.65,,2093
2098,others,"Mesoporous
silica",0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,,,,2098
2098,others,"Mesoporous
silica",1.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,,,1.90526315789474,2098
2098,others,"Mesoporous
silica",1.0,,none,peptide,"IL-13
peptide",receptor mediated,others,IL13 receptor α2,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,,,2.16578947368421,2098
2105,extracellular vesicles,Macrophage exosomes,0.0,,none,none,none,receptor mediated,others,C-type lectin receptors and integrin LFA-1/ICAM-1,0.0,,116.2,0.134,-18.0,,,others,i.v.,,,none,none,0.00215,,,2105
2105,extracellular vesicles,Macrophage exosomes,0.0,,none,none,none,receptor mediated,others,C-type lectin receptors and integrin LFA-1/ICAM-1,0.0,,116.2,0.134,-18.0,,,normal,i.v.,,,none,none,0.000372,,,2105
2105,extracellular vesicles,BDNF-Macrophage exosomes complex,0.0,,none,none,none,receptor mediated,others,C-type lectin receptors and integrin LFA-1/ICAM-1,0.0,,209.5,,,,,others,i.v.,,,none,none,0.0007476,2.21,,2105
2105,extracellular vesicles,BDNF-Macrophage exosomes complex,0.0,,none,none,none,receptor mediated,others,C-type lectin receptors and integrin LFA-1/ICAM-1,0.0,,209.5,,,,,normal,i.v.,,,none,none,0.0002056,1.39,,2105
2105,free drug,,,,none,none,none,receptor mediated,others,C-type lectin receptors and integrin LFA-1/ICAM-1,0.0,,36.1,,,,,others,i.v.,,,none,none,0.0003388,1,,2105
2105,free drug,,,,none,none,none,receptor mediated,others,C-type lectin receptors and integrin LFA-1/ICAM-1,0.0,,36.1,,,,,normal,i.v.,,,none,none,0.0001476,1,,2105
2112,polymer-based nanoparticles,PLA,0.0,,none,peptide,AP1,receptor mediated,others,interleukin-4 receptor,0.0,,120.0,,-26.3,53.74,0.0137,brain tumor,i.v.,,,doxorubicin,none,,,,2112
2112,polymer-based nanoparticles,PLA,0.0,,none,none,none,passive transport,,,0.0,,110.0,,-29.7,56.33,0.0143,brain tumor,i.v.,,,doxorubicin,none,,,,2112
2112,free drug,,0.0,,none,none,none,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,,,,2112
2113,others,Dextran–spermine,0.0,,none,none,none,receptor mediated,transferrin receptor,,0.0,,96.0,0.23,6.0,,,brain tumor,i.v.,44.0,20.0,Capecitabine,magnectic field,,,0.0124752366552393,2113
2113,others,Dextran–spermine,0.0,,none,none,none,absorption mediated,,,0.0,,80.0,0.178,19.0,26.1,0.116,brain tumor,i.v.,,,Capecitabine,magnectic field,,,1,2113
2115,others,mPEG2000-PLA2000,1.0,50.0,none,none,none,passive transport,,,0.0,,24.78,0.082,,82.32,25.83,brain tumor,i.v.,,,PTX,none,,,1,2115
2115,others,AE-PEG3000-PLA2000,0.0,,none,peptide,L-AE,receptor mediated,others,receptors EGFR and EGFRvIII,0.0,,28.06,0.093,,84.65,23.41,brain tumor,i.v.,,,PTX,none,,,1.30555555555556,2115
2115,others,AE-PEG3000-PLA2000,0.0,,none,peptide,RI-AE,receptor mediated,others,receptors EGFR and EGFRvIII,0.0,,26.7,0.103,,85.63,25.02,brain tumor,i.v.,,,PTX,none,,,1.08333333333333,2115
2115,others,AE-PEG3000-PLA2000,0.0,,none,peptide,D-AE,receptor mediated,others,receptors EGFR and EGFRvIII,0.0,,27.4,0.075,,83.02,24.32,brain tumor,i.v.,,,PTX,none,,,2,2115
2115,,,,,,,,,,,,,,,,,,,,,,,,,,,2115
2134,others,multiwalled carbon nanotubes,0.0,,polysorbate,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,BRB,none,,3.6096,,2134
2134,others,multiwalled carbon nanotubes,0.0,,phospholipid,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,BRB,none,,3.8008,,2134
2134,others,multiwalled carbon nanotubes,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,BRB,none,,2.7012,,2134
2135,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,166.95,0.287,-32.12,29.16,,normal,i.v.,,,MAOS,none,,2.3437,,2135
2140,polymer-based nanoparticles,PLGA,0.0,,polysorbate 80,non-antibody protein,anti-nestin antibody,receptor mediated,others,anti-nestin,0.0,,106.1,0.291,-22.3,73.2,,normal,i.v.,,,TMZ,none,,0.84,,2140
2140,polymer-based nanoparticles,PLGA,0.0,,none,non-antibody protein,anti-nestin antibody，transferrin antibody,receptor mediated,transferrin receptor,anti-nestin，transferrin,0.0,,86.01,0.331,-11.11,75.5,,normal,i.v.,,,TMZ,none,,2.72,,2140
2150,polymer-based nanoparticles,PLGA,1.0,,cell membrane coating,none,,passive transport,,,0.0,,,,-26.7,97.0,,normal,i.v.,,,Fluorescein,none,,,1,2150
2150,polymer-based nanoparticles,PLGA,1.0,,cell membrane coating,peptide,CDX peptide,receptor mediated,choline transporter,nicotinic acetylcholine receptors,0.0,,75.0,,-22.2,101.0,,normal,i.v.,,,Fluorescein,none,,,1.62,2150
2155,free drug,,,,,none,,passive transport,,,0.0,,,,,,,others,i.v.,,,Coumarin 6,none,0.008215,1,,2155
2155,polymer-based nanoparticles,poly (N-butyl) cyanoacrylate,0.0,,none,none,,passive transport,,,0.0,,175.6,0.264,-28.5,,,others,i.v.,,,Coumarin 6,none,0.045126,5.49298861,1,2155
2155,polymer-based nanoparticles,poly (N-butyl) cyanoacrylate,1.0,,none,none,,passive transport,,,0.0,,185.4,0.133,-0.66,,,others,i.v.,,,Coumarin 6,none,0.069842,8.50153374,1.54770642,2155
2156,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,docetaxel,none,0.000224,1,,2156
2156,liposome,SPC/cholesterol,0.0,,none,none,,passive transport,,,0.0,,45.9,0.27,-56.8,,,normal,i.v.,,,docetaxel,none,5e-05,4.52727273,,2156
2157,free drug,,,,,none,,passive transport,,,,,,,,,,normal,i.n.,,,Rivastigmine hydrogen tartarate,none,0.016,1,,2157
2157,liposome,DsPE-PE/lecithin/didecyldimethyl ammonium bromide(DDAB)/Tween 80 ,1.0,2.0,none,none,,passive transport,,,0.0,,478.0,0.557,-8.0,48.0,,normal,i.n.,,,Rivastigmine hydrogen tartarate,none,0.076374,1.8,,2157
2180,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,,1,,2180
2180,micelle,poly(2-ethyl-2-oxazoline) pyridyl disulfide,0.0,,none,none,,passive transport,,,0.0,,160.2,,,,,brain tumor,i.v.,,,doxorubicin,none,,1.36,,2180
2180,micelle,poly(2-ethyl-2-oxazoline) pyridyl disulfide,0.0,,none,none,,passive transport,,,0.0,,140.6,,,,,brain tumor,i.v.,,,doxorubicin,none,,1.4,,2180
2180,micelle,poly(2-ethyl-2-oxazoline) pyridyl disulfide,0.0,,none,none,,passive transport,,,0.0,,97.3,,,,,brain tumor,i.v.,,,doxorubicin,none,,2.44,,2180
2181,liposome,SPC,1.0,,none,peptide,"a dual receptor recognizing cell penetrating peptideRRRRRRRRdGR (R8dGR, lower case letter representsd-amino acid residue)",receptor mediated,others, both integrin αvβ3 and neuropilin-1 receptors,0.0,,100.0,,-4.6,70.0,,brain tumor,i.v.,,,ZD6474（tyrosine kinase inhibitor）,none,0.024,3.43,2.53,2181
2181,liposome,,,5.0,none,none,,passive transport,,,,,,,-5.0,,,brain tumor,i.v.,,,ZD6474（tyrosine kinase inhibitor）,none,0.0095,1.36,,2181
2181,free drug,,,,none,none,,passive transport,,,,,,,,,,brain tumor,i.v.,,,ZD6474（tyrosine kinase inhibitor）,none,0.007,1,,2181
2181,liposome,,,,none,peptide,"a dual receptor recognizing cell penetrating peptideRRRRRRRRdGR (R8dGR, lower case letter representsd-amino acid residue)",receptor mediated,others, both integrin αvβ3 and neuropilin-1 receptors,0.0,,100.0,,-4.6,90.0,,brain tumor,i.v.,,,hydroxychloroquine,none,0.021792,4.94,2.51,2181
2181,liposome,,,5.0,none,none,,passive transport,,,,,,,-5.0,,,brain tumor,i.v.,,,hydroxychloroquine,none,0.00864,1.97,,2181
2181,free drug,,,,none,none,,passive transport,,,,,,,,,,brain tumor,i.v.,,,hydroxychloroquine,none,0.004383,1,,2181
2186,polymer-based nanoparticles,PLGA,0.0,,none,peptide,angiopep-2,receptor mediated,low density lipoprotein-related receptor,low density lipoprotein receptor-related protein,0.0,,30.0,0.16,-48.0,91.0,1.8,brain tumor,i.v.,,179.0,DOX,none,0.00565056,,1.98,2186
2186,,,,,,,,,,,,,,,,,,,,,,,none,0.005292,,1.86,2186
2186,,,,,,,,,,,,,,,,,,,,,,,none,0.002844,,1,2186
2187,polymer-based nanoparticles,PLGA,1.0,,none,others,Ascorbic acid,transporter mediated,others,Sodium dependent-vitamin C transporters,0.0,,96.4,0.098,-7.9,80.1,,Alzheimer's disease,i.v.,,,galantamine,none,0.0036,7.2,3.44,2187
2187,polymer-based nanoparticles,PLGA,1.0,,none,others,Ascorbic acid,transporter mediated,others,Sodium dependent-vitamin C transporters,0.0,,96.2,,-6.3,80.7,,Alzheimer's disease,i.v.,,,galantamine,none,0.00103,2.09,,2187
2187,polymer-based nanoparticles,PLGA,1.0,,none,others,Ascorbic acid,transporter mediated,others,Sodium dependent-vitamin C transporters,0.0,,,,,,,Alzheimer's disease,i.v.,,,galantamine,none,0.0012,2.4,,2187
2187,polymer-based nanoparticles,PLGA,1.0,,none,others,Ascorbic acid,transporter mediated,others,Sodium dependent-vitamin C transporters,0.0,,,,,,,Alzheimer's disease,i.v.,,,galantamine,none,0.0005,,,2187
2189,polymer-based nanoparticles,Carboxymethyl chitosan,0.0,,,none,,,,,0.0,,216.5,0.189,34.9,33.72,,others,i.n.,,,carbamazepine,none,,2.93,,2189
2193,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,,1,,2193
2193,inorganic nanoparticles,SiO2,0.0,,none,none,,passive transport,,,0.0,,196.0,,-11.2,,,brain tumor,i.v.,,,doxorubicin,none,,1.36111111,,2193
2193,inorganic nanoparticles,SiO2,0.0,,none,antibody,Bevacizumab,receptor mediated,others,VEGF,0.0,,253.0,,-11.9,,,brain tumor,i.v.,,,doxorubicin,none,,1.66666667,,2193
2193,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,,1,,2193
2193,inorganic nanoparticles,SiO2,0.0,,none,none,,passive transport,,,0.0,,196.0,,-11.2,,,brain tumor,i.v.,,,doxorubicin,none,,1,,2193
2193,inorganic nanoparticles,SiO2,0.0,,none,antibody,Bevacizumab,receptor mediated,others,VEGF,0.0,,253.0,,-11.9,,,brain tumor,i.v.,,,doxorubicin,none,,1.57142857,,2193
2226,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,cardiogreen,none,,1,,2226
2226,polymer-based nanoparticles,PLGA-PEG,1.0,,none,none,,passive transport,,,0.0,,81.5,0.12,-2.4,,,brain tumor,i.v.,,,cardiogreen,none,,2.29251701,1,2226
2226,polymer-based nanoparticles,PLGA-PEG,1.0,,none,antibody,ITEM4 antibody,receptor mediated,others,Fn14,0.0,,94.2,0.17,-4.8,,,brain tumor,i.v.,,,cardiogreen,none,,3.2244898,1.40652819,2226
2241,liposome,SPC/cholesterol,0.0,,none,none,,passive transport,,,0.0,,45.9,0.27,-56.8,87.81,5.48,normal,i.v.,,,Docetaxel (DTX),none,4.5e-05,4.4,,2241
2241,free drug,,,,,none,,passive transport,,,,,,,,,,normal,i.v.,,,Docetaxel (DTX),none,1e-05,,,2241
2242,liposome,"DSPE-PEG/EPC/didecyldimethyl
ammonium bromide (DDAB)/ Tween 80",1.0,2.0,none,none,,passive transport,,,,,478.0,0.557,-8.0,48.89,,normal,i.n.,,,Rivastigmine ,,0.000315,1.81,,2242
2242,free drug,,,,,none,,passive transport,,,,,,,,,,normal,i.n.,,,Rivastigmine ,,0.000174,,,2242
2265,polymer-based nanoparticles,DSPE-PEG2000/Gd-DOTAMA(C18)2,1.0,,none,peptide,C*NNSKSHTC*,receptor mediated,others,VCAM-1,0.0,,17.0,0.2,,,,others,i.v.,,,,none,0.0031,,,2265
2316,polymer-based nanoparticles,PLA2000,0.0,,none,none,none,passive transport,,,0.0,,,,,,,normal,i.v.,,,DiR,none,,,1,2316
2316,polymer-based nanoparticles,mPEG-PLA2000,1.0,,none,none,none,passive transport,,,0.0,,,,,,,normal,i.v.,,,DiR,none,,,2.95,2316
2316,polymer-based nanoparticles,mPEG-PLA2000,1.0,,none,peptide,Lc(LyP-1)(CGNKRTRGC),receptor mediated,others, cell-surface protein p32/gC1qR,0.0,,,,,,,normal,i.v.,,,DiR,none,,,3.16,2316
2316,polymer-based nanoparticles,mPEG-PLA2000,1.0,,none,peptide,Dc(LyP-1)(CGNKRTRGC),receptor mediated,others, cell-surface protein p32/gC1qR,0.0,,,,,,,normal,i.v.,,,DiR,none,,,3.16,2316
2316,polymer-based nanoparticles,mPEG-PLA2000,1.0,,none,peptide,D CDX(GREIRTGRAERWSEKF),receptor mediated,choline transporter, cell-surface protein p32/gC1qR+nicotinic acetylcholine receptor,0.0,,,,,,,normal,i.v.,,,DiR,none,,,5.7,2316
2316,polymer-based nanoparticles,mPEG-PLA2000,1.0,,none,peptide,Lc(LyP-1)+D CDX,receptor mediated,choline transporter, cell-surface protein p32/gC1qR+nicotinic acetylcholine receptor,0.0,,,,,,,normal,i.v.,,,DiR,none,,,5.59,2316
2316,polymer-based nanoparticles,mPEG-PLA2000,1.0,,none,peptide,Dc(LyP-1)+D CDX,receptor mediated,choline transporter, cell-surface protein p32/gC1qR+nicotinic acetylcholine receptor,0.0,,,,,,,normal,i.v.,,,DiR,none,,,5.32,2316
2316,polymer-based nanoparticles,PLA2000,0.0,,none,none,none,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,,1,2316
2316,polymer-based nanoparticles,mPEG-PLA2000,1.0,,none,none,none,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,,10,2316
2316,polymer-based nanoparticles,mPEG-PLA2000,1.0,,none,peptide,Lc(LyP-1)+D CDX,receptor mediated,choline transporter, cell-surface protein p32/gC1qR+nicotinic acetylcholine receptor,0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,,32.5,2316
2316,polymer-based nanoparticles,mPEG-PLA2000,1.0,,none,peptide,Dc(LyP-1)+D CDX,receptor mediated,choline transporter, cell-surface protein p32/gC1qR+nicotinic acetylcholine receptor,0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,,18,2316
2327,solid lipid nanoparticles,"Glyceryl monostearate/poloxamer 188/1,2-dipalmitoyl-sn-glycero-3-phosphocholine",0.0,,none,none,none,passive transport,,,0.0,,,,-13.5,98.7,,others,i.v.,,,Dil,none,,,1,2327
2327,solid lipid nanoparticles,"Glyceryl monostearate/poloxamer 188/1,2-dipalmitoyl-sn-glycero-3-phosphocholine",0.0,,none,peptide, N-Acetyl Pro–Gly–Pro (PGP) ,cell mediated,,neutrophil mediated,0.0,,,,-12.6,99.1,,others,i.v.,,,Dil,none,,,4.6,2327
2344,polymer-based nanoparticles,mPEG-PLA,1.0,,none,none,none,passive transport,,none,0.0,,62.4,,-22.48,91.23,,normal,i.n.,,,rotigotine,none,,,1,2344
2344,polymer-based nanoparticles,mPEG-PLA,1.0,,none,peptide,lactoferrin,receptor mediated,,lactoferrin receptor,0.0,,118.4,,-21.94,88.07,,normal,i.n.,,,rotigotine,none,,,10,2344
2368,liposome,cholestrol/EPC,0.0,,none,none,none,passive transport,,,0.0,,,,-4.77,,,normal,i.v.,,,DiR,none,,,1,2368
2368,liposome,cholestrol/EPC/DSPE-PEG,1.0,,none,peptide, rabies virus glycoprotein (RVG) derivative,receptor mediated,choline transporter,acetylcholine receptors,0.0,,98.6,0.27,-3.94,,,normal,i.v.,,,DiR,none,,,2.33,2368
2373,solid lipid nanoparticles,monostearate/PEG-monostearate/EPC,1.0,,none,none,none,,,,0.0,,87.0,0.088,-24.59,,,normal,i.v.,,,Cy7,none,,,1,2373
2373,solid lipid nanoparticles,monostearate/PEG-monostearate/EPC,1.0,,none,others,borneol,,,,0.0,,86.9,0.017,-24.97,,,normal,i.v.,,,Cy7,none,,,8.16,2373
2382,free drug,,,,none,none,none,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,methotrexate,none,,1,,2382
2382,polymer-based nanoparticles,PLGA,0.0,,none,none,none,passive transport,,,0.0,,72.17,,-12.56,87.0,,brain tumor,i.v.,,,methotrexate,none,,5.32,1,2382
2382,polymer-based nanoparticles,PLGA,0.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,86.43,,-11.21,78.2,,brain tumor,i.v.,,,methotrexate,none,,6.32,1.19,2382
2382,polymer-based nanoparticles,PLGA,0.0,,polysorbate 80,non-antibody protein,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,97.24,,-10.03,73.6,,brain tumor,i.v.,,,methotrexate,none,,40.72,7.65,2382
2382,polymer-based nanoparticles,PLGA,0.0,,polysorbate 80,non-antibody protein,transferrin+folic acid,receptor mediated,transferrin receptor,transferrin receptor,0.0,,109.7,,-9.38,71.0,,brain tumor,i.v.,,,methotrexate,none,,15.44,2.9,2382
2389,gold nanoparticles,Au,1.0,,none,none,none,passive transport,,,0.0,,92.6,0.079,-27.2,,,normal,i.v.,,,,none,9.72e-05,,1,2389
2389,gold nanoparticles,Au,1.0,,none,none,isotye IgG,passive transport,,,0.0,,75.1,0.249,-24.9,,,normal,i.v.,,8.8,,none,0.00018,,1.85185185,2389
2389,gold nanoparticles,Au,1.0,,none,antibody,Anti-TfRA,receptor mediated,transferrin receptor,transferrin receptor,0.0,,75.2,0.217,-21.4,,,normal,i.v.,,6.5,,none,0.000216,,2.22222222,2389
2389,gold nanoparticles,Au,1.0,,none,antibody,Anti-TfRD,receptor mediated,transferrin receptor,transferrin receptor,0.0,,74.8,0.245,-167.0,,,normal,i.v.,,8.6,,none,0.00036,,3.7037037,2389
2389,gold nanoparticles,Au,1.0,,none,antibody,Anti-TfRA/BACE1,receptor mediated,transferrin receptor,transferrin receptor,0.0,,77.0,0.25,-24.1,,,normal,i.v.,,7.5,,none,0.001296,,13.3333333,2389
2393,polymer-based nanoparticles,PLGA,0.0,,none,antibody,none,passive transport,,,0.0,,,,,,,encephalomyelitis,i.v.,,,Indocyanine green,none,,,1,2393
2393,polymer-based nanoparticles,PLGA,0.0,,none,antibody,CD 47,receptor mediated,others,T cell receptor,0.0,,,,,,,encephalomyelitis,i.v.,,,Indocyanine green,none,,,3.19,2393
2407,magnetic nanoparticles,PLGA/PCL-b-PEG/PLGA-b-PEG/SPION,1.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,,none,0.001692,,,2407
2407,magnetic nanoparticles,PLGA/PCL-b-PEG/PLGA-b-PEG/SPION,1.0,,polysorbate 80,none,,passive transport,,,0.0,,250.0,0.11,-18.0,30.0,0.87,brain tumor,i.v.,,,,none,0.001692,,,2407
2407,magnetic nanoparticles,PLGA/PCL-b-PEG/PLGA-b-PEG/SPION,1.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,,magnetic field,0.002232,,,2407
2423,free drug,,,,none,,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,Cy5.5,none,,1,,2423
2423,polymer-based nanoparticles,DSPE-PEG,1.0,,none,none,,passive transport,,,0.0,,104.0,,,90.0,,brain tumor,i.v.,,,Cy5.5,none,,2.83,,2423
2423,polymer-based nanoparticles,DSPE-PEG,1.0,,none,peptide,CSSPIQGSWTWENGK(C)WTWGIIRLEQ,receptor mediated,amino acid transporter,"extra-domain
B",0.0,,112.0,,,90.0,,brain tumor,i.v.,,,Cy5.5,none,,6.12,2.16,2423
2425,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,5.001e-05,1,,2425
2425,polymer-based nanoparticles,poly-(metronidazole)25,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,0.00201999,40.3917217,,2425
2425,polymer-based nanoparticles,poly-(metronidazole)48,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,doxorubicin,none,0.00203001,40.5920816,,2425
2425,polymer-based nanoparticles,PLGA,1.0,,none,none,,passive transport,,,0.0,,79.52,0.23,,,,brain tumor,i.v.,,,doxorubicin,none,0.00167001,33.3935213,,2425
2425,polymer-based nanoparticles,DSPE-PEG2000/lecithin/angiopep-2-DSPE-PEG2000/poly-(metronidazole)25,1.0,,none,peptide,angiopep-2,receptor mediated,low density lipoprotein-related receptor,low density lipoprotein-related receptor,0.0,,61.66,0.21,,,,brain tumor,i.v.,,,doxorubicin,none,0.00249999,49.989802,,2425
2425,polymer-based nanoparticles,DSPE-PEG2000/ lecithin/ angiopep-2-DSPE-PEG2000 /poly-(metronidazole)48,1.0,,none,peptide,angiopep-2,receptor mediated,low density lipoprotein-related receptor,low density lipoprotein-related receptor,0.0,,76.71,0.26,,,,brain tumor,i.v.,,,doxorubicin,none,0.00261,52.1895621,,2425
2435,free drug,,,,,,,passive transport,,,0.0,,,,,,,Parkinson's disease,i.v.,,,Epigallocatechin gallate,none,4.32e-05,1,,2435
2435,polymer-based nanoparticles,SPION/DSPE-PEG,1.0,,none,peptide,B6,receptor mediated,transferrin receptor,transferrin receptor,0.0,,80.0,,-0.68,,,Parkinson's disease,i.v.,,,Epigallocatechin gallate,none,0.00864,200,,2435
2435,polymer-based nanoparticles,SPION/DSPE-PEG,1.0,,none,peptide,B6+mazindol,receptor mediated,transferrin receptor+dopamine receptor,transferrin receptor+dopamine receptor,0.0,,80.0,,-0.65,,,Parkinson's disease,i.v.,,,Epigallocatechin gallate,none,0.01098,254.166667,,2435
2447,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,temozolomide,none,,1,,2447
2447,dendrimer,PAMAM/chitosan,0.0,,none,none,,passive transport,,,0.0,,201.4,0.84,24.0,72.58,,normal,i.v.,,,temozolomide,none,,1.92,,2447
2452,others,,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,indocyanine green,none,,,,2452
2452,others,SiO2,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,indocyanine green,none,,2.851485149,,2452
2452,others,SiO2,0.0,,none,none,,,,,0.0,,,,,,,brain tumor,i.v.,,,indocyanine green,ultrasound,,11.52475248,,2452
2456,inorganic nanoparticles,selenium nanoparticle,1.0,,none,antibody,HER2 antibody,receptor mediated,,HER2,0.0,,150.0,,7.35,,,normal,i.v.,,,Fe,none,0.023,,,2456
2456,inorganic nanoparticles,selenium nanoparticle,1.0,,none,antibody,HER2 antibody,receptor mediated,,HER2,0.0,,150.0,,7.35,,,normal,i.v.,,,Se,none,0.0628,,,2456
2457,micelle,mPEG2000-PLA,1.0,,none,none,,,,,0.0,,22.0,,,,,brain tumor,i.v.,,,DiR,none,,,1,2457
2457,micelle,mPEG2000-PLA,1.0,,none,peptide,LVS (VSWFSRHRYSPFAVS),receptor mediated,others,α6β1 and αvβ3,0.0,,22.0,,,,,brain tumor,i.v.,,,DiR,none,,,1.081966255,2457
2457,micelle,mPEG2000-PLA,1.0,,none,peptide,DVS (VSWFSRHRYSPFAVS),receptor mediated,others,α6β1 and αvβ3,0.0,,22.0,,,,,brain tumor,i.v.,,,DiR,none,,,1.266392985,2457
2474,liposome,distearoylphosphatidylcholine/cholesterol/mPEG2000/distearoylphosphatidylethanolamine,1.0,,none,none,none,passive transport,,,0.0,,156.3,0.201,,,,ischemic stroke,i.v.,,,DiR,none,,,1,2474
2474,liposome,distearoylphosphatidylcholine/cholesterol/mPEG2000/distearoylphosphatidylethanolamine,1.0,,none,antibody,anti-PirB antibody,receptor mediated,others, Paired immunoglobulin-like receptor B,0.0,,167.1,0.124,,,,ischemic stroke,i.v.,,,DiR,none,,,2.64,2474
2485,free drug,,,,none,none,,,,,0.0,,,,,,,brain tumor,i.v.,,,Cy5,none,,1,,2485
2485,albumin nanoparticles,bovine serum albumin,0.0,,none,none,,,,,0.0,,123.7,0.22,-16.8,,,brain tumor,i.v.,,,Cy5,none,,34.48,1,2485
2485,albumin nanoparticles,bovine serum albumin,0.0,,none,peptide,mannose,receptor mediated,transferrin receptor,mannose receptor,0.0,,128.0,0.087,-17.1,,,brain tumor,i.v.,,,Cy5,none,,40.245,1.167198376,2485
2485,albumin nanoparticles,bovine serum albumin,0.0,,none,others,"T12
(THRPPMWSPVWP) and mannose",receptor mediated,transferrin receptor,transferrin receptor and mannose receptor,0.0,,132.2,0.14,-18.7,,,brain tumor,i.v.,,,Cy5,none,,50.775,1.472592807,2485
2535,polymer-based nanoparticles,mPEG-PLGA,1.0,,none,peptide,RVG29-Cyspeptide,receptor mediated,acetylcholine receptors,nicotinic acetylcholine receptor (nAchR),0.0,,116.5,,-8.16,,,brain tumor,i.v.,,,Docetaxel,none,0.02503,,2.132027257,2535
2535,polymer-based nanoparticles,mPEG-PLGA,1.0,,none,none,,passive transport,,,,,95.0,,-10.16,,,brain tumor,i.v.,,,Docetaxel,none,0.01174,,1,2535
2535,free drug,,,,,,,,,,,,,,,,,brain tumor,i.v.,,,Docetaxel,none,0.00877,,,2535
2535,,,,,,,,,,,,,,,,,,,,,,,,,,,2535
2535,,,,,,,,,,,,,,,,,,,,,,,,,,,2535
2544,liposome,lipid S100/cholesterol/mPEG2000-DSPE,1.0,,none,none,,passive transport,,,0.0,,114.8,0.195,-17.0,55.3,6.46,normal,i.v.,,,"N-3,4-bis(pivaloyloxy)-dopamine",none,,,1,2544
2544,liposome,lipid S100/mal-PEG2000-DSPE/mPEG2000-DSPE,1.0,,none,peptide,RVG29,receptor mediated,choline transporter,choline transporter,0.0,,134.7,0.25,-13.5,52.52,6.15,normal,i.v.,,,"N-3,4-bis(pivaloyloxy)-dopamine",none,,,13.1346643178704,2544
2561,gold nanoparticles,HAuCl4/CuCl2,1.0,,none,none,,passive transport,,,0.0,,6.5,,10.8,,,brain tumor,i.v.,,,,none,,,,2561
2561,gold nanoparticles,HAuCl4/CuCl2,1.0,,none,none,,passive transport,,,0.0,,5.6,,0.04,,,brain tumor,i.v.,,,,none,,,,2561
2561,gold nanoparticles,HAuCl4/CuCl2,1.0,,none,none,,passive transport,,,0.0,,5.2,,-15.3,,,brain tumor,i.v.,,,,none,,,,2561
2561,gold nanoparticles,HAuCl4/CuCl2,1.0,,none,none,,passive transport,,,0.0,,6.5,,10.8,,,brain tumor,i.v.,,,,ultrasound,,,,2561
2561,gold nanoparticles,HAuCl4/CuCl2,1.0,,none,none,,passive transport,,,0.0,,5.6,,0.04,,,brain tumor,i.v.,,,,ultrasound,0.016,,,2561
2561,gold nanoparticles,HAuCl4/CuCl2,1.0,,none,none,,passive transport,,,0.0,,5.2,,-15.3,,,brain tumor,i.v.,,,,ultrasound,,,,2561
2605,liposome,SPC,1.0,,none,none,,,,,,,97.66,0.206,-9.86,93.15,,brain tumor,i.v.,,,,,,,,2605
2605,liposome,SPC,1.0,,none,folic acid,Folic,receptor mediated,others,others,0.0,,98.42,0.211,-10.8,92.29,,brain tumor,i.v.,,,DID,none,,,1.34042553191489,2605
2605,liposome,SPC,1.0,,none,peptide,"KIKKVKKKGRKKIKKVKKKGRK-cys, dNP2-cys",receptor mediated,others,others,0.0,,96.05,0.189,-4.36,92.83,,brain tumor,i.v.,,,DID,none,,,2.72340425531915,2605
2605,liposome,SPC,1.0,,none,others,"Folic AND KIKKVKKKGRKKIKKVKKKGRK-cys, dNP2-cys",receptor mediated,others,others,0.0,,104.1,0.23,-6.52,92.83,,brain tumor,i.v.,,,DID,none,,,3.53191489361702,2605
2605,liposome,SPC,1.0,,none,others,"acid-cleavable Folic AND KIKKVKKKGRKKIKKVKKKGRK-cys, dNP2-cys",receptor mediated,others,others,0.0,,103.4,0.211,-6.64,92.37,,brain tumor,i.v.,,,DID,none,,,3.74468085106383,2605
2613,polymer-based nanoparticles,PLGA,1.0,30.0,polysorbate 80,none,,passive transport,,,0.0,,250.0,0.11,-18.0,30.0,,brain tumor,i.v.,,,Fe,magnetic field,0.0022,,1.27580607747622,2613
2613,polymer-based nanoparticles,PLGA,1.0,30.0,polysorbate 80,none,,passive transport,,,,,203.0,0.07,-21.0,31.0,,brain tumor,i.v.,,,,none,0.0016956,,0.983298538622129,2613
2613,polymer-based nanoparticles,PLGA,1.0,30.0,none,none,,passive transport,,,,,,,,,,,,,,,none,0.0017244,,1,2613
2625,liposome,cholesterol/HSPC/mPEG2000-DSPE ,1.0,5.0,none,none,,,,,0.0,,,,,,,normal,i.v.,,,DiR,none,,,1,2625
2625,liposome,cholesterol/HSPC/mPEG2000-DSPE/DA7R-PEG3400-DSPE,1.0,6.0,none,peptide,DA7R (DRDPDPDLDWDTDA),receptor mediated,others,"vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 2",0.0,,,,,,,normal,i.v.,,,DiR,none,,,1.384615,2625
2625,liposome,cholesterol/HSPC/mPEG2000-DSPE/MC-PEG3400-DSPE,1.0,6.0,none,others,Myristic acid (MC),receptor mediated,,,0.0,,,,,,,normal,i.v.,,,DiR,none,,,4.884615,2625
2625,liposome,cholesterol/HSPC/mPEG2000-DSPE/MC-PEG3400-DSPE,1.0,6.0,none,others,"Myristic acid-DRDPDPDLDWDTDA, MC-DA7R",receptor mediated,,,0.0,,,,,,,normal,i.v.,,,DiR,none,,,6,2625
2625,liposome,cholesterol/HSPC/mPEG2000-DSPE ,1.0,5.0,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,,1,2625
2625,liposome,cholesterol/HSPC/mPEG2000-DSPE/MC-PEG3400-DSPE,1.0,6.0,none,peptide,DA7R (DRDPDPDLDWDTDA),receptor mediated,others,"vascular endothelial growth factor receptor 2, vascular endothelial growth factor receptor 2",0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,,1.652174,2625
2625,liposome,cholesterol/HSPC/mPEG2000-DSPE/MC-PEG3400-DSPE,1.0,6.0,none,others,Myristic acid (MC),receptor mediated,,,0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,,3.782609,2625
2625,liposome,cholesterol/HSPC/mPEG2000-DSPE/MC-PEG3400-DSPE,1.0,6.0,none,others,"Myristic acid-DRDPDPDLDWDTDA, MC-DA7R",receptor mediated,,,0.0,,,,,,,brain tumor,i.v.,,,DiR,none,,,8.086957,2625
2626,gold nanoparticles,Cu/Au,0.0,,none,none,,passive transport,,,0.0,,5.6,,-0.4,,,brain tumor,i.v.,,,64Cu,none,0.666,,,2626
2629,others,layered double hydroxide/bovine serum albumin,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,Cy7,none,,,,2629
2629,others,layered double hydroxide/bovine serum albumin,0.0,,none,peptide,Angiopep-2(TFFYGGSRGKRNNFKTEEYC),receptor mediated,low density lipoprotein-related receptor,,0.0,,175.0,0.193,-15.0,,,brain tumor,i.v.,,,Cy7,none,,,1.75,2629
2629,others,layered double hydroxide/bovine serum albumin,0.0,,none,peptide,RVG29 (TWMPENPRPGTPCDIFTNSRGKRASNGGGGGGC) ,receptor mediated,choline transporter,nicotinic acetylcholine receptors (nAchR) ,0.0,,176.0,0.185,-13.8,,,brain tumor,i.v.,,,Cy7,none,,,1,2629
2631,polymer-based nanoparticles,PAMAM(G4),0.0,,none,none,,passive transport,,,0.0,,,,,,,others,i.v.,,,Cy5,none,0.03816842105,,,2631
2631,polymer-based nanoparticles,PAMAM(G4),0.0,,none,glycosol,Mannose,receptor mediated,hexose transporter,Mannose receptor [Cluster of Differentiation (CD) 206] ,0.0,,,,,,,others,i.v.,,,Cy5,none,0.05334736842,,"1.397683398
",2631
2637,gold nanoparticles,Au,0.0,,none,none,,passive transport,,,0.0,,12.0,,-19.0,,,normal,i.v.,,,,laser,0.090064795,,,2637
2637,gold nanoparticles,Au,1.0,33.3,none,peptide,Transferrin (230 peptides),receptor mediated,transferrin receptor,,0.0,,12.0,,2.0,,,normal,i.v.,,,,laser,0.00213822894,,2.374100719,2637
2637,gold nanoparticles,Au nanorod,0.0,,none,none,,passive transport,,,0.0,,,,2.0,,,normal,i.v.,,,,laser,0.074514,,,2637
2637,gold nanoparticles,Au nanorod,1.0,33.3,none,peptide,Transferrin (169 peptides),receptor mediated,transferrin receptor,,0.0,,,,2.8,,,normal,i.v.,,,,laser,0.100432,,1.347826087,2637
2637,gold nanoparticles,Au nanorod,1.0,33.3,none,peptide,Transferrin (169 peptides),receptor mediated,transferrin receptor,,0.0,,,,2.8,,,normal,i.v.,,,,laser,0.207991,,2.791304348,2637
2637,,,,,,,,,,,,,,,,,,,,,,,,,,,2637
2650,others,SPION,1.0,,none,none,,passive transport,,,0.0,,113.2,,-28.1,,,brain tumor,i.v.,,,Dil,none,,,1,2650
2650,others,SPION,1.0,,none,peptide,RGE(RGERPPR),receptor mediated,others,NPR-1,0.0,,122.7,,-24.1,,,brain tumor,i.v.,,,Dil,none,,,2.85,2650
2656,others,CeO2,1.0,,oleic acid,none,,,,,,,,,,,,,,,,,,,,,2656
2656,others,CeO2,1.0,,oleic acid,peptide,Angiopep-2 (TFFYGGSRGKRNNFKTEEYC) ,receptor mediated,,,,,,,,,,,,,,,,,,,2656
2706,liposome,DOPE/DOTAP/cholesterol,1.0,,none,none,,passive transport,,,0.0,,,,,,,,i.v.,,,DiR,none,0.030204,,1,2706
2706,liposome,DOPE/DOTAP/cholesterol,1.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,,,,,,,i.v.,,,DiR,none,0.028296,,0.93682956,2706
2706,liposome,DOPE/DOTAP/cholesterol,1.0,,none,peptide,penetratin,absorption mediated,others,,0.0,,,,,,,,i.v.,,,DiR,none,0.029628,,0.98092968,2706
2706,liposome,DOPE/DOTAP/cholesterol,1.0,,none,others,transferrin and penetratin,others,others,,0.0,,,,,,,,i.v.,,,DiR,none,0.043128,,1.42789035,2706
2723,free drug,,,,,,,passive transport,,,,,,,,,,brain tumor,i.v.,,,IR780,none,,1,,2723
2723,others,,0.0,,none,none,,passive transport,,,0.0,,172.0,,13.0,,,brain tumor,i.v.,,,IR780,none,,12.879746835443,,2723
2723,others, cell-penetrating peptide TAT-D-α-tocopheryl polyethylene glycol succinate (TPGS),0.0,,none,cell-penetrating peptide,cell-penetrating peptide TAT,absorption mediated,,,0.0,,177.0,,22.0,,,brain tumor,i.v.,,,IR780,none,,17.9746835443038,1.3955773955774,2723
2728,free drug,,,,,,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,,none,,1,,2728
2728,cationic liposome,DOTAP/cholesterol/DOPC/DSPE-PEG2000,1.0,10.0,none,others,Angiopep-2,receptor mediated,others,LRP-1,0.0,,88.0,,9.54,,,brain tumor,i.v.,0.5,,Cy5-siRNA,none,,3.2700000025477,,2728
2764,polymer-based nanoparticles,oxidized nanocrystalline mesoporous carbon,1.0,,none,peptide,pep-22,receptor mediated,low density lipoprotein-related receptor,LDLR,0.0,,224.8,,-40.5,,,brain tumor,i.v.,,,DOX,none,,,1.4549356223176,2764
2764,polymer-based nanoparticles,oxidized nanocrystalline mesoporous carbon,1.0,,none,none,,passive transport,,,0.0,,156.1,,-58.0,,,brain tumor,i.v.,,,DOX,none,,,1,2764
2769,polymer-based nanoparticles,NH2 of PEG,1.0,,none,peptide,RVG,receptor mediated,choline transporter,acetylcholine receptor,0.0,,101.0,,6.4,,,normal,i.v.,,,Ru,none,,,,2769
2769,polymer-based nanoparticles,NH2 of PEG,1.0,,,none,,passive transport,,,,,110.0,,-24.9,,,normal,i.v.,,,Ru,none,,,,2769
2775,solid lipid nanoparticles,Glyceryl monostearate/SL/stearic acid,0.0,,tween 80,none,,passive transport,,,,,79.0,0.21,-20.0,90.0,,brain tumor,i.v.,,,DTX,none,0.00332316,1.65001340602377,,2775
2775,solid lipid nanoparticles,Glyceryl monostearate/SL/stearic acid,0.0,,tween 80,peptide,angiopep-2,receptor mediated,low density lipoprotein-related receptor,LRP-1,0.0,,111.4,0.31,-16.4,87.0,,brain tumor,i.v.,,,DTX,none,0.0081567,4.04995978192868,,2775
2805,free drug,,,,,,,,,,0.0,,,,,,,brain tumor,i.v.,,,paclitaxel,none,0.000792,1,,2805
2805,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,220.4,,1.2,76.5,0.0364,brain tumor,i.v.,,,paclitaxel,none,0.00087,1.09848484848485,,2805
2805,polymer-based nanoparticles,PLGA,0.0,,none,peptide,L-carnitine,receptor mediated,others,Na+-coupled carnitine transporter 2,0.0,,275.3,,1.8,65.4,0.031,brain tumor,i.v.,,,paclitaxel,none,0.00614,7.75252525252525,7.05747126436782,2805
2805,polymer-based nanoparticles,PEG500-PLGA,1.0,,none,peptide,L-carnitine,receptor mediated,others,Na+-coupled carnitine transporter 2,0.0,,204.1,,1.5,71.0,0.0338,brain tumor,i.v.,,,paclitaxel,none,0.0040446,5.10681818181818,4.64896551724138,2805
2805,polymer-based nanoparticles,PEG1000-PLGA,1.0,,none,peptide,L-carnitine,receptor mediated,others,Na+-coupled carnitine transporter 2,0.0,,205.6,,1.2,91.4,0.0435,brain tumor,i.v.,,,paclitaxel,none,0.009049,11.4255050505051,10.4011494252874,2805
2805,polymer-based nanoparticles,PEG2000-PLGA,1.0,,none,peptide,L-carnitine,receptor mediated,others,Na+-coupled carnitine transporter 2,0.0,,206.9,,1.4,57.8,0.0275,brain tumor,i.v.,,,paclitaxel,none,0.0009,1.13636363636364,1.03448275862069,2805
2843,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,DiR,none,0.1030928,1,,2843
2843,solid lipid nanoparticles,stearic acid/phospholpon 90G/nicotinamide,0.0,,none,none,,passive transport,,,0.0,,107.0,,-40.9,,,normal,i.v.,,,DiR,none,0.2247423,2.18,1,2843
2843,solid lipid nanoparticles,stearic acid/phospholpon 90G/nicotinamide/PS,0.0,,none,others,phosphatidylserine (PS),cell mediated,,,0.0,,124.0,,-46.1,,,normal,i.v.,,,DiR,none,0.3608247,3.5,1.605505,2843
2843,solid lipid nanoparticles,stearic acid/phospholpon 90G/nicotinamide/PA,0.0,,none,others,phosphatidic acid (PA),cell mediated,,,0.0,,137.0,,-50.6,,,normal,i.v.,,,DiR,none,0.2948454,2.86,1.311927,2843
2843,free drug,,,,,,,,,,,,,,,,,normal,i.p.,,,DiR,none,0.123711,1,,2843
2843,solid lipid nanoparticles,stearic acid/phospholpon 90G/nicotinamide,0.0,,none,none,,passive transport,,,0.0,,107.0,,-40.9,,,normal,i.p.,,,DiR,none,0.216495,1.75,1,2843
2843,solid lipid nanoparticles,stearic acid/phospholpon 90G/nicotinamide/PS,0.0,,none,others,phosphatidylserine (PS),cell mediated,,,0.0,,124.0,,-46.1,,,normal,i.p.,,,DiR,none,0.352577,2.85,1.628571,2843
2843,solid lipid nanoparticles,stearic acid/phospholpon 90G/nicotinamide/PA,0.0,,none,others,phosphatidic acid (PA),cell mediated,,,0.0,,137.0,,-50.6,,,normal,i.p.,,,DiR,none,0.276289,2.233333,1.27619,2843
2847,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,156.9,,,,,brain tumor,i.v.,,,DiR,none,,,1,2847
2847,polymer-based nanoparticles,PLGA,0.0,,none,none,,cell mediated,,,0.0,,10000.0,,,,,brain tumor,i.v.,,,DiR,none,,,2.541667,2847
2854,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,336.5,0.33,-12.45,5.1,,others,i.n.,,,DiR,none,0.086364,,,2854
2868,polymer-based nanoparticles,PLGA,1.0,,oleic acid,others,WGA,absorption mediated,,GlcNAc,0.0,,139.0,,-23.3,59.99,,ischemic stroke/reperfusion,i.n.,,,DIR,none,,,1.259,2868
2899,micelle,DSPE-PEG-Bor/DSPE-PEG-Pep-1/DSPE-PEG /DOPE,1.0,,none,peptide and others,Pep-1 peptide；Borneol(Bor),receptor mediated,amino acid transporter,Interleukin-13 receptor(IL-13R),,,32.6,0.113,-21.3,95.5,3.4,brain tumor,i.v.,,,Carmustine(CMS),none,,,8.34,2899
2899,micelle,DSPE-PEG-Bor/DSPE-PEG-Pep-1/DSPE-PEG /DOPE,1.0,,none,peptide,Pep-1 peptide,receptor mediated,amino acid transporter,Interleukin-13 receptor(IL-13R),,,30.1,0.102,-19.3,94.5,3.1,brain tumor,i.v.,,,Carmustine(CMS),none,,,3.67,2899
2899,micelle,DSPE-PEG/DOPE,1.0,,none,none,,,,,,,27.5,0.084,-22.9,96.5,3.3,brain tumor,i.v.,,,Carmustine(CMS),none,,,1,2899
2901,micelle, ch-K5(s-s)R8-An/pEGFP,0.0,,none,peptide,MMP-2-responsive peptides,receptor mediated,low density lipoprotein-related receptor,Angiopep-2,,,119.5,,25.0,,,brain tumor,i.v.,,,,none,,,2.6,2901
2937,liposome,EPC/cholesterol/DSPE-PEG,1.0,,none,none,,passive transport,,,0.0,,92.5,,20.7,,,normal,i.v.,,,doxorubicin,none,,,1,2937
2941-2960,liposome,DOTAP/EPC/cholesterol/DSPE-PEG,1.0,,oleic acid,cell-penetrating peptide,octa-arginine (R8),absorption mediated,,,0.0,,95.4,,12.1,,,normal,i.v.,,,doxorubicin,none,,,2.4,2941-2960
2964,albumin nanoparticles,human serum albumin,0.0,,none,none,,passive transport,,,0.0,,191.4,,-49.0,,,brain tumor,i.v.,,,Cy5.5,others(ultrasound),,,1.55,2964
2964,albumin nanoparticles,human serum albumin,0.0,,none,none,,passive transport,,,0.0,,191.4,,-49.0,,,brain tumor,i.v.,,,Cy5.5,none,,,1,2964
2975,solid lipid nanoparticles,Glyceryl monostearate,0.0,,none,none,,passive transport,,,0.0,,386.0,0.481,-3.61,89.01,,normal,i.n.,,,Vinpocetine (VPN),none,,,,2975
2975,others,,0.0,,none,none,,passive transport,,,0.0,,590.0,0.444,1.89,97.34,,normal,i.n.,,,Vinpocetine (VPN),none,,,,2975
2975,liposome,,1.0,25.0,none,none,,passive transport,,,0.0,,205.0,0.494,-52.27,59.05,,normal,i.n.,,,Vinpocetine (VPN),none,,,,2975
2975,others,,0.0,,none,none,,passive transport,,,1.0,TPGS,13.0,0.484,-2.79,100.0,,normal,i.n.,,,Vinpocetine (VPN),none,0.001588,,9.925,2975
2975,others,,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,Vinpocetine (VPN),none,0.00016,,1,2975
2975,,,,,,,,,,,,,,,,,,,,,,,,,,,2975
2993,gold nanoparticles,Au,1.0,,none,antibody,OX26,receptor mediated,transferrin receptor,transferrin receptor,0.0,,32.0,,3.4,,,normal,i.v.,,,,none,,,35.5,2993
2993,gold nanoparticles,Au,0.0,,none,none,,passive transport,,,0.0,,25.27,,-40.4,,,normal,i.v.,,,,none,,,1,2993
3076,polymer-based nanoparticles,cholera toxin B subunit/chelated gadolinium,0.0,,none,others,cholera toxin B subunit,cell mediated,others,monosialoganglioside GM1,0.0,,110.0,,-11.0,,,Alzheimer's disease,i.n.,,,Cy5.5,none,,,1.43776824,3076
3076,albumin nanoparticles,bovine serum albumin/chelated gadolinium,0.0,,none,none,,passive transport,,,0.0,,143.0,,-14.7,,,Alzheimer's disease,i.n.,,,Cy5.5,none,,,,3076
3078,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,MTX,none,1.0,,,3078
3078,solid lipid nanoparticles,sodium stearate/PVA9000,0.0,,none,none,,passive transport,,,0.0,,353.0,0.24,,,,normal,i.v.,,,MTX,none,0.000463,,1,3078
3078,solid lipid nanoparticles,sodium stearate/PVA9000/,0.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,,0.0,,437.0,0.122,,,,normal,i.v.,,,MTX,none,0.000289,,0.625,3078
3078,solid lipid nanoparticles,sodium stearate/PVA9000/,0.0,,none,others,insulin,receptor mediated,insulin receptor,,0.0,,429.0,0.222,,,,normal,i.v.,,,MTX,none,0.000289,,0.625,3078
3078,solid lipid nanoparticles,sodium stearate/PVA9000/stearyl-PEG-maleimide,1.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,,0.0,,500.0,0.209,,,,normal,i.v.,,,MTX,none,0.001561,,3.375,3078
3078,solid lipid nanoparticles,sodium stearate/PVA9000/stearyl-PEG-maleimide,1.0,,none,others,insulin,receptor mediated,insulin receptor,,0.0,,445.0,0.103,,,,normal,i.v.,,,MTX,none,0.001908,,4.125,3078
3081,emulsion,Indinaviroleic acid/α-tocopherol/span 8 / olive oil ,0.0,,oleic acid,none,,others,others,,0.0,,110.3,0.2,-34.6,,,normal,i.v.,,,Indinaviroleic acid,none,0.00414,,1,3081
3081,emulsion,Indinaviroleic acid/α-tocopherol/span 8 / olive oil ,0.0,,oleic acid,non-antibody protein, Lactoferrin ,receptor mediated,transferrin receptor,,0.0,,112.6,0.19,-33.2,,,normal,i.v.,,,Indinaviroleic acid,none,0.00934,,2.25,3081
3098,others,,0.0,,none,none,,passive transport,others,,0.0,,,,,,,normal,i.v.,,,native nimotuzumab,none,0.001224,,1,3098
3098,,,0.0,,none,others,"Acetylcholine,Choline",receptor mediated,choline transporter," nicotinic acetylcholine receptor (nAChRs),choline transporter (ChT)",0.0,,25.0,,,,,normal,i.v.,,,native nimotuzumab,none,0.0216,,17.64,3098
3118,others,mesoporous silica,,,none,none,,passive transport,,,,,105.77,,-15.9,95.1,,normal,i.p.,,,Thymoquinone（TQ）,none,0.055578,1.11,,3118
3118,free drug,,,,,,,passive transport,,,,,,,,,,normal,i.p.,,,Thymoquinone（TQ）,none,0.049766,1,,3118
3120,others,mPEG-PCL/SPION,1.0,,none,none,,passive transport,,,,,137.0,0.12,-6.5,78.5,15.5,normal,i.v.,,,naproxen,magnetic field,0.01315,3.67,,3120
3120,others,mPEG-PCL/SPION,1.0,,none,none,,passive transport,,,,,242.0,0.26,-4.8,84.3,15.0,normal,i.v.,,,naproxen,magnetic field,0.00655,1.83,,3120
3120,free drug,,,,,,,passive transport,,,,,,,,,,normal,i.v.,,,naproxen,none,0.0036,1,,3120
3139,solid lipid nanoparticles,PLGA,0.0,,SDS,none,,passive transport,,,,,60.3,0.27,-31.0,51.3,,normal,i.v.,,,,none,0.035774,,,3139
3145,others,Kolliphor HS15/lipoid S75/Labrafac lipophile WL 1349,0.0,,none,none,,passive transport,,,,,21.11,0.037,,,,normal,i.v.,,,DiD,none,0.0018,,,3145
3145,others,Kolliphor HS15/lipoid S75/Labrafac lipophile WL 1349,0.0,,none,none,,passive transport,,,,,40.43,0.105,,,,normal,i.v.,,,DiD,none,0.0011,,,3145
3145,others,Kolliphor HS15/lipoid S75/Labrafac lipophile WL 1349,0.0,,none,none,,passive transport,,,,,38.6,0.106,,,,normal,i.v.,,,DiD,none,0.003,,,3145
3145,others,Kolliphor HS15/lipoid S75/Labrafac lipophile WL 1349,0.0,,cannabidiol,none,,passive transport,,,,,52.4,0.064,,,,normal,i.v.,,,DiD,none,0.0011,,,3145
3152,solid lipid nanoparticles,cetyl palmitate/Cremephor RH 40/Peceo/propylene glycol ,1.0,,none,peptide,iRGD (CCRGDKGPDC),receptor mediated,others,αv integrin,0.0,,15.4,,,,,brain tumor,i.v.,,,,none,,,1,3152
3168,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,cy5.5,none,,1,,3168
3168,gold nanoparticles,Au,1.0,,none,none,,passive transport,,,0.0,,18.03,,,,,normal,i.v.,,,cy5.5,none,,10.8609271523179,,3168
3171,polymer-based nanoparticles,PEG-phenylboronic ester-modified polylysine,1.0,100.0,none,none,,passive transport,,,0.0,,58.7,0.18,5.27,,,ischemic stroke/reperfusion,i.v.,,,BODIPY,none,0.00027,,,3171
3171,polymer-based nanoparticles,PEG-phenylboronic ester-modified polylysine,1.0,100.0,none,peptide,fibrin-binding peptide (CREKA),absorption mediated,,,0.0,,65.8,0.16,6.42,,,ischemic stroke/reperfusion,i.v.,,,BODIPY,none,0.00037,,1.37037037037037,3171
3181,others,Se,1.0,,none,antibody,OX26,receptor mediated,transferrin receptor,,0.0,,12.0,,1.17,,,"stroke(ischemic stroke, hemorrhagic stroke)",i.p.,,,none,none,0.0001,,,3181
3181,others,Se,1.0,,none,none,,passive transport,,,0.0,,,,-24.0,,,"stroke(ischemic stroke, hemorrhagic stroke)",i.p.,,,none,none,0.0,,,3181
3199,polymer-based nanoparticles,PLGA-PLL,1.0,10.0,none,peptide,Angiopep-2,receptor mediated,others,LRP1,0.0,,116.5,0.129,-9.54,94.46,8.63,normal,i.v.,,178.0,Doxorubicin,none,,,1.36080586080586,3199
3199,polymer-based nanoparticles,PLGA-PLL,1.0,10.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,Doxorubicin,none,,,1,3199
3199,polymer-based nanoparticles,PLGA-PLL,1.0,10.0,none,peptide,Angiopep-2,receptor mediated,others,LRP1,0.0,,116.5,0.129,-9.54,94.46,8.63,normal,i.v.,,178.0,Doxorubicin,none,,,1.40710382513661,3199
3199,polymer-based nanoparticles,PLGA-PLL,1.0,10.0,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,Doxorubicin,none,,,1,3199
3199,,,,,,,,,,,,,,,,,,,,,,,,,,,3199
3213,polymer-based nanoparticles,pluronic F127,0.0,,none,peptide,RGDyK,receptor mediated,,,0.0,,70.0,,,,,brain tumor,i.v.,,,DTX,none,0.011675664,,,3213
3213,polymer-based nanoparticles,pluronic F127,0.0,,none,,,passive transport,,,0.0,,70.0,,,,,brain tumor,i.v.,,,DTX,none,0.002335176,,,3213
3213,,,,,,,,,,,,,,,,,,,,,,,,,,,3213
3222,polymer-based nanoparticles,chitosan,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,"Nicardipine hy-
drochloride",none,0.006336,,,3222
3222,polymer-based nanoparticles,chitosan,0.0,,HAMC gel,none,,absorption mediated,,,0.0,,439.6,0.307,21.05,,0.1779,normal,i.n.,,,"Nicardipine hy-
drochloride",none,0.00552,,0.87,3222
3222,polymer-based nanoparticles,chitosan,0.0,,HAMC gel+PMMA film,none,,absorption mediated,,,0.0,,,,,,,normal,i.n.,,,"Nicardipine hy-
drochloride",none,0.007056,,1.11,3222
3222,polymer-based nanoparticles,chitosan,0.0,,HAMC gel+PLA film,none,,absorption mediated,,,0.0,,,,,,,normal,i.n.,,,"Nicardipine hy-
drochloride",none,0.003888,,0.61,3222
3222,,,,,,,,,,,,,,,,,,,,,,,,,,,3222
3246,liposome,DOPE/DOTAP/cholesterol/DSPE-PEG ,1.0,4.0,none,non-antibody protein,HIV-1 trans-activating protein (TAT),absorption mediated,,,0.0,,,,,,,normal,i.v.,4.0,,none,none,0.0112212,,,3246
3246,liposome,DOPE/DOTAP/cholesterol/DSPE-PEG ,1.0,4.0,none,non-antibody protein,HIV-1 trans-activating protein (TAT) and transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,,,,,,normal,i.v.,4.0,,none,none,0.02754,,,3246
3288,emulsion,mixing fish oil,0.0,,none,none,,cell mediated,,,0.0,,155.6,0.067,25.3,,,normal,i.v.,,,Rapamycin,none,0.004,,,3288
3288,emulsion,mixing fish oil,1.0,0.3,none,none,,cell mediated,,,0.0,,138.6,0.049,17.0,,,normal,i.v.,,,Rapamycin,none,0.0069,,,3288
3288,emulsion,mixing fish oil,0.0,,none,none,,cell mediated,,,0.0,,455.7,0.45,27.2,,,normal,i.v.,,,Rapamycin,none,0.0046,,,3288
3288,emulsion,mixing fish oil,1.0,0.3,none,none,,cell mediated,,,0.0,,870.2,0.21,24.3,,,normal,i.v.,,,Rapamycin,none,0.0064,,,3288
3288,free drug,,0.0,,none,none,,cell mediated,,,0.0,,,,,,,normal,i.v.,,,Rapamycin,none,0.0094,,,3288
3288,,,,,,,,,,,,,,,,,,,,,,,,,,,3288
3304,polymer-based nanoparticles,PVA/PEG,1.0,,none,antibody,anti-VCAM-1 antibody,others,others,VCAM1,0.0,,200.0,,,,,others,i.v.,,,tritium,none,0.01681491,,4.272727,3304
3304,polymer-based nanoparticles,PVA/PEG,1.0,,none,none,,passive transport,,,0.0,,200.0,,,,,others,i.v.,,,tritium,none,0.0039354,,,3304
3304,polymer-based nanoparticles,PVA/PEG,1.0,,none,antibody,anti-VCAM-1 antibody,others,others,VCAM1,0.0,,,,,,,others,i.v.,,,tritium,none,0.01806708,,4.391304348,3304
3304,polymer-based nanoparticles,PVA/PEG,1.0,,none,none,,passive transport,,,0.0,,,,,,,others,i.v.,,,tritium,none,0.00411429,,,3304
3308,free drug,,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,bevacizumab,none,0.019,1,,3308
3308,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,185.0,0.056,,82.47,,normal,i.n.,,,bevacizumab,none,0.0354,1.863158,,3308
3313,polymer-based nanoparticles,poly(methacrylic acid)-polysorbate 80-grafted starch,0.0,,none,none,,passive transport,,,0.0,,138.0,0.22,-42.3,,,brain tumor,i.v.,,,HiLyte Fluor 750 (HF 750) ,none,,,,3313
3313,polymer-based nanoparticles,poly(methacrylic acid)-polysorbate 80-grafted starch,0.0,,none,peptide,iRGD,receptor mediated,others,αvβ3 and αvβ5,0.0,,126.0,0.2,-43.6,,,brain tumor,i.v.,,,HiLyte Fluor 750 (HF 750) ,none,,,2.636363636,3313
3356,polymer-based nanoparticles,mPEG-PCL,1.0,,none,none,,passive transport,,,0.0,,107.15,0.22,0.79,,,Alzheimer's disease,p.o.,,,Donepezil hydrochloride (DNP),none,0.077616,0.77,1,3356
3356,polymer-based nanoparticles,mPEG-PCL,1.0,,none,peptide,amyloid beta,transporter mediated,others,ApoE3,0.0,,124.26,0.17,-6.97,,,Alzheimer's disease,p.o.,,,Donepezil hydrochloride (DNP),none,0.120008,1.19,1.55,3356
3356,polymer-based nanoparticles,mPEG-PCL,1.0,,polysorbate 80,peptide,amyloid beta,transporter mediated,others,ApoE3,0.0,,137.65,0.19,-2.08,,,Alzheimer's disease,p.o.,,,Donepezil hydrochloride (DNP),none,0.218176,2.17,2.81,3356
3356,free drug,,,,,,,,,,,,,,,,,Alzheimer's disease,p.o.,,,Donepezil hydrochloride (DNP),none,0.100544,1,,3356
3393,free drug,,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,Memantine,none,2.925e-05,1,,3393
3393,polymer-based nanoparticles,PAMAM,0.0,,none,none,,passive transport,,,0.0,,11.54,0.19,19.21,,,normal,i.v.,,,Memantine,none,6.588e-05,2.25230769,,3393
3393,polymer-based nanoparticles,PAMAM,0.0,,none,peptide,lactoferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,131.72,0.16,20.13,,,normal,i.v.,,,Memantine,none,0.00037314,12.7569231,5.66393443,3393
3415,free drug,,,,,,,,,,0.0,,,,,,,normal,i.v.,,,siRNR,none,0.0123,1,,3415
3415,others,,0.0,,none,peptide,15-amino acid peptide GYRPVHNIRGHWAPG (GYR peptide),receptor mediated,transferrin receptor,transferrin receptor,0.0,,169.0,,1.55,,,normal,i.v.,,,siRNR,none,0.0246,2,,3415
3415,,,,,,,,,,,,,,,,,,,,,,,,,,,3415
3429,others,SPION,1.0,,none,folic acid,folic acid (FA),receptor mediated,others,folate receptor,0.0,,58.61,0.25,-29.85,61.0,6.85,brain tumor,i.v.,,,Temozolomide (TMZ),magnectic field,,,1.76083707,3429
3429,others,SPION,1.0,,none,folic acid,folic acid (FA),receptor mediated,others,folate receptor,0.0,,58.61,0.25,-29.85,61.0,6.85,brain tumor,i.v.,,,Temozolomide (TMZ),none,,,1.45720250521921,3429
3429,others,SPION,1.0,,none,none,,passive transport,,,0.0,,55.24,0.194,-34.61,68.0,7.34,brain tumor,i.v.,,,Temozolomide (TMZ),magnectic field,,,1,3429
3429,others,SPION,1.0,,none,none,,passive transport,,,0.0,,55.24,0.194,-34.61,68.0,7.34,brain tumor,i.v.,,,Temozolomide (TMZ),none,,,1,3429
3450,polymer-based nanoparticles,PLGA,0.0,,none,peptide,specific peptide against Tf receptor,receptor mediated,transferrin receptor,transferrin receptor,0.0,,216.3,0.067,-19.6,,,normal,i.n.,,,Venlafaxine,none,,,,3450
3450,polymer-based nanoparticles,PLGA,0.0,,none,peptide,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,218.6,0.078,-19.5,,,normal,i.n.,,,Venlafaxine,none,,,,3450
3450,polymer-based nanoparticles,PLGA,0.0,,none,none,,passive transport,,,0.0,,206.3,0.041,-26.5,,,normal,i.n.,,,Venlafaxine,none,,,,3450
3457,polymer-based nanoparticles,Trimethyl Chitosan Hydrogel ,0.0,,none,none,,passive transport,,,0.0,,204.0,0.25,27.0,80.0,,normal,i.n.,,,D-9-progesterone,none,0.0427,,,3457
3457,,,,,,,,,,,,,,,,,,,,,,,,,,,3457
3458,others,Iron Oxide ,0.0,,none,none,,passive transport,,,0.0,,33.0,,,,,normal,i.v.,,,none,none,0.013457,,,3458
3458,,,,,,,,,,,,,,,,,,,,,,,,,,,3458
3444,liposome,PEG2000-DSPE,1.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,177.45,0.212,-6.5,65.32,,normal,i.v.,,,DOX,none,,8.3,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,cell-penetrating peptide,TAT,absorption mediated,,,0.0,,173.6,0.259,20.35,66.91,,normal,i.v.,,,DOX,none,,7.4,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,cell-penetrating peptide,QLPVM,absorption mediated,,,0.0,,171.9,0.197,19.27,65.06,,normal,i.v.,,,DOX,none,,7.6,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,,,,,,0.0,,174.9,0.254,15.03,65.72,,normal,i.v.,,,DOX,none,,15.3,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,,,,,,0.0,,175.57,0.246,14.87,66.47,,normal,i.v.,,,DOX,none,,14.8,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,,,,,,0.0,,174.45,0.173,5.85,64.8,,normal,i.v.,,,DOX,none,,2.3,,3444
3444,free drug,,,,none,,,,,,0.0,,,,,,,normal,i.v.,,,DOX,none,,1,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,177.45,0.212,-6.5,53.84,,normal,i.v.,,,erlotinib,none,,1.76,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,cell-penetrating peptide,TAT,absorption mediated,,,0.0,,173.6,0.259,20.35,52.67,,normal,i.v.,,,erlotinib,none,,1.16,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,cell-penetrating peptide,QLPVM,absorption mediated,,,0.0,,171.9,0.197,19.27,51.28,,normal,i.v.,,,erlotinib,none,,1.05,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,,,,,,0.0,,174.9,0.254,15.03,54.61,,normal,i.v.,,,erlotinib,none,,2.83,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,,,,,,0.0,,175.57,0.246,14.87,53.37,,normal,i.v.,,,erlotinib,none,,2.79,,3444
3444,liposome,PEG2000-DSPE,1.0,,none,,,,,,0.0,,174.45,0.173,5.85,53.79,,normal,i.v.,,,erlotinib,none,,1.09,,3444
3444,free drug,,,,,,,,,,0.0,,,,,,,normal,i.v.,,,erlotinib,none,,1,,3444
3444,,,,,,,,,,,,,,,,,,,,,,,,,,,3444
3531,liposome,SPC,1.0,0.4,none,peptide,rabies virus glycoprotein-derived peptide,receptor mediated,,,0.0,,,,,,,others,i.v.,,,Ruthenium Complex,none,,,1.71,3531
3557,extracellular vesicles,,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,DiR,none,,"1.603718744
",,3557
3633,polymer-based nanoparticles,,1.0,,none,none,none,passive transport,,,0.0,,182.3,0.217,-7.31,96.4,,normal,i.v.,,,docetaxel,none,0.0011,,,3633
3637,polymer-based nanoparticles,PEG-PLA,1.0,,none,none,,passive transport,,,0.0,,,,,,,Alzheimer's disease,i.n.,,,DiR,none,,,1,3637
3637,polymer-based nanoparticles,PEG-PLA,1.0,,none,others,Wheat germ agglutinin,absorption mediated,others,oligosaccharides,0.0,,191.0,0.25,,75.6,,Alzheimer's disease,i.n.,,,DiR,none,,,1.21,3637
3670,polymer-based nanoparticles,PEG-b-PCL,1.0,31.7,none,peptide,Angiopep-2,transporter mediated,low density liproprotein-related receptor,"low-density lipoprotein receptor-related protein
(LRP)",0.0,,42.0,,,73.6,12.8,normal,i.v.,,,DiR,none,,,2.18,3670
3670,polymer-based nanoparticles,PEG-b-PCL,1.0,31.7,none,none,,passive transport,,,0.0,,22.2,,,74.1,12.9,normal,i.v.,,,DiR,none,,,,3670
3670,,,,,,,,,,,,,,,,,,,,,,,,,,,3670
3679,others,,0.0,,none,peptide,Angiopep-2,transporter mediated,low density liproprotein-related receptor,"low-density lipoprotein receptor-related protein
(LRP)",0.0,,120.0,,,,,brain tumor,i.p.,,,Camptothecin (CPT),none,,,,3679
3679,,,,,,,,,,,,,,,,,,,,,,,,,,,3679
3678,magnetic nanoparticles,Fe2O3,1.0,,none,none,,passive transport,,,0.0,,10.09,,-28.0,,,brain tumor,i.v.,,,Fe,none,0.08532,,1,3678
3678,magnetic nanoparticles,Fe2O3,1.0,,none,peptide,"Angiopep-2 (ANG, TFFYGGSRGKRNNFKTEEY",receptor mediated,low density lipoprotein-related receptor,lipoprotein receptor-related protein ,0.0,,14.6,,-46.1,,,brain tumor,i.v.,,,Fe,none,0.09072,,1.06329114,3678
3678,magnetic nanoparticles,Fe2O3,1.0,,none,none,,passive transport,,,0.0,,10.09,,-28.0,,,brain tumor,i.v.,,,Fe,none,,,1,3678
3678,magnetic nanoparticles,Fe2O3,1.0,,none,peptide,"Angiopep-2 (ANG, TFFYGGSRGKRNNFKTEEY",receptor mediated,low density lipoprotein-related receptor,lipoprotein receptor-related protein ,0.0,,14.6,,-46.1,,,brain tumor,i.v.,,,Fe,none,,,2.1,3678
3691,others,Vitamin C/methionine/sodium thiosulfate,0.0,,none,none,,passive transport,,,0.0,,53.0,,,,,normal,i.v.,,,ruthenium,none,,,1,3691
3691,others,Vitamin C/methionine/sodium thiosulfate/poly-α-cyanoacrylate/Triton-100,0.0,,none,none,,passive transport,,,0.0,,2100.0,,,,,normal,i.v.,,,ruthenium,none,,,1,3691
3691,others,Vitamin C/methionine/sodium thiosulfate/poly-α-cyanoacrylate/riton-100,0.0,,none,none,,passive transport,,,0.0,,2100.0,,,,,normal,i.v.,,,ruthenium,ultra sound,,,16.547619,3691
3691,,,,,,,,,,,,,,,,,,,,,,,,,,,3691
3685,polymer-based nanoparticles,PLGA,0.0,,none,peptide,RGD,receptor mediated,others,αvβ3 receptor,1.0,Glucose ,192.2,0.189,,52.2,3.2,brain tumor,i.v.,,,DOX,none,,,0.833338916619209,3685
3685,polymer-based nanoparticles,PLGA,0.0,,none,none,,,,,1.0,Glucose ,182.2,0.147,,75.3,4.9,brain tumor,i.v.,,,DOX,none,,,1,3685
3685,polymer-based nanoparticles,PLGA,0.0,,none,peptide,RGD,receptor mediated,others,αvβ3 receptor,1.0,Glucose ,192.2,0.189,,52.2,3.2,brain tumor,i.n.,,,DOX,none,,,2.03614119379274,3685
3685,polymer-based nanoparticles,PLGA,0.0,,none,none,,,,,1.0,Glucose ,182.2,0.147,,75.3,4.9,brain tumor,i.n.,,,DOX,none,,,1,3685
3687,polymer-based nanoparticles,PEG-b-PCL,1.0,,none,peptide,"Angiopep-2
",receptor mediated,low density lipoprotein-related receptor,LRP,0.0,0,20.6,,,,,normal,i.v.,,,DIR,none,,6.56,2.18518498875173,3687
3687,polymer-based nanoparticles,PEG-b-PCL,1.0,,,,,,,,,,17.9,,,,,normal,i.v.,,,DIR,none,,3,1,3687
3712,free drug,PC,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,Doxorubicin,ultrasound,,1,,3712
3712,liposome,PC,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,Doxorubicin,none,,1.46311475409836,,3712
3712,liposome,PC,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,Doxorubicin,ultrasound,,2.25,,3712
3720,free drug,,0.0,,none,none,,,,,0.0,,,,,,,normal,i.v.,,,pacli-taxel,none,,,,3720
3720,others,Chitosan oligosaccharide,0.0,,none,none,,passive transport,,,0.0,,41.1,,,78.84,0.0729,normal,i.v.,,,,none,,,,3720
3720,,,,,,,,,,,,,,,,,,,,,,,,,,,3720
3720,,Chitosan oligosaccharide,0.0,,none,peptide,angiopep-2,receptor mediated,low density lipoprotein-related receptor,LRP1,0.0,,73.7,,18.2,,,normal,i.v.,,,,none,,,,3720
3761,polymer-based nanoparticles,PLGA,0.0,,,,,passive transport,,,,,97.36,0.263,-17.98,82.49,5.09,normal,i.n.,,,thymoquinone (THQ),none,0.004014,14.97,,3761
3761,free drug,PLGA,0.0,,,,,passive transport,,,,,,,,,,normal,i.n.,,,,none,0.000268,1,,3761
3761,inorganic nanoparticles,PLGA,0.0,,none,none,,passive transport,,,,,,,,,,normal,i.v.,,,,none,0.000972,5.43,,3761
3761,free drug,PLGA,0.0,,,,,passive transport,,,,,,,,,,normal,i.v.,,,,none,0.000179,1,,3761
3.251,liposome,DOPE/DOTAP,0.0,,none,peptide,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,130.6,0.147,22.5,83.6,,normal,i.v.,,,lissamine rhodamine-phosphatidylethanolamine,none,,,1.47,3.251
3.251,,,,,,,,,,,,,132.1,0.143,33.2,86.1,,normal,i.v.,,,lissamine rhodamine-phosphatidylethanolamine,none,,,,3.251
3769,magnetic nanoparticles,PLGA/SPION,0.0,,none,none,,passive transport,,,,,87.56,0.641,9.14,,,brain tumor,i.v.,,,radiosensitizers  IUdR,magnetic field,0.0031,,1.17,3769
3769,,,,,,,,,,,,,,,,,,,,,,radiosensitizers  IUdR,,0.0027,,,3769
3770,micelle,MA4-PEG-CA8/CBA4-PEG-CA8,0.0,,none,none,maltobionic acid,transporter mediated,others,GLUT1 ,0.0,,140.2,0.201,,90.0,,brain tumor,i.v.,,,Cy 7.5,none,,4.06,,3770
3770,,,,,,,,,,,,,,,,,,,,,,,,,1.11,3.67,3770
3770,,,,,,,,,,,,,,,,,,,,,,,,,0.97,4.19,3770
3770,,,,,,,,,,,,,,,,,,,,,,,,,0.985,4.12,3770
3770,,,,,,,,,,,,,,,,,,,,,,,,,,,3770
3783,liposome,SPC/cholesterol/DSPE-PEG2000-OMe/DSPE-PEG2000-R6dGR,1.0,5.0,none,peptide,R6dGR,receptor mediated,others,αvβ3,0.0,,100.0,,,,,brain tumor,i.v.,,,PPR/ p DNA-cy5,none,,"2.304
",,3783
3788,free drug, catechin hydrate,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,catechin hydrate,none,0.001413,1,,3788
3788,free drug, catechin hydrate,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,catechin hydrate,none,0.000729,1,,3788
3788,polymer-based nanoparticles, catechin hydrate/PVA/PLGA,0.0,,none,none,,passive transport,,,0.0,,93.69,0.104,-12.39,,,normal,i.n.,,,catechin hydrate,none,0.011256,7.967742,,3788
3788,polymer-based nanoparticles, catechin hydrate/PVA/PLGA/chitosan,0.0,,chitosan,none,,passive transport,,,0.0,,106.31,0.239,21.64,80.36,0.0598,normal,i.n.,,,catechin hydrate,none,0.018091,12.80645,1.607287449,3788
3788,polymer-based nanoparticles, catechin hydrate/PVA/PLGA,0.0,,none,none,,passive transport,,,0.0,,93.69,0.104,-12.39,,,normal,i.v.,,,catechin hydrate,none,0.001732,2.375,,3788
3788,polymer-based nanoparticles, catechin hydrate/PVA/PLGA/chitosan,0.0,,chitosan,none,,passive transport,,,0.0,,106.31,0.239,21.64,80.36,0.0598,normal,i.v.,,,catechin hydrate,none,0.002278,3.125,1.315789474,3788
3798,liposome,COATSOME NC-50/stearyl cyclic SLS derivative (SLS-STR peptide)/cholesterol,0.0,,none,peptide,stearyl cyclic SLS derivative (SLS-STR peptide),receptor mediated,,,0.0,,150.0,,,,,normal,i.v.,,,DiO,none,0.021564,,,3798
3813,,,,,,,,,,,,,,,,,,,,,,,,,,,3813
3869,cationic liposome,DSPE-PEG2000,1.0,,none,none,,transcytosis,,,0.0,,67.1,,8.7,,,brain tumor,i.v.,,,NIR-dye,none,0.396,,,3869
3869,cationic liposome,DSPE-PEG2000,1.0,,none,none,,transcytosis,,,0.0,,60.2,,13.0,,,brain tumor,i.v.,,,NIR-dye,none,0.504,,,3869
3869,cationic liposome,DSPE-PEG2000,1.0,,none,none,,transcytosis,,,0.0,,64.6,,14.6,,,brain tumor,i.v.,,,NIR-dye,none,0.3564,,,3869
3835,inorganic nanoparticles,phospholipin 90G/propylene glycol/vitamin E,0.0,,none,none,,passive transport,,,0.0,,209.7,0.366,,,,normal,i.n.,,,Tramadol,none,0.024821,6.79,,3835
3835,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,p.o.,,,Tramadol,none,0.003657,1,,3835
3877,dendrimer,PAMAM（G5）,0.0,,none,none,,passive transport,,,0.0,,6.4,,25.9,,,brain tumor,i.v.,,,Arsenic trioxide,none,0.009936,,,3877
3877,dendrimer,PAMAM（G5）,0.0,,none,peptide,iRGD,receptor mediated,others,αvβ3,0.0,,21.8,,23.5,,,brain tumor,i.v.,,,Arsenic trioxide,none,0.01926,,,3877
3877,dendrimer,PAMAM（G5）,0.0,,none,peptide, TGN peptide (TGNYKALHPHNG),receptor mediated,others,,0.0,,24.3,,24.3,,,brain tumor,i.v.,,,Arsenic trioxide,none,0.024984,,,3877
3877,dendrimer,PAMAM（G5）,0.0,,none,peptide,iRGD and TGN,receptor mediated,others,αvβ3,0.0,,27.4,,17.6,,,brain tumor,i.v.,,,Arsenic trioxide,none,0.027684,,,3877
3887,free drug,,,,,,,,,,0.0,,,,,,,brain tumor,i.n.,,,Levofloxacin,none,8.1e-05,1,,3887
3887,solid lipid nanoparticles,Compritol 888 ATO/Stearic acid,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.n.,,,Levofloxacin,none,0.000946,11.679012345679,,3887
3887,free drug,,,,,,,,,,0.0,,,,,,,brain tumor,i.n.,,,Doxycycline,none,0.000348,1,,3887
3887,solid lipid nanoparticles,Compritol 888 ATO/Stearic acid,0.0,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.n.,,,Doxycycline,none,0.00081,2.32758620689655,,3887
3890,free drug,,,,,,,,,,0.0,,,,,,,Alzheimer's disease,i.n.,,,memantine,none,0.008352,1,,3890
3890,emulsion,Labrasol,0.0,,none,none,,passive transport,,,0.0,,11.0,0.08,-19.6,,,Alzheimer's disease,i.n.,,,memantine,none,0.01296,1.55172413793103,,3890
3890,emulsion,Labrasol,0.0,,none,none,,passive transport,,,0.0,,11.0,0.08,-19.6,,,Alzheimer's disease,i.g.,,,memantine,none,0.002016,,,3890
3890,emulsion,Labrasol,0.0,,none,none,,passive transport,,,0.0,,11.0,0.08,-19.6,,,Alzheimer's disease,i.v.,,,memantine,none,0.006228,,,3890
3892,liposome,DOPC/CH/L-α-phosphatidic acid,0.0,,none,none,,passive transport,,,0.0,,,,,,,Parkinson's disease,i.p.,,,dopamine,none,,,,3892
3892,liposome,DOPC/CH/L-α-phosphatidic acid,0.0,,none,non-antibody protein,amyloid precursor protein,receptor mediated,,,0.0,,100.0,,-27.0,,,Parkinson's disease,i.p.,0.5,,dopamine,none,,,11.2,3892
3894,polymer-based nanoparticles,poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate),1.0,100.0,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,BRD4 inhibitor JQ1,none,0.00016,,,3894
3894,polymer-based nanoparticles,poly(ethylene glycol)-block-poly(2-methyl-2-benzoxycarbonyl-propylene carbonate),1.0,100.0,none,peptide,ApoE mimetic peptide,receptor mediated,low density lipoprotein-related receptor,very low-density lipoprotein (VLDL) receptor,0.0,,,,,,,brain tumor,i.v.,,,BRD4 inhibitor JQ1,none,0.0005,,3.125,3894
3895,polymer-based nanoparticles,PEG-polycaprolactone,1.0,,none,none,,passive transport,,,0.0,,72.6,,5.98,85.7,,brain tumor,i.n.,,,coumarin,none,,,,3895
3895,polymer-based nanoparticles,PEG-polycaprolactone,1.0,,none,peptide,Bombesin peptide (GQWAVGHLM),receptor mediated,others,gastrin-releasing peptide receptor (GRPR),0.0,,68.1,,6.74,73.3,,brain tumor,i.n.,,,coumarin,none,,,0.554750194149625,3895
3904,emulsion,"isopropyl myristate/ethyl oleate
",0.0,,none,none,,passive transport,,,0.0,,45.52,,-21.28,,,normal,p.o.,,,Stiripentol,none,0.004452,2.32253016,,3904
3904,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,normal,p.o.,,,Stiripentol,none,0.001917,1,,3904
3907,liposome,bovine serum albumin-poly(ε-caprolactone,0.0,,none,none,,passive transport,,,0.0,,180.0,0.164,-38.7,,,brain tumor,i.t.,,,doxorubicin,none,0.393,2.46,,3907
3907,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.t.,,,doxorubicin,none,0.16,1,,3907
3926,liposome,DSPC/DSPE-mPEG2000/DOPC,1.0,,none,none,,passive transport,,,0.0,,134.31,0.105,,,,brain tumor,i.v.,,,DiR,none,,,1,3926
3926,liposome,DSPC/DSPE-mPEG2000/DOPC,1.0,,none,peptide,angiopep-2,receptor mediated,low density lipoprotein-related receptor,low density lipoprotein-related receptor,0.0,,143.74,0.104,,,,brain tumor,i.v.,,,DiR,none,,,2.4893617,3926
3926,liposome,DSPC/DSPE-mPEG2000/DOPC,1.0,,none,none,,passive transport,,,0.0,,134.31,0.105,,,,brain tumor,i.v.,,,DiR,ultrasound,,,3.87234043,3926
3926,liposome,DSPC/DSPE-mPEG2000/DOPC,1.0,,none,peptide,angiopep-2,receptor mediated,low density lipoprotein-related receptor,low density lipoprotein-related receptor,0.0,,143.74,0.104,,,,brain tumor,i.v.,,,DiR,ultrasound,,,5,3926
3934,liposome,DOPE/DOTAP/Cholesterol,1.0,,none,cell-penetrating peptide, R9F2,absorption mediated,,,0.0,,164.2,,31.4,,,,,,,DiR,none,0.008604,,,3934
3934,liposome,DOPE/DOTAP/Cholesterol,1.0,,none,cell-penetrating peptide+transferrin, R9F2+transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,159.7,,27.3,,,,,,,DiR,none,0.023256,,,3934
3934,,,,,,,,,,,,,,,,,,,,,,,,,,,3934
3923,others,PEG-PLL,1.0,,none,glycosol,Glucose,transporter mediated,hexose transporter,GLUT,1.0,Glucose,45.0,0.15,,58.78,,Alzheimer's disease,i.v.,25.0,,3D6-Fab,none,,,17.2352941176471,3923
3923,others,PEG-PLL,1.0,,none,none,,passive transport,,,,,45.0,0.15,,,,Alzheimer's disease,i.v.,,,3D6-Fab,none,,,1,3923
3923,others,PEG-PLL,1.0,,none,none,,passive transport,,,,,,,,,,Alzheimer's disease,i.v.,,,3D6-Fab,none,,,,3923
3923,others,PEG-PLL,1.0,,none,none,,passive transport,,,,,,,,,,Alzheimer's disease,i.v.,,,3D6-Cit-Fab,none,,,,3923
3927,liposome,DSPE-PEG2000-Amine/Cholesterol/DOPE,1.0,,none,peptide,RGDK,receptor mediated,others,αvβ3/αvβ35,0.0,,136.6,0.236,-7.2,,,brain tumor,i.v.,,,WP1066/NIR dye,none,,,,3927
3927,liposome,DSPE-PEG2000-Amine/Cholesterol/DOPE,1.0,,none,peptide,RGEK,passive transport,,,0.0,,157.0,0.202,-15.5,,,brain tumor,i.v.,,,WP1066/NIR dye,none,,,,3927
3938,liposome,DOPE/DOTAP/Cholesterol,1.0,,none,non-antibody protein,transferrin,receptor mediated,transferrin receptor,transferrin receptor,0.0,,168.7,,25.0,80.0,,normal,i.v.,,,pDNA,none,,,,3938
3938,liposome,DOPE/DOTAP/Cholesterol,1.0,,none,cell-penetrating peptide,R9F2,absorption mediated,,,0.0,,164.2,,30.4,80.0,,normal,i.v.,,,pDNA,none,,,,3938
3949,free drug,,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,p.o.,,,Topiramate,none,0.056,1,,3949
3949,emulsion,capmul MCM C8,0.0,,none,none,,passive transport,,,0.0,,4.73,,10.74,,0.047,normal,p.o.,,,Topiramate,none,0.09025,1.61160714285714,,3949
3949,free drug,,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,Topiramate,none,0.06175,1,,3949
3949,emulsion,capmul MCM C8,0.0,,none,none,,passive transport,,,0.0,,4.73,,10.74,,0.047,normal,i.n.,,,Topiramate,none,0.086,1.39271255060729,,3949
3951,emulsion,Labrafac PG 8/Labrafac WL-1349/Peceol/Maisine,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,,none,0.000576,,,3951
3951,emulsion,Labrafac PG 8/Labrafac WL-1349/Peceol/Maisine,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,,none,0.001656,,,3951
3951,emulsion,Labrafac PG 8/Labrafac WL-1349/Peceol/Maisine,0.0,,none,none,,passive transport,,,0.0,,21.2,0.355,-14.12,,,normal,i.n.,,,,none,0.002047,,,3951
3951,,,,,,,,,,,,,,,,,,,,,,,,,,,3951
4019,emulsion,"ethyl oleate/Cremophor® RH 40/1,2-propanediol",0.0,,none,none,,passive transport,,,0.0,,45.52,0.076,-21.67,,,others,p.o.,,,stiripentol (STP) ,none,,2.32,,4019
4021,free drug,,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,, pyridine-2-aldoxime methochloride (2-PAM),none,0.007895,1,,4021
4021,cationic liposome,"SPC/alkanediyl-α,ω-bis(N-hexadecyl-N-2-hydroxyethyl-N-methylammonium bromide/pyridine-2-aldoxime methochloride",0.0,,none,none,,passive transport,,,0.0,,115.0,0.096,45.0,72.0,47.0,normal,i.v.,,, pyridine-2-aldoxime methochloride (2-PAM),none,0.016138,"2.044025157
",,4021
4056,liposome,DOTAP/cholesterol/DSPE-PEG,1.0,,,none,,passive transport,,,0.0,0,148.0,0.102,33.0,,,normal,i.v.,,,miR 603,none,,,,4056
4056,,,,,,,,,,,,,,,,,,,,,,,,,,,4056
4056,,,,,,,,,,,,,,,,,,,,,,,,,,,4056
4056,,DOTAP/cholesterol/{succinyl[methoxy(polyethylene glycol)2000]} (PEG2000-Cer16) (cer-PEG),1.0,,none,others,{succinyl[methoxy(polyethylene glycol)2000]} (PEG2000-Cer16) (cer-PEG),passive transport,others,,0.0,0,148.0,0.102,16.0,,,normal,i.v.,,,miR 603,none,, ,2.34,4056
4110,solid lipid nanoparticles,GYNASAN 114/glycerol/Lipoid S75,1.0,,none,none,,passive transport,,,0.0,,80.0,0.26,-55.0,70.0,,normal,i.v.,,,pralidoxime chloride,none,0.0176,,,4110
4111,others,stearic acid/SPC/PLGA,1.0,,none,none,,passive transport,,,0.0,,362.2,0.39,,,,normal,i.v.,,,DiR,none,0.0096,,,4111
4116,free drug,,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.n.,,,alendronate,none,,1,,4116
4116,polymer-based nanoparticles,chitosan/sodium tripolyphosphate,0.0,,none,none,,passive transport,,,0.0,,173.66,0.49,22.0,72.46,,normal,i.n.,,,alendronate,none,,4.57,,4116
4122,solid lipid nanoparticles,glycerol monostearate,0.0,,none,none,,passive transport,,,0.0,,121.38,0.077,-29.55,83.17,,Alzheimer's disease,i.v.,,,DiR,none,,,1,4122
4122,solid lipid nanoparticles,glycerol monostearate,1.0,5.0,none,others,DSPE-PEG-triphenylphosphine (TPP),absorption mediated,,,0.0,,122.51,0.132,24.64,82.48,,Alzheimer's disease,i.v.,5.0,,DiR,none,,,1.54,4122
4122,solid lipid nanoparticles,glycerol monostearate,1.0,7.5,none,peptide,DSPE-PEG-RVG29 peptide,receptor mediated,,,0.0,,124.23,0.101,-32.27,81.76,,Alzheimer's disease,i.v.,7.5,,DiR,none,,,7.67,4122
4122,solid lipid nanoparticles,glycerol monostearate,1.0,12.5,none,others,DSPE-PEG-triphenylphosphine (TPP)+DSPE-PEG-RVG29 peptide,receptor mediated,,,0.0,,123.19,0.167,19.13,82.31,,Alzheimer's disease,i.v.,12.5,,DiR,none,,,8.19,4122
4142,gold nanoparticles,Au,0.0,,none,none,,transporter mediated,transferrin receptor,transferrin receptor 1,0.0,,13.17,,,,,brain tumor,i.v.,,,C6,none,,4.61,,4142
4142,free drug,,,,none,none,,passive transport,,,0.0,,,,,,,brain tumor,i.v.,,,C6,none,,1,,4142
4152,liposome,HSPC/PEG-PE/Cholesterol,1.0,5.0,none,none,,passive transport,,,0.0,,85.1,0.059,-5.61,,,brain tumor,convention-enhanced delivery (CED),,,DiR,none,,,,4152
4152,liposome,HSPC/PEG-PE/Cholesterol/DOTAP,1.0,3.85,none,none,,passive transport,,,0.0,,80.8,0.076,8.9,,,brain tumor,convention-enhanced delivery (CED),,,DiR,none,,,,4152
4152,liposome,HSPC/PEG-PE/Cholesterol/DOTAP,1.0,3.85,none,none,,passive transport,,,0.0,,83.6,0.091,13.9,,,brain tumor,convention-enhanced delivery (CED),,,DiR,none,,,,4152
4152,liposome,HSPC/DOTAP,0.0,,none,none,,passive transport,,,0.0,,73.9,0.094,52.7,,,brain tumor,convention-enhanced delivery (CED),,,DiR,none,,,,4152
4153,polymer-based nanoparticles,PLGA,1.0,,none,none,,passive transport,,,0.0,,,,,,,"stroke(ischemic stroke, hemorrhagic stroke)",i.n.,,,miRNA-124,none,,,,4153
4153,polymer-based nanoparticles,PLGA,0.0,,none,none,,receptor mediated,peptide,nicotinic acetylcholine receptor (nAchR),0.0,,,,,,,"stroke(ischemic stroke, hemorrhagic stroke)",i.n.,,,miRNA-124,none,,,,4153
4153,polymer-based nanoparticles,PLGA,1.0,,none,none,,receptor mediated,peptide,nicotinic acetylcholine receptor (nAchR),0.0,,204.0,,,28.2,,"stroke(ischemic stroke, hemorrhagic stroke)",i.n.,,,miRNA-124,none,,,1.84,4153
4161,albumin nanoparticles,bovine serum albumin,0.0,,none,glycosol,Chondroitin sulfate,receptor mediated,others,CD44,0.0,,222.3,0.217,-32.8,62.0,4.0,normal,i.v.,,,Temozolomide,none,,1.48743196471454,,4161
4161,albumin nanoparticles,bovine serum albumin,0.0,,none,,,,,,0.0,,160.6,0.153,-25.3,71.0,10.0,normal,i.v.,,,Temozolomide,none,,1.34993933305351,,4161
4161,free drug,,,,,,,,,,,,,,,,,normal,i.v.,,,Temozolomide,none,,1,,4161
4163,others,4-aminophenylboronic acid/methacrylic anhydride,0.0,,none,peptide,Lactoferrin,receptor mediated,others,Lactoferrin receptor,0.0,,193.9,0.125,-21.63,83.33,18.18,normal,i.v.,,,DOX,none,,10.01,11.2448979591837,4163
4163,others,5-aminophenylboronic acid/methacrylic anhydride,0.0,,none,,,,,,0.0,,117.1,0.249,-35.77,,,normal,i.v.,,,DOX,none,,0.89,,4163
4163,,,,,,,,,,,,,,,,,,,,,,,,,,,4163
4182,free drug,,,,,,,,,,,,,,,,,,,,,obidoxime (LuH-6）,,,1,,4182
4182,liposome, SPC/ DOPS/cholesterol/DSPE-PEG2000,1.0,4.0,none,none,,,,,0.0,,135.1,0.092,-32.19,,,normal,i.v.,,,obidoxime (LuH-6）,none,,2.72,,4182
4182,liposome, SPC/ DOPS/cholesterol/DSPE-PEG2001,1.0,4.0,none,peptide,transferrin receptor (TfR) aptamer,receptor mediated,transferrin receptor ,transferrin receptor (TfR),0.0,,138.7,0.066,-31.5,61.4,,normal,i.v.,,,obidoxime (LuH-6）,none,,10.89,4,4182
4182,,,,,,,,,,,,,,,,,,,,,,,,,,,4182
4255,micelle,P(MeOx39-b-PBuOx25-b-PMeOx39),0.0,,none,,,,,,,,41.5,0.03,3.81,98.36,,brain tumor,i.v.,,,vismodegib,none,,2.47,,4255
4268,free drug,,0.0,,none,none,,passive transport,,,,,,,,,,normal,i.n.,,,bexarotene,none,0.023684,1,,4268
4268,polymer-based nanoparticles,PCL,0.0,,none,none,,passive transport,,,0.0,,103.5,0.109,-39.9,67.2,,normal,i.n.,,,bexarotene,none,0.030789,1.594202899,,4268
4268,polymer-based nanoparticles,PCL-PEG,1.0,5.0,none,none,,passive transport,,,0.0,,120.2,0.149,-19.7,66.8,,normal,i.n.,,,bexarotene,none,0.059684,2.739130435,1.718181818,4268
4271,free drug,,0.0,,none,none,,passive transport,,,0.0,,,,,,,normal,i.v.,,,levetiracetam,none,0.0058666666666666,1,,4271
4271,albumin nanoparticles,bovine serum albumin,0.0,,none,none,,passive transport,,,0.0,,153.7,,-10.08,,,normal,i.v.,,,levetiracetam,none,0.0113222222222222,1.94,,4271
4271,albumin nanoparticles,bovine serum albumin,0.0,,polysorbate 80,none,,absorption mediated,,,0.0,,,,,,,normal,i.v.,,,levetiracetam,none,0.0206,3.54,1.824742268,4271
